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Abstract
Phenoxodiol is an isoflavonoid based drug presently in clinical trials in Australia
and America for use in prostate cancer. It has been shown to work through various
mechanisms of action, including 5-α-reductase inhibition. The aims of this study were
to develop new analogues related to phenoxodiol in order to increase 5-α-reductase
inhibition and to introduce α1A adrenoceptor antagonism in the next generation of
isoflavonoid derivatives. The α1A adrenoceptor antagonistic activity was expected to
ameliorate the symptoms associated with prostate enlargement.
Work towards the design of synthetic target molecules was the focus of the
initial stages of the study. Pharmacophores for each of the human 5-α-reductase type I
and type II and the rat type II isozymes were generated using CATALYST®. Standard
parameters were used and variable weight options were trialled during the generation
process.

The

mapping

of

phenoxodiol

on

the

human-based

5-α-reductase

phamacophores predicted that an additional aromatic ring should increase 5-α-reductase
inhibition. Pharmacophores for α1A adrenoceptor antagonism, which were previously
generated by Bremner et al, were utilized for the mapping of phenoxodiol. It was
concluded that a basic nitrogen moiety was required for the introduction of α1A
adrenoceptor antagonism.
In the light of these findings, isoflavonoids derivatised at the 2- and 4- positions
were designed and assessed on the pharmacophores. Isoflavene derivatives 70 and 67,
which incorporated a basic nitrogen at the 2- and 4- positions respectively, were
predicted to have α1A adrenoceptor antagonism. The synthetic targets which

xxv

incorporated an additional aromatic group entailed the 5-methyl thienylisoflavene 71,
the phenyl hydrazone 76 and the 2-thiazolyl isoflavene 77. In an attempt to integrate an
increase of 5AR inhibition and α1A adrenoceptor antagonism, the target compound 78
was designed which encompasses both an extra aromatic moiety and a basic nitrogen.
A new approach to 2-substituted isoflavene derivatives was developed based on
nucleophilic attack on an isoflavylium salt. The isoflavylium salt intermediate was
generated from a preformed isoflavene by hydride abstraction using a trityl salt. Eight
derivatives were synthesized using this method.
Eight 4-aryl hydrazone derivatives were synthesized by reacting an isoflavone
with the appropriate aryl hydrazine. A number of other 4-substituted isoflavene
derivatives were synthesised either by nucleophilic attack on the carbonyl of an
isoflavone or by electrophilic addition to the enol tautomer of an isoflavone. A new
rearrangement of a C-4 thienyl substituted isoflavanol to a benzo[b]furan system was
discovered. Another new rearrangement involving the transformation of the
imidazolylhydrazone 162 to the benzo[b]furan derivative 163 was also found. While
nitrile precursors of targets incorporating basic amine groups were obtained, reduction
to the amines was not successfully achieved.
A human 5AR type I assay was developed sourcing LnCap cells for the enzyme.
Unfortunately, LnCap cell line contamination occurred resulting in corruption of the
assay. Compounds synthesised in this study were also tested for biological activity
against a variety of cancer cell lines and a number of compounds with potent anti-cancer
properties were identified. In particular the p-nitrophenylhydrazone 159d showed
excellent growth inhibitory activity against the androgen dependent prostate cancer cell

xxvi

line and is a potential lead compound for further development. This result indicates that
the 5AR pharmacophores generated are predictive.
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Chapter 1 Introduction
1.1

Prostate Cancer
By the age of 75, around one in eleven Australian males will confront a disease

that has the potential to challenge what many men would consider the essence of their
masculinity and manhood. However, this will just be the first liability for a quarter of
these men, as it will rob them of their lives.1 This disease is prostate cancer!
Prostate cancer kills more than 2500 men each year in Australia, while 10% of
Australian men will be diagnosed with the disease each year.1 Prostate cancer is the
second largest cancer killer of men in Australia, after lung cancer.1 There has not been
any obvious trend in the overall incidence of prostate cancer. The symptoms of prostate
cancer are difficult, painful and frequent urination or ejaculation, blood in the urine,
pain in the lower back, hips or upper thighs.2
There are many factors that are thought to influence the initiation, development
and progression of prostate cancer, including age, familial genetics, race,3 diet4,5 and the
stage of cancer progression at the time of diagnosis6. These factors are poorly
understood and there is a great deal of research needed for a reasonable understanding
of all factors playing a role in prostate cancer. Unfortunately, the public profile of
prostate cancer in Australia is relatively low and needs to be increased, so that further
research may be supported. This low profile affects the number of men being screened
for prostate cancer and unfortunately this could affect prognosis, as prostate cancers
have an increased chance of going undiagnosed.1
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1.2

What is the Prostate?
The prostate is a donut shaped male sex gland that is about the same size as a

walnut in healthy men. It is located just below the bladder and surrounds the urethra.
The outer layer of the prostate is called the epidermis and the inner part is called
the stroma. Its function is to produce a milky white fluid that aids sperm viability during
sexual intercourse.

1.2.1

Benign Prostatic Hyperplasia
It is common for older men to develop a condition known as Benign Prostatic

Hyperplasia (BPH). This condition is defined as an enlargement or swelling of the
prostate. This enlargement constricts the urethra, which causes the patient pain during
urination. BPH is not a cancerous condition and is generally, although debatably, not
considered to be a condition which leads to cancer. Usual treatment is to prescribe α1A
adrenoceptor blockers (Figure 1.1), which antagonise the action of the endogenous
ligands, adrenaline or noradrenaline at this receptor.7

Typical
BPH
constricted
urethra

α1A
adrenoceptor
blocker treated
BPH urethra

Prostate
with
BPH

Non-treated
BPH

α1A adrenoceptor
blocker treated
BPH

Figure 1.1: The smooth muscle relaxant effect of an α1A adrenoceptor blocker on the
urethra through the prostate.
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The adrenoceptor family is part of the peripheral, autonomic, sympathetic
nervous system. The adrenoceptors control smooth muscles in the body, including heart,
blood vessel walls, lung, urinary and digestive tracts.

1.3

What is Cancer?

1.3.1

General
Cells in our bodies grow and divide each day of our lives. Cell growth and

division is carried out through a cyclic pattern of cellular events, called the cell cycle.
The cell cycle is a highly regulated cycle, it contains controls to regiment cell division
and cell death. When a cell has escaped the cell cycle division and death controls and
gains the ability to invade other tissues it becomes cancerous.8 Cancer may develop
from any part of the body. A cancer is named from where the initial cancerous cells
originate.
Metastatic cancer occurs when a cancerous cell has escaped its primary site of
growth and has invaded other sites of the body. Common sites for cells to invade are the
bone,9 lung10 and brain11. Metastatic cancer is difficult to treat and is far more
dangerous than a tumour or localized cancer (see next paragraph). Metastatic cancer
cells commonly possess the ability to degrade membranes and other natural barriers of
the body to facilitate their escape.12
Localized cancers consist of a group of rapidly dividing cells in a specific
region, which also have the potential to invade other tissues. These cases may be
treatable by surgery. However, when one is diagnosed with a localized cancer, there is a
risk that there are minute numbers of cells which have metastasised and are
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undetectable at the time of screening. There is also the risk of impotence with surgery
for prostate cancer.13
Localised cancers are often confused with benign tumours, and their similarity
lies in the fact that both conditions contain cells that are rapidly dividing. However, the
difference between the conditions is that benign tumour cells do not have the ability to
migrate to other organs of the body (metastasis). Benign tumours may also be treated
with surgical removal.8

1.3.2

Cell Cycle
Cancerous cells divide at a more rapid rate than normal cells and are thus

understood to be undertaking the cell cycle at an increased rate. The cell cycle contains
various checkpoints and regulations that disallow a cell to undergo rapid proliferation,
however in cancer these controls are over-ridden through various mechanisms.14
The cell cycle is broken up into phases
and each phase has a specific function essential
for normal cell growth and division (Figure

M

G1

G2

S

1.2). The two main phases are mitosis (M) and
interphase. In short, mitosis is where the nucleus
divides into two and interphase is the rest of the
cell cycle. Interphase can be further broken
down into the G1 phase, S phase and G2
phase. S phase is the time in which the cell
synthesises DNA, and G1 and G2 phases are

Figure 1.2: Phases of the cell cycle.
M=mitosis
G1=Gap1
S=Synthesis of DNA
G2=Gap2
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rest times where the cell is checking its health and repairing any damage.8
An example of a cell cycle regulation protein is the p53 protein. This protein
stops the cell from entering mitosis, allowing time for repairing damaged DNA before
division.15 However, in over 50% of all cancers, the gene encoding the p53 protein is
mutated, allowing the cell to skip this time for repair and increasing the cell division
rate. It has been found that 39% of prostate cancers have a mutation in the gene
encoding the p53 protein.16

1.3.3

Cell Cycle Regulation and How Cancer Cells Escape Regulation
Cell cycle regulation is an extremely complex process, involving numerous

interactions between proteins, DNA and RNA. There are many factors and signals
influencing this regulation system, including endogenous and non-endogenous
substances. Endogenous substances may be intracellular or extra-cellular. Extra-cellular
signals that increase cell cycle rate are termed growth factors, which range from small
molecules to large proteins. An example of a protein growth factor is insulin-like
growth factor, with a role in many cancers17; and testosterone is an example as a small
molecule growth factor18.
As mentioned in the previous paragraph, growth factors are essential for healthy
cell viability. Upon growth factors binding to their appropriate receptors a signal
transduction cascade is triggered. This cascade includes the participation of numerous
protein interactions and modifications, and phosphorylation of proteins by cellular
kinases is one of the most notable of these modifications.19 The signal transduction
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cascade then influences DNA expression and induces cellular growth and division. In
cancer many of the proteins in signal transduction cascades may be upregulated.20
In prostate cancer kinases are frequently found to be upregulated.21 There are
many different types of kinases, which are named after the substrate they phosphorylate.
Common kinases frequently found to be up-regulated or highly active in prostate cancer
are tyrosine22 and sphingosine kinases23.
Sphingosine kinases are found on the cell surface and upon activation block the
activity of the cell’s death receptors. These death receptors activate caspases, which are
proteolytic enzymes. Activated caspases degrade intracellular proteins inducing cellular
apoptosis. Therefore a higher sphingosine kinase activity than normal will halt apoptosis
by blocking the initial death receptor activation.23
NADH oxidase (c-NOX) is a protein receptor present on living cells. It sets time
for growth of the cell and defines an allowed growth time.24 If the growth and division
is not met in this growth time, the cell undergoes apoptosis. Cellular growth associated
with c-NOX occurs in a 24 minute cycle and responds to the presence of growth factors
and growth hormones.24
A variant of c-NOX is t-NOX which is expressed in human cancer cells. Morre
et al.24 have shown that t-NOX is vital to the survival of all human tumour cells. It has
the same roles as c-NOX, however associated growth occurs in a 22 minute cycle and is
unresponsive to the presence of growth factors and growth hormones. t-NOX and cNOX are expressed by different genes, indicating that t-NOX expression is usually
suppressed in normal cells.24

8

1.3.4

COX-2

Recently it has been observed that cancers express an enzyme which most noncancerous cells do not express. This enzyme is cyclooxygenase-2 (COX-2). There is a
related COX-1 enzyme that it has not been found to be expressed in cancer cells. COX2 converts arachidonic acid into various prostaglandins.25 There is one prostaglandin
which is of particular interest in cancer development, namely prostaglandin E2 (PGE2).
PGE2 has been found to inhibit apoptosis and exhibit immunosuppressive properties
towards various cancer cell lines. PGE2 also induces the production of interleukin-6
which promotes angiogenesis.26

1.3.5

Metastasising Mechanisms
A cancerous cell must develop mechanisms which allow it to break free of its

original growth site, travel throughout the body and implant itself into a new tissue.
Then it must also find a way to sustain rapid growth at the new site.
One mechanism which has allowed cancerous cells to break organ and tissue
membranes is through the expression and secretion of proteases. Proteases are enzymes
which break down proteins. These proteases degrade inter-cellular adhesive proteins
which sustain the integrity of membranes and tissues. Cathepsin B is an example of a
protease which enables some prostate cancer cells to break through tissues and
membranes.27
Once a cell has embedded itself into a new tissue, it requires nutrients, oxygen
and a method for waste removal. An integral mechanism providing cancerous cells with
these requirements is angiogenesis. Angiogenesis is a process by which a cell sets up a
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blood supply to itself, which includes the development of local capillaries.28 It is
actually this process which provides cancer with its name. Original observers of cancers
thought that a cancer with blood vessels radiating from it looked like a crab (cancer is
Latin for crab). If this process can be inhibited it has been shown that the cancer can be
starved and suffocated to death.29

1.4

Prostate Cancer Development
Non-cancerous prostate cells are dependant on various growth factors for their

normal growth and development. Androgens, for example testosterone (1), are a class of
growth factors required for normal prostatic growth. Androgens, which are typically
steroids, are natural hormones that are necessary for the development of male sex
organs and characteristics. Androgens primarily are formed in the testes and adrenal
gland, and to a lesser extent in peripheral tissues.30
In the early stages of prostate cancer, the cancer is dependant on androgen for
growth and division. This stage of the cancer is termed androgen dependant cancer. As
the cancer progresses and advances, its growth becomes independent of androgen
presence. Once this occurs the cancer usually becomes more aggressive and more
difficult to treat.31,32
Androgens exert their effects on cellular growth, division and sex organ
development through binding with the androgen receptor, which is a membrane receptor
located in the nuclear membrane.32
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Testosterone

1

is

an

androgen

which

is

reductively

converted

to

dihydrotestosterone (DHT) 2 by the enzyme 5-α-reductase (Figure 1.3). DHT 2 is 40
times more potent as a growth factor at the androgen receptor than testosterone. Slowing
the growth of androgen dependant prostate cancer is therefore achievable by inhibiting
the conversion of testosterone to dihydrotestosterone.33
OH

OH

5-α-reductase
O

O

1

H

2

Figure 1.3: Conversion of testosterone 1 into dihydrotestosterone 2.

It has been shown that DHT binds to the androgen receptor within the prostate
cell, forming a complex, which then binds to the androgen response elements in
prostatic DNA, inducing DNA synthesis and subsequent cellular proliferation.34
There are two isozymes of 5-α-reductase, type I and type II. They have different
anatomical distributions and are encoded by different genes on different chromosomes.
5-α-Reductase type I is found mainly on the skin and is encoded on
chromosome 5, by the SRD5A1 gene.35 It is also found to a smaller extent in prostate
epithelial cells. When prostate cancer originates from these cells the cancer tends to be
more aggressive than its type 2 counterparts. Excessively active 5-α-reductase type I is
also responsible for male patterned baldness.36 Interestingly, a correlation between
specific types of male patterned baldness and aggressive prostate cancer has also been
found in various studies.37,38
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5-α-Reductase type II is mainly found in the stroma of the prostate and in
genital skin, and is encoded on chromosome 2, by the SRD5A2 gene.35,39
Differences between 5-α-reductase enzymes between species have also been
ascertained. Specifically, it has been shown that inhibitors of the 5-α-reductase
isozymes in mice, rats, dogs, monkeys and humans bind to these enzymes with different
affinities.40,41 This finding leads to the conclusion that the enzymes are different
between species and calls for caution in the use of animal models during the testing of
inhibitors of the human enzyme.

1.5

Factors Influencing Cancer Development

1.5.1

Genetics, Familial and Racial Differences
Statistical studies involving familial history and racial differences of prostate

cancer patients reveal the important role that genetics plays in the development of the
disease.3 For example, if a male has a brother who has had prostate cancer, his
likelihood of prostate cancer development increases by nearly three times42. Genetics
also comes into play when examining the incidence of the disease between races.
African American men are 40-60 times more likely to develop prostate cancer than are
Asian men.3
Many genetic studies have investigated the reasons behind these prostate cancer
familial and racial factors. Androgen levels have been implicated for the differences
between races. Over 22 mutations in the SDA5A2 gene have been reported. The A49T
mutation (a substitution of threonine for alanine at codon 49) has been investigated by
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seven different studies. Two of these studies report that this mutation is associated with
more aggressive prostate cancers to a statistically significant degree, while others did
not find this association. Four other mutations have been studied, however no
correlations were made.39
Many findings from the genetic studies have been debatable and many groups
have found conflicting results. The main problem with most genetic studies has been
methodological limitations, such as a low number of participants or mutant alleles
within the study. Past studies have had a mutant allele population of less than 5%,
placing limitations on conclusive findings. Typically studies containing less than 500
men have been performed, however it is now recommended that over 500 men
participate, so that findings can be statistically significant. The combination of certain
alleles and the functional consequences of the mutations also need to be considered
within genetic studies.39

1.5.2

Diet
Encouragingly, it has been observed that typical Asian diets have produced a

low incidence of prostate cancer. This is highlighted by the low incidence rate in Asian
men living in Asia, however as they immigrate to western countries the incidence for
men with Asian ancestry increased.43 Asian diets are high in soya products.44 Their use
of soya comes in many forms including soya sauce and tofu (Figure 1.4).
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Figure 1.4: Sources of
soy in the asian diet.
From left to right:
soya beans, soya
sauce and tofu.

There are various constituents of soya which have anti-cancer activity.45 These
constituents include lignans, phytates,46,47 phytoestrols, saponins48 and isoflavonoids
(Figure 1.5).49 Their biological properties include protease inhibition, kinase inhibition
and anti-androgenic action. An example of a saponin is Syringaresinol 3 which has been
shown to possess acetylcholinesterase inhibitory activity.50 In particular, isoflavonoids
in soya have been shown to possess numerous anti-cancer actions. One isoflavonoid,
genistein 4 demonstrated a 74% reduction of prostatic cancers in in vitro and in vivo
animals models of the cancer.51 Another isoflavonoid found in soya is daidzein 5, a
compound which has been shown to protect against many different types of cancer,
including prostate cancer.51 The phytate, phytic acid 6 shows calcium binding
properties.51
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Figure 1.5: Components of soya products exhibiting anti-cancer activity.
3 Syringaresinol (a saponin)
4 genistein (an isoflavonoid)
5 daidzein (an isoflavonoid)
6 phytic acid (a phytate)

1.6

Cancer Drug Targets

1.6.1

Hormonal Regulation of Androgens
Hormonal regulation of androgens is achieved at various glands in the body and

relies on the blood stream for transportation of hormones throughout the body. The
main organs controlling androgen levels are the hypothalamus gland, pituitary gland,
testes, prostate, and adrenal gland. Dysfunctions in these organs may cause
inappropriate androgen levels and lead to diseases such as prostate cancer.30
As discussed in section 1.4, testosterone is converted into dihydrotestosterone by 5-αreductase in the prostate. Testosterone is mainly produced in the testes from cholesterol.
Testosterone production in the testes is controlled by luteinizing hormone (LH) which is
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released from the pituitary gland. Upon LH release from the pituitary gland and
transportation through the blood stream, LH binds to the luteinizing hormone receptor
in the testes, which upregulates the synthesis of testosterone. The release of LH in the
pituitary gland is upregulated when luteinizing hormone releasing hormone (LHRH)
(also known as gonadotropin releasing hormone) is released from the hypothalamus.30
(Figure 1.6)
The prostate is not the only source of dihydrotestosterone. The adrenal gland
produces adrenal androgens from cholesterol, which are transported into the prostate
and there converted into dihydrotestosterone.30
Androgen synthesis is also regulated by testosterone (T) in the hypothalamus and
pituitary gland in a negative feedback fashion (Figure 1.6). The presence of testosterone
itself in the hypothalamus and pituitary gland causes a decrease in the production of LH
and LHRH. Through this mechanism testosterone (T) regulates its own production, so
that when T levels are too high, it effectively works to down-regulate itself.30 (Figure
1.6)

Estrogens (E) down-regulate the LHRH production in the hypothalamus. Upon
estrogen (E) binding to the estrogen receptor in the hypothalamus, a signal transduction
cascade occurs, eventually causing a decrease in the LHRH levels. This eventually leads
to a decrease in T and DHT levels.30 Various drugs can be used to moderate aspects of
these processes as noted in Figure 1.6.

16

ER

LHRH

PR

E
Cyproterone acetate
Megesterol

AR
Flutamide
Bicalutamide
Nilutamide

LH
Cyprote
rone

C
T

KEY
C=cholesterol
E=estrogen
T=testosterone
DHT=dihydrotesterone
AA=adrenal androgens
LH=luteinizing hormone
LHRH=luteinizing hormone releasing hormone
AR=androgen receptor
ER=estrogenrecptor PR=progesterone receptor
Upregulatory effect
Down regulatory effect

AR

T

Cholesterol
Conversion
Inhibitors

DHT

AA
C

Figure 1.6: Androgen regulation by hormones and manipulation by drugs.
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1.7

Current (Prostate) Cancer Drugs
The first effective systematic therapy, not just for prostate cancer, but, for any

type of cancer, was castration in conjunction with oral estrogen (a form of androgen
ablation) in the 1940s. Remarkably androgen ablation remains the most frequently used
therapy for prostate cancer, even today.52 Currently however, androgen ablation is not
achieved through estrogen treatment, but most commonly by the use of Finasteride 7
(Figure 1.7).30 Once prostate cancer becomes hormone independent, androgen ablation
techniques are of little use, and then the usual next line of defence is the use of cytotoxic
agents. 53
Monotherapy for prostate cancer will almost inevitably lead to drug resistance.
A way to circumvent this problem is the use of multiple drugs for treatment.54 Multiple
drug therapy commonly alleviates pain associated with cancer as well as decreasing the
dosage of some toxic drugs.55 Many trials are in place to evaluate the various regimes of
multiple drug therapy.

1.7.1

Androgen Ablation
The prostatic effects of androgen ablation have been observed for centuries,

initially through castration. These effects include a shrinking in the size of the prostate.
Androgen ablation can be achieved by surgery and chemotherapeutically through taking
advantage of androgen synthetic and regulation mechanisms.30
5-α-Reductase is an attractive biological target for androgen dependant prostate
cancer as its inhibition will hinder the synthesis of DHT. Finasteride 7 is the most
frequently utilized drug for androgen dependant cancer. It is a steroidal compound,
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which inhibits 5-α-reductase type 2.56 However, it produces steroidal side effects. These
effects include weight gain and moodiness. It has also been shown that finasteride 7
may be taken to prevent prostate cancer.57 Recently, a dual inhibitor of 5-α-reductase
type 1 and 5-α-reductase type 2, dutasteride 8 (Figure 1.7), has been developed and it is
currently in clinical trials.58-60 Dutasteride 8 has been reported to shrink prostate size,
alleviating urinary obstruction to such a degree in most BPH patients that α1Aadrenoceptor blockers aren’t required for symptom relief.61 Unfortunately, 8 is also a
steroidal compound, with the potential to produce steroidal side effects, such as
gynecomastia (the excessive development of breasts in males). No specific 5-αreductase type 1 inhibitors have been clinically developed so far.
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Figure 1.7: Structures of 5-α-reductase inhibitors.
Finasteride 7
Dutasteride 8

Long term dosing of LHRH agonists reduces serum testosterone levels by 75%.
Although the response duration is highly variable, the median response duration lasts
about 14-20 months. This therapy relies on the negative feedback mechanism of
testosterone (Figure 1.6). A disadvantage of this type of therapy is that in the short term,
testosterone levels flare up. There are a number of LHRH analogs which have been
developed for clinical use, including leuprolide 9 (Lepron)62, (Figure 1.8), goserlin

19

(Zolarex)63, buserelin64 and nafarelin65. Leuprolide 9 has been approved in a depot form
of the drug which is administered quarterly. 62
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Figure 1.8: The structure of the LHRH analog Leuprolide 9.

Another way to utilize androgen regulation mechanisms is by the antagonism of
LHRH, causing a down-stream decrease in synthesis of T (Figure 1.6). LHRH
antagonists such as Cetrorelix 10, (Figure 1.8), Abarelix and Ganirelix66 have recently
been in clinical trials. Preliminary clinical trial data shows that these compounds are just
as effective as LHRH agonists, however they do not produce a testosterone flare up.67
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Androgens produce their effects by binding to the androgen receptor (AR). AR
antagonists have been developed and they are mainly steroidal compounds. An example
of a pure AR antagonists is Cyproterone 11,68 (Figure 1.10), while examples of partial
agonists are Bicalutamide and Nilutamide. Pure antagonists bind the androgen receptors
competitively without acting as an agonist, whereas a partial agonist binds as well as
effecting some agonistic response. Pure antagonists bind to the AR in the hypothalamus
and pituitary gland as well as the prostate. This blocks the negative feedback
mechanism of testosterone and leads to an increase in serum LH and T.69
In order to overcome the spiking of LH and T problem associated with
Cyproterone being a pure AR antagonist, an acetate group was added to the 17αhydroxy position. This converts Cyproterone into a partial AR agonist and a potent
progesterone agonist, inhibiting LH release from the pituitary gland. This decreases the
amount of testosterone synthesized, while retaining AR antagonism. Cyproterone
acetate use does incur side effects, namely hot flushes, loss of libido and sexual potency
due to its central action on androgen secretion.70,69
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Figure 1.10: Structure of Cyproterone 11 and its conversion to its acetate analog 12.
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The androgen ablation strategies mentioned above are not able to cure advanced
prostate cancer as they do not address the fact that adrenal androgens are still being
secreted into the blood stream. The adrenal gland produces adrenal androgens which
contribute to the production of DHT in the prostate (Figure 1.6). Ketoconazole71 14 and
Aminoglutethimide 13 (Figure 1.11) suppress this adrenal androgen synthesis.
Ketoconazole is currently frequently used as second line hormone therapy and is less
toxic than aminoglutethimide.72
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Figure 1.11: Structures of aminoglutethimide 13 and ketoconazole 14.

1.7.2

Cytotoxic Agents

Cytotoxic agents are regularly used in many cancers as a first line treatment,
however in prostate cancer they are commonly used as a second choice treatment after
androgen ablation, for metastatic hormone refractory prostate cancer. Cytotoxic agents
exert their effects through various mechanisms. Commonly these mechanisms cause
DNA damage.73 The cell checks for DNA damage at various checkpoints during the cell
cycle. When DNA damage is detected it is commonly followed by cell death.74 Because
cancer cells undergo the cell cycle more rapidly than normal cells, cytotoxic induced
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DNA damage is detected more readily in cancerous cells than normal cells. This induces
a higher rate of death in cancerous cells than normal cells.
It has been found that many cancers are becoming resistant to cytotoxic agents when
used as monotherapy. Recently, the synergistic use of cytotoxic agents with androgen
ablation and/or anti-angiogenic agents is emerging as a new trend and is the focus of
many new studies.
Commonly used cytotoxic agents in prostate cancer are Cyclophosphamide75,
Estramustine phosphate76 (Emcyt), Doxorubicin75 (Adriamycin), Mitoxantrone75
(Novantrone) and Cisplatin75 (Cisplatinium). More recently, Etoposide75,76 (Vepsid),
Paclitaxel75 (Taxol), Docetaxel77 (Taxotere) and Vinblastine76 (Velban) have been
used. 75

Cisplatin 15 (Figure 1.12) is an extremely commonly used drug in
Cl

Cl

many cancers. Cisplatin is known to bind at DNA sites with a high

Pt
H3C

CH3

15
Figure 1.12:
The
structure of
ciplatin 15.

cytidine (cytosine) and guanidine content.78 Upon cisplatin entering
the cell nucleus its two chlorine atoms are exchanged by two
adjacent

guanidine

bases

from

a

DNA

strand.79

X-ray

crystallography has revealed that this causes a DNA bend and
unwinding at the site of attachment. This causes binding of high mobility group (HMG)
domain proteins at the bent site of the DNA and it is thought that HMG-domain proteins
prevent cell replication.78 Cisplatin is known to posses neurotoxicity and kidney
toxicity.80 Chemoresistance to cisplatin is known81 and this resistance is mediated by an
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efflux pump which exhibits cross resistance with other cytotoxic agents such as
cyclophosphamide.82

Cyclophosphamide 16 (Figure 1.13) is a nitrogen mustard, an alkylating agent
which crosslinks DNA83 and is cell cycle non-specific. Its adverse effects include
myelosuppression, leukemogenesis, vomiting and diarrhea. It is metabolically activated
by the hepatic CP450 enzymes (Figure 1.13), through hydroxylation alpha to the
nitrogen. This first step of this metabolism produces an amino alcohol, which is in
equilibrium with the ring opened aldehyde compound. This ring-opened compound then
further degrades into two biologically active components, the amino phosphate 17 and
the vinylic aldehyde 18.83 Resistance to cyclophosphamide is facilitated through various
mechanisms including DNA repair mechanisms.84
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Figure 1.13: The hepatic metabolism of cyclophosphamide 16 producing biologically
active compounds.
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Estramustine phosphate 19 (Figure
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1.14) combines an estrogenic structure with
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a nitrogen mustard moiety and this takes

Cl

advantage of two distinct mechanisms.

Figure 1.14: The structure of
Etramustine
phosphate 19.

Firstly its estrogenic functionality utilizes
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androgen ablative pathways through estrogenic receptor binding, while exploiting the
actions of nitrogen mustards on DNA. Additionally, Estramustine metabolites are
microtubule inhibitors leading to cellular growth inhibition.85 Adverse effects include
fluid retention, nausea,86 diarrhea87, dyspnea,88 and allergic reactions,89 while
gynecomastia87 and impotence are associated with its estrogenic effects.85

Vinblastine 20 (Figure 1.15) comes from the traditional
folk medicine plant, periwinkle.90 It binds in a specific

N

manner to tubulin and inhibits its polymerization, which

N
H
O

COOCH3

causes ineffective chromosome separation and leads to
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apoptotic cell death.91 It blocks the cell cycle in the G2/M

N

phases.92 Resistance to Vinblastine can occur. Mechanisms

N

H
HO
H3COOC
H3COCO

for resistance include cellular production of a multi-drug
efflux pump93 and altered tubulin causing reduced affinity

Figure 1.15: Structure
of Vinblasatine 20.

for vinblastine94. Side effects include myelosuppression95,

neurotoxicity, leukopenia, alopecia and gastrointestinal (GI) disturbances96.
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Taxol 21 (Figure 1.15) was first isolated from
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the western yew tree.97 Taxol promotes the
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polymerisation of tubulin.98,99 This induces the
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production of the tumour suppressor gene, p53.
Taxol blocks the cell cycle in the G2/M phases

Figure 1.16: Structure of Taxol 21.

and cells will then undergo cell death.99
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Resistance also occurs with this drug, and clinically the mechanism for resistance has
been found to be due to mutant tubulin.100 Bone marrow suppression101,102 and
peripheral neuropathy102 have been observed in patients using Taxol.
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Doxorubicin 22 (Figure 1.17) is an antibiotic derived from
streptomyces bacteria.103 It exerts its actions in cancer through
intercalation of DNA. The amino sugar is directed into the

O

OH

O

O

for intercalation are those with two adjacent GC base pairs

O

22
OH

DNA minor groove during intercalation.104 Preferential sites

NH2

flanked by an AT base pair,104,105 leading to DNA and RNA

Figure 1.17:
Structure of
Doxorubicin 22.

synthesis inhibition. Specifically, Doxorubicin intercalation
leads to double stranded breaks, mediated either by

topoisomerase or the generation of free radicals.106 There are three main mechanisms
responsible for doxorubicin resistance, the production of a multi-drug resistance efflux
pump,107 increased glutathione peroxidase activity108 and decreased topoisomerase
activity109. Adverse effects have been found, including myelosuppression,110 alopecia,111
GI disturbances111 and cumulative cardiac toxicity111.
H
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C/G specific DNA intercalation.112,113 It has a lower
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Mitoxantrone 23 (Figure 1.18) exerts its toxic effects by
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Figure 1.18: Structure of
Mitoxantrone 23.

cardiotoxicity than other anthracyclines, such as
doxorubicin.114.

The

main

adverse

effect

is
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myelosupression.115 Chemoresistance to Mitoxantrone 23 is also known to occur.116

There is a great need for a wider variety of drugs to treat prostate cancer
patients, particularly drugs with non-steroidal structures and of low toxicity. There are
numerous biological targets for prostate cancer and therefore there is a need to explore
new structural drug types. One place to start looking for such new structural types is in
nature. In this context, one particular structural type of interest are the isoflavonoids
found in soya products, as they have been found to possess many beneficial properties,
particularly protection against anti-cancer properties. A further discussion of
isoflavonoids follows.

1.8

Benzopyrans
The core chemical moiety of isoflavonoids is the benzopyran ring system.

Benzopyrans are a fascinating class of compounds, whose applications range from
medicinal use to laser dyes. There are numerous structural variants of the benzopyrans,
many possessing commonly used nomenclature as a result of their significance in
natural product chemistry. Numbering of the benzopyran system starts from the oxygen
in the pyran ring (Figure 1.19).
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O

3-phenyl-1benzopyrylium
(Isoflavylium)

Figure 1.19: Benzopyran derivatives, shown with IUPAC and common nomenclature.

Benzopyrans are a class of compounds widely distributed in the plant kingdom
and many are biologically active. Some of these activities include anti-coagulant,117
anti-asthma,118 anti-cancer,119 anti-fungal,120 cardiovascular,121 anti-hypertensive,122
fragile capillary protectant, sedative relaxant,123 appetite stimulation, respiratory
stimulatory, contraceptive,124 anti-osteoporotic,125 anti-obesity, non-insulin dependent
diabetes mellitus agent,126 liver protector,127 anti-oxidant,128 night-blindness treatment
and anti-parasitic129. To highlight the range involved the activities of some natural
benzopyrans and synthetic analogues are summarised in Table 1. One compound of
particular interest in the context of the work in this thesis was the isoflavone genistein 4.

Table 1: Biological Action of selected benzopyran compounds.
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Name

Structure
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1.9

Phenoxodiol
Studies on daidzein 5 have shown anti-prostatic cancer properties.

130-132

However, it has also been shown to be metabolized by intestinal bacteria to phenoxodiol
32 (dihydroequol) through the hydroxy intermediate 31 (Figure 1.20).133-135
Phenoxodiol is a more effective agent than daidzein 5 against prostate cancer.136
Phenoxodiol also exhibits greater anti-oxidant potency than daidzein.137 Phenoxodiol
has exhibited activity against breast,138 prostatic,136 ovarian,139 lung, colorectal, head
and neck cancers, and against mesotheliomas, leukemias, rhabdomyosarcoma and
neuroglioma in in vitro studies. These studies have also shown that, upon phenoxodiol
exposure cancer cells cease dividing immediately and show signs of distress within
several hours. The cells die within 24-48 hours by apoptosis. The remarkable property
of this compound is its specificity towards cancer cells, with normal cells remaining
healthy and viable during and after exposure to phenoxodiol.140
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Figure 1.20: Human Colorectal and intestinal bacterial metabolism of daidzein 5 to
equol 32.
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In the course of incubation with prostate cancer cells, phenoxodiol causes a
G0/G1 arrest during the cell cycle.136 It has been established that phenoxodiol has
numerous additional modes of biological actions against cancer. These actions include
inhibition of 5-α-reductase type 1 and 2 (with greater inhibition of type 1)141, COX-2
inhibition, and signal transduction inhibition141. The signal transduction inhibition
specifically includes insulin growth factor inhibition, tNOX inhibition and down
regulation of sphingosine kinase expression. In vitro cell line studies incorporating the
use of other cancer chemotherapy agents, such as cisplatin, carbo-platin and paclitaxel,
have revealed the synergistic ability of phenoxodiol to restore chemo-sensitivity to
resistant cell lines. Synergism between phenoxodiol and cisplatin has also been
reported.142
Phenoxodiol has been developed by Novogen (Marshall Edwards) as a drug for
various cancers, including prostate cancer. This is the first isoflavonoid compound to
enter into clinical trials for use against cancer. It may be given orally or intravenously.
Phenoxodiol is currently in phase II clinical trials for hormone independent prostate
cancer in Australia and America as a mono-therapeutic. Other clinical trials with
phenoxodiol include mono-therapeutic use against ovarian cancer, cutaneous squamous
cell carcinoma, and basal cell carcinoma in Australia, and monotherapeutic use in
squamous cell carcinoma and adenocarcinoma of the cervix, vagina and vulva in
America. 143
Remarkably, phenoxodiol has shown no or little cytotoxicity during cell based
and animal testing, which is a huge benefit for anti-cancer drugs.140
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There is continuing interest in developing further analogues related to
phenoxodiol as anti-cancer agents, and also to incorporate other activities, for example
α1A adrenoceptor antagonism which would alleviate symptoms associated with the
partial blockage of the urethra.

1.10 Aims
The aims of this project were thus to use phenoxodiol as a lead for the molecular
design, synthesis and evaluation of a new range of isoflavonoid compounds which
would be useful for prostate cancer treatment.
Specifically this included the potential incorporation of α1A adrenoceptor inhibitory
activity into phenoxodiol-type compounds, as this would alleviate symptoms associated
with prostate cancer. Increasing 5-α-reductase inhibitory activity was an additional
biological activity sought which would be beneficial for phenoxodiol-like compounds.
Increasing 5-α-reductase type 1 inhibitory activity was of particular interest as there are
no specific prostate cancer therapeutics which have high inhibitory activities against this
enzyme. Associated with this, it was also planned to develop an appropriate assay for
the analysis of the reductase-enzyme inhibitory activities of the synthesised compounds.
In this thesis, Chapter 2 deals with pharmacophore generation and the design of
synthetic targets, Chapter 3 covers the synthesis of 2-substituted isoflavene derivatives,
Chapter 4 discusses the synthesis of compounds derivatised at the 4-position of the
isoflavonoids, Chapter 5 reports on the development of the 5AR inhibitory assay, and
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Chapter 6 discusses the biological testing results. The full experimental details are then
covered in Chapter 7.

33

Chapter 2
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Chapter 2

Molecular Modeling, Pharmacophore
Development and Target Design

2.1 Introduction
Often the three-dimensional (3D) structure of an enzyme or receptor is unknown and
the most useful information on its structure comes from ligand binding. The information
obtained from ligands is especially useful for the drug design process. The 3D structures
for the 5-α-reductase type I (5AR type I) enzyme, the 5-α-reductase type II enzyme
(5AR type II), the α1A adrenoceptor, α1B adrenoceptor and α1D adrenoceptor are all
unknown at the present time making them candidates for a ligand-based drug design
process. These enzymes and receptors play a role in the treatment of prostate cancer.
Among other roles, adrenoceptors control smooth muscle tone throughout the body.
Urethral smooth muscle tone is influenced by the α1A adrenoceptor. Blocking the α1A
adrenoceptor alleviates symptoms of prostate cancer associated with painful and
impaired urination.144 Pharmacophores for the human α1A adrenoceptor, α1B
adrenoceptor and α1D adrenoceptor have been generated by Bremner et al.145 and were
utilized in this study. Bremner et al.145 generated the adrenoceptor pharmacophores
using CATALYST® from Accelrys.
5AR

converts

the

androgen,

testosterone

to

dihydrotestosterone.

Dihydrotestosterone is 40 times more potent an androgenic growth promoter of prostate
cells than testosterone. As prostate cancer is androgen dependant in the early stages, the
inhibition of 5AR is beneficial in treatment.31 Comparative examination of the
pharmacophores may reveal key features characterizing the differences between the
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different isoforms of the enzymes and receptors. Pharmacophores for the 5-α-reductase
enzymes were generated during this study to assist with the design of new chromene
target compounds for synthesis. CATALYST® version 4.5 from Accelrys was utilized
for 5AR pharmacophore generation. As there are differences in 5AR inhibitor activities
between animal species40, pharmacophores must be generated in a species distinct
manner. 5AR inhibitors are most commonly tested on human and rat enzymes therefore
human and rat 5AR pharmacophores were generated.

2.1.1

Selection of Training Set Molecules for 5-α-Reductase Pharmacophores
For all pharmacophores, compounds from the literature with a range of 5AR

enzyme inhibitory activities, spanning at least 4 orders of magnitude, were included in
the training sets (Table 2). This is important as this provides CATALYST with enough
structural information to differentiate between active and non-active compounds. The
IC50 values (concentration required to inhibit 50% of T conversion to DHT) were taken
from the literature; standard deviations were not given. Training set compounds and
references to the literature are given in Appendix 1. Training sets were collated with no
redundant information present, as redundant information could bias the pharmacophore
generated. Redundant information is defined as different compounds with similar
activities which provide the pharmacophore with the same structural information. This
is exemplified by the compounds 33 and 34 which are exhibited in Figure 2.1 and have
the similar 5AR type II activity, however only compound 33 is part of the 5AR type II
training set. These two compounds both provide the information that an aromatic group
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in necessary for IC50 activity within the same magnitude (0.29nM and 0.35 nM
respectively)146.
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34

S

0.29nM

O

0.35nM

Figure 2.1: Compounds 33 and 34 (with their human 5AR type II IC50s) which
provide redundant information, therefore only compound 33 is included in the
training set.

Table 2: The number of compounds and their range of activities included in each of
the 5AR inhibitor pharmacophore training set.
Pharmacophore
Human type I
Human type II
Rat type II

Number of compounds
included
15
46
27

Range of activity
IC50 (nM)
3.4 to1400
0.29 to 10000
1.1 to 12000

Only non-steroidal molecules with defined stereochemistry were included, so
racemates were excluded. A range of different structural types was also incorporated
into the pharmacophores. The human 5AR type I isozyme pharmacophore contains
biphenyls147, tricyclic lactams148,149 and tricyclic thiolactams148. The human 5AR type II
pharmacophore

includes

tricyclic

lactams149,150,

indoles146,151,

piperidines150,

biphenyls147,150,152 and benzoquinones147, while the rat 5AR type II isozyme
pharmacophore contains biphenyl, indole and arylpiperazine derivatives. CATALYST®
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version 4.5 does not account for a loss of activity as a result of steric hindrance.153
Compounds which had a low biological activity for suspected steric reasons, were thus
excluded from the training sets. For example, the biphenyl compound 35, which has a
very low activity compared to 36, was excluded from the human type II pharmacophore
as the extra phenyl ring marked by the arc in Figure 2.2, was likely to sterically inhibit
binding.

HOOC

O

HOOC

O

O

35

36

Figure 2.2: The biphenyl compound 35, which was excluded from the human 5AR
type II pharmacophore training set on steric grounds, compared with
36 which was believed to have no problems with steric issues.

The compounds were also chosen according to the type of biological testing
performed on them. All the included training set compounds had been tested on protein
extracts of cells; results obtained from cell-based assays were not included. The source
of protein was considered to be critically important. Ideally, training set compounds
should be tested on extracts taken from cells containing recombinant enzyme consisting
of a pure isozyme. However, compounds tested in this manner are a very limited group
in the literature and insufficient for meaningful pharmacophore generation. Thus
compounds tested on human scalp protein extracts were used for the human type I
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isozyme pharmacophore, while for the human type II isozyme pharmacophore, data
based on protein extracts from benign hyperplastic prostatic tissue were used. These
tissues were chosen as the sources as they contained a dominant amount of the relevant
isozyme.19 For the rat type II enzyme inhibition data from rat prostatic tissue was used.

2.1.2

Conformer Generation

Conformers of each molecule were generated using the standard 20 kcal/mol limit
(relative to the lowest energy conformer found) and the best conformer search option.
While the energy limit of 20 kcal/mol of a conformer is high, it is the recommended
value for CATALYST®, as it provides a large spread of conformers. CATALYST®
accounts for conformers of a high energy during the hypothesis generation process
through a penalty system and CATALYST® is in fact optimised for a 20kcal/mol limit.
CATALYST® uses the ‘poling algorithm’154-156 to ensure effective sampling of
conformational space.

2.1.3

Pharmacophore Generation

CATALYST® generates hypotheses consisting of features. These features are
displayed as round mesh balls, which represent an area in space relative to the other
features where a characteristic of a molecule should be to induce the desired activity
(location constraints).
CATALYST® generates hypotheses with a heavy emphasis on a group of molecules
which are the most active of the training set with activities falling into a certain activity
range. The upper limit of this activity range is defined by CATALYST® to be the
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product of the square of the uncertainty value multiplied by the activity of the most
active compound in the training set.157 The lower limit of the activity range is the
activity belonging to the most active molecule. It is very important that the hypotheses
generated are not biased by any one chemical structure type. In order to ensure a nonbiased hypotheses generation, it is necessary that compounds of more than one
structural type are included in the most active group in the training set, and this can be
controlled by varying the uncertainty value.
In this study, the uncertainty was three, therefore the upper limit of the most
active group of compounds for each training set was set by multiplying the activity of
the most active compounds by nine. For example the most active compound in the
human 5AR type I training set is compound 37 (Figure 2.3, below) with an activity of
3.4nM, therefore the upper limit for the most active group of compounds is 30.6nM.
All compounds in the training set with activities between 3.4nM and 30.6nM heavily
biased the human type I pharmacophore generation, including the biphenyl 36. The
most active compound in the human type II training set was the biphenyl derivative 38
(Figure 2.3), with an IC50 of 0.29nM, the compounds which were considered to be the
most active had an activity up to 2.61nM. For the human type II inhibitor training set,
this group included compound 38 and the indoles 39 and 40 (Figure 2.3). The
CATALYST® program again heavily biases pharmacophores on this most active set of
compounds. As the biphenyl compound 38 is quite different structurally from the
indoles 39 and 40, it is reasonable to assume that the pharmacophore generated is not
biased towards one type of compound. The most active compound in the rat 5AR type II
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training set was 41 which had an IC50 of 1.5nM, which indicated that compounds 41-45
are in the most active group of the rat 5AR type II training set (Figure 2.3).
In this study, hypotheses were generated using default parameters including a
minimum number of features of three. The allowed set of features were hydrophobic,
hydrophobic (aromatic), ring aromatic, hydrogen bond acceptor and negative ionisable
groups. A ring aromatic feature is defined as a feature which maps 5- and 6- membered
aromatic rings (which may be next to a charge) and the negative ionisable feature is
defined as a feature which maps atoms or groups of atoms that are likely to be
deprotonated at physiological pH.158 Hydrogen bond donor (HBD) groups were trialled,
but CATALYST® never included any HBD feature in the generated pharmacophores
and they were thus omitted. The negative ionisable feature was included in the allowed
set as a number of the inhibitors had carboxylic acid groups.
The CATALYST® default mode generates hypotheses where each feature
relatively has equal importance or weight within the hypothesis. However, it is possible
to generate a hypothesis with different relative weights for features, thus allowing
different features to have ranked importance. This variable weight option was
considered for each pharmacophore generated. For the human type II pharmacophores
the variable weight option was not utilised, since when this option was trialled, the
configurational cost (see next section for a discussion of hypotheses costs) was too high
and the same pharmacophores were generated without this option. However, for the
human 5AR type I and rat type II pharmacophores, the variable weight option was
utilized as the correlations increased (from 0.76 to 0.79 and 0.85 to 0.94 respectively;
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see next section for a discussion of hypothesis costs) making the sacrifice of a high
configurational cost (22 and 32 respectively) worthwhile.

2.2

Results and Discussion:
CATALYST® generates hypotheses by assigning chemical features to the

training set molecules, then arranging the features so that the molecules map with a
ranking which correlates with their activity. The hypothesis generation places a greater
importance on the molecules contained in the most active group of the training set.
CATALYST® produces 10 hypotheses (sometimes 9) which are arranged in a
hierarchical manner according to the CATALYST® cost analysis, which takes into
account many factors including the size of the training set. The most influential
parameter contributing to this cost analysis is the correlation between the hypothesis
estimated activity values and the real activity values. The correlation value can lie
between zero and one, with one being a perfect correlation. CATALYST® cost analysis
also takes into account a configurational parameter which describes the complexity of
the problem. Costs are expressed as the number of bits necessary to describe the
hypothesis (this parameter should be under 17, otherwise not all possibilities for
patterns will be searched exhaustively). CATALYST® cost analysis also employs the
principle of Occam’s razor159 whereby a hypothesis should be as simple as possible.
This cost analysis allows one to assess the validity of the produced hypotheses. This
involves the use of three cost parameters:
1.

The null hypothesis cost parameter assumes that all training set
molecules have the same activity, so that there is no statistically
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significant structure in the training set. This cost parameter has the
highest numerical value of all the cost parameters.
2.

The ideal hypothesis cost parameter assumes all training set molecules
fit the simplest possible hypothesis perfectly. This cost parameter has
the smallest numerical value of all the hypotheses cost parameters.

3.

The individual hypothesis cost, which results in a ranking of generated
hypotheses. This parameter takes into account the correlation of the
training set molecule’s tested activity with the activity estimated by
the hypothesis.

To determine whether the pharmacophores produced are statistically significant,
the individual hypothesis costs are subtracted from the null hypothesis cost, giving rise
to the resultant cost. If the resultant cost is over 60 bits then the hypothesis is deemed
statistically significant (over 90% chance that the hypothesis is a true correlation), while
a resultant cost of 40-60 bits translates into a 75-90% statistical probability and for a
value below 40 bits the probability drops to below 50%.158,160
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Figure 2.3: Compounds which were included in the most
active group of the corresponding training sets. Hypotheses shown for inhibition of the
rat and human 5AR enzymes ((a) human type I, and (b) human type II) with the most
active compounds 36(hI), 37(hIIB), 38(hIIA), 39(hIIA), and 40(hIIB) in the training
sets mapped onto them.
The wire cage spheres represent the pharmacophore features. For hydrogen bond
acceptor (HBA) and ring aromatic features the smaller sphere represents the area where
the feature of the molecule lies during the mapping, and the larger sphere represents the
interaction point of the enzyme. The coloured circles on the two dimensional chemical
structures show where a feature has been mapped onto a compound.
Colour coding: dark blue, negative ionisable; blue, hydrophobic aromatic; light
blue, hydrophobic; orange, ring aromatic; green, HBA.
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Figure 2.3 cont: Compounds which were included in the most active group of the
corresponding training sets. Hypotheses shown for inhibition of the rat 5AR type II
enzyme ((c) rat type II) with the most active compounds 41-45 in the training sets
mapped onto them.
The wire cage spheres represent the pharmacophore features. For hydrogen bond
acceptor (HBA) and ring aromatic features the smaller sphere represents the area where
the feature of the molecule lies during the mapping, and the larger sphere represents the
interaction point of the enzyme. The coloured circles on the two dimensional chemical
structures show where a feature has been mapped onto a compound.
Colour coding: dark blue, negative ionisable; blue, hydrophobic aromatic; light
blue, hydrophobic; orange, ring aromatic; green, HBA.
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2.2.1
2.2.1.1

Hypothesis Analysis
Human type I Inhibitor Pharmacophore
Hypothesis generation for the human 5AR type I training set produced 9

pharmacophores instead of the usual ten. The pharmacophore which was scored as the
sixth highest hypothesis (hI) was chosen as the most accurate pharmacophore. The
highest scoring hypothesis was blank and the next four were rejected on the basis that
they contained a ‘pseudo-feature’ which meant the pharmacophores consisted of less
than the required three features. A pseudo-feature is defined as a feature which only
maps the most active compound and none of the other compounds in the training set.
Although the hypothesis generation was limited to a minimum of three features the five
top scoring hypotheses each essentially contained two features only.
Pharmacophore hI consists of (Figure 2.3; Table 3) three features and one
pseudo-feature: a HBA, a hydrophobic, a hydrophobic-aromatic feature and a HBA
pseudo-feature. The pseudo-HBA feature was not considered as an accurate feature and
will not be discussed. The distances and angles between features are shown in Table 4.
Although the pharmacophore generation was set up for variable weights, the hI
pharmacophore features had similar weightings of around 2. The resultant cost of the 6th
scoring hypothesis is -14 (Table 3) and the correlation 0.72. The resultant cost is
obviously not large enough to deem the pharmacophores statistically significant and
therefore it was considered a qualitative and not a quantitative pharmacophore.
Compound 37 and the structurally different biphenyl 36 (Figure 2.3) are
considered by CATALYST® to be among the most active compounds in the training set,
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and they therefore heavily biased the pharmacophore generation. Figure 2.3a depicts
the mapping of compound 37 onto hypothesis hI.

Table 3: Summary of discussed pharmacophores, including features, resultant costs
and feature weights for inhibition of 5-α-reductase.
Pharmacophore Enzyme type
Features
Resultant
Feature
Name
Cost (null- Weighting
hypothesis)
hI
Human type I
HBA,
-14
1.96120
Hydrophobic
1.96120
Hydrophobic2.54956
aromatic
hIIA
Human type II
HBA
100
equal
Neg. Ionisable
Ring Aromatic
Ring Aromatic
hIIB
Human type II
HBA
96
equal
Hydrophobic
Ring Aromatic
Ring Aromatic
rIIA
Rat type II
HBA
32
2.57685
Hydrophobic1
2.57685
Hydrophobic2
1.61053
Ring aromatic
2.57685
rIIB
Rat type II
HBA
30
2.50054
Neg. Ionisable
2.50054
Hydrophobic
1.34644
Hydrophobic2.50054
aromatic
Chen et al161
Human type II
HBA1
22
equal
HBA2
Hydrophobic
Hydrophobic
Hydrophobic
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2.2.1.2

Human type II Inhibitor Pharmacophore
The training set for human 5AR type II produced two different types of

hypotheses. The highest scoring hypothesis for each type is presented (Figure 2.3),
these being the top scoring hypothesis (hIIA) and the 4th scoring hypothesis (hIIB). The
fourth scoring hypothesis was chosen as the top three were the same type of hypothesis.
The difference between the cost of the null hypothesis and the hIIA and hIIB hypotheses
are 100 and 96 respectively (Table 3), indicating both are statistically valid. The
configurational cost for this set of hypotheses is 16.5, thus all pharmacophore options
were considered by Catalyst®.

Table 4: Distances and angles of the 5AR inhibitor pharmacophores from this work and
the pharmacophore of Chen et al.
Distance Ranges (Å) and Angles(°) between Featuresa
HBA-H,3.4-5.4; HBA-HA, 6.2-8.2;
H-HBA-HA,24.2°-34.2°
hIIA
HBA-NI, 9.3-11.3; HBA-RA1, 8.5-10.5; HBA-RA2, 5.5-7.5
RA1-NI-RA2, 25.5-°35.5°
hIIB
HBA-H, 3.9-5.9; HBA-RA1, 7.0-9.0; HBA-RA2, 2.9-4.9
RA1-H-RA2, 31.8°-41.8°
rIIA
HBA-H1, 7.6-9.6; HBA-H2, 3.3-5.3; HBA-RA, 2.8-4.8
H1-RA-H2, 104.7°-114.7°
rIIB
HBA-HA, 6.8-8.8; HBA-NI, 7.4-9.4;HBA-H, 3.7-5.7
HA-NI-H, 87.5°-97.5°
HBA1-H1, 2.2-2.4; HBA1-HP2, 6.1-8.1; HBA1-HBA2, 9.8-11.8;
Chen et al161
HBA1-H3, 10.8-12.8; H1-H2, 3.2-5.2;
H1-HBA2, 7.2-9.2;
H1-H3, 8.9-10.9; H2-HBA2, 3.3-5.3; H2-H3, 5.6-7.6;
HBA2-H3, 2.3-4.3
a: Abbreviations used for features: HBA, hydrogen bond acceptor; RA, ring aromatic;
Pharmacophore
h1

NI, negative ionisable; H, hydrophobic; HA, hydrophobic-aromatic.
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Hypothesis IIA consisted of a hydrogen bond acceptor, negative ionisable group
and two ring aromatic features (Tables 3 and 4). This pharmacophore mapped all the
features for the most active compound of the training set. However, the other two
compounds in the most active group of the training set mapped all but the hydrogen
bond acceptor feature.
Hypothesis hIIB consisted of a hydrogen bond acceptor, hydrophobic and two
ring aromatic features (Tables 3 and 4). While this hypothesis may be considered for
deletion due to its high non-specific feature content (non specific features being defined
as non polarized features) if the importance of the hydrophobic nature of 5AR inhibitors
is considered,15 then the hypothesis should be deemed valid. Further validation of this
hypothesis was forthcoming from the fact that all compounds that constituted the most
active group in the training set plus the next most active compound, mapped all four
features of the hypothesis, while all other compounds in the training set missed at least
one feature when they were mapped, which explained their lower activities.
A distinguishing feature between the hypotheses is the error of the training set
compound 46 (Figure 2.4), when mapped onto the hypotheses. For hypothesis IIA, 46
with an experimental IC50 of 9.8nM. had an error of +68, however, in the hypothesis
hIIB 46 had an error of 5.4; this may be due to the nitro functionality mimicking the
carboxylate ion. Thus it was concluded that hypothesis hIIB was more appropriate for
inhibitors of this isozyme.
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Figure 2.4: The training set compound 46 that distinguished the two types
of human 5AR type II hypotheses IIA and IIB.

2.2.1.3 Rat Type II Inhibitor Pharmacophore
The training set of the rat 5AR inhibitors was trialled with and without variable
weights. These two trials produced similar results in terms of the cost analysis, however,
the correlations improved from 0.8 to 0.9 with the introduction of variable weights.
The pharmacophores produced can be categorized into one of two groups:
pharmacophores which contain one HBA or negative ionisable feature and
pharmacophores which contain two HBA or negative ionisable features. The top scoring
pharmacophores of each group is presented in Figure 2.3. The pharmacophores with
pseudo-features are not included.
The two top scoring pharmacophores contained pseudo-features. Therefore, the
3rd scoring hypothesis (rIIA) is presented as it was the top scoring pharmacophore with
one HBA group (and no negative ionisable group) which does not contain a pseudofeature. The highest scoring pharmacophore containing a HBA and a negative ionisable
group with no pseudo-features, is the 9th scoring pharmacophore (rIIB).
Pharmacophore rIIA contained one HBA group, a ring aromatic feature and two
hydrophobic features of unequal weighting (Table 3). The distances and angles between
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the features are shown in Table 4. The resultant cost is 32 bits which was interpreted as
a hypothesis of moderate statistical validity.
The pharmacophore rIIB contained a HBA feature, a negative ionisable feature,
a hydrophobic feature and a hydrophobic-aromatic feature also of unequal weighting
(Table 3). The distances and angles between the features are shown in Table 4. The
resultant cost is 30 bits which was interpreted in the same way as for rIIA.
The resultant costs of the pharmacophores rIIA and rIIB did not reach the 60 bit
statistical validation threshold, thus an additional statistical analysis was performed.
This additional analysis is done by generating hypotheses with the same training set,
however the activities were randomly mixed, and the process was repeated 8 times.
These generations produced hypotheses with smaller resultant cost and correlation
values than those of the hypotheses which are attributed to the true training set. This
gives an additional statistical validation to the rIIA and rIIB hypotheses. It was also
observed that the decline in the correlations was much more marked in the randomized
hypotheses than in the true hypotheses (Figure 2.5).
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The correlation trends of the rat 5AR type II real and
randomised hypotheses

correlation

1
0.8
0.6
0.4
0.2
0
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hypothesis rank

Figure 2.5: The correlation trends of the rat 5AR type II non-randomised and
randomised hypotheses. The solid line represents correlations from the
unrandomised rat 5AR type II training set and the broken lines represent
correlations of hypotheses generated using the randomized training sets.

The isoflavonoid rat 5AR type II inhibitors used in a paper by Chen et al161 were
mapped onto both rat type II pharmacophores. These inhibitors have larger IC50’s than
the inhibitors found in the training set. The rat type II pharmacophores predicted these
isoflavonoid rat 5AR type II inhibitors to be poor inhibitors, thus giving additional
validation to the pharmacophores.

2.2.1.4 Comparisons between training sets and pharmacophores of human 5AR
type II inhibitors and previously published work
Chen et al’s recently published pharmacophore161 for inhibitors of human 5AR
type II has points of similarity and difference between the human 5AR type II
pharmacophores which are presented in this thesis. The major difference in the training
sets is that Chen et al used both steroidal and non-steroidal compounds, while we have
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only used non-steroidal compounds. As it is not known whether steroidal structures bind
in the same way as non steroidal structures (and to eventually develop new inhibitors
free of steroidal side effects), we decided to restrict our training set to non-steroidal
compounds. The inclusion of steroidal training set molecules may bias Chen et al’s
pharmacophore. In fact, their most active compound Finasteride 7 (IC50, 0.18nM) is an
aza-steroidal derivative. Chen et al. also used standard parameters in the generation of
their pharmacophore. Presumably, this included an uncertainty of three, which meant
that only compounds with an IC50 of 1.62nM or below were included in their most
active compound group. This criterion is only met by Finasteride 7 in their training set,
thus giving their pharmacophore a bias toward this compound. Another difference is in
the number of compounds used in the training set, with 46 in this study and 15 in that of
Chen et al. This variation is reflected in the resultant cost of Chen et al.’s and our
hypotheses (22 and ~100 respectively). The main similarity between the two training
sets is the use of similar indole compounds 47-51 which exhibit a high degree of
structural similarity (Figure 2.6).
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Figure 2.6: The similar compounds used in the human type II (this work)
and Chen et al training sets. Compounds 47 and 49 are from our human
5AR type II training set, the others are from Chen et al.161

Chen et al. presented their top scoring human 5AR type II pharmacophore,
which consisted of two hydrogen bond acceptor (HBA) and three hydrophobic features
(Table 3). The main difference between this pharmacophore and our pharmacophores
was that the last two only contained four features while the first contained five. Since
they only allowed hydrophobic and HBA features for pharmacophore generation, their
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pharmacophore can also be thought of as two negatively polarised features and three
non-polar features.
When considering the two types of pharmacophores generated from our human
type II training set, the Chen et al. pharmacophore is most similar to the IIA
pharmacophore, which included a HBA and a negative ionisable feature. This can also
be thought of as two negatively polarized functionalities, therefore equating with Chen
et al.’s HBA features. Strong similarities are evident, however, in the distance ranges
and angles between these features in each pharmacophore, as can be seen in Table 4.
The distances between two of Chen et al.’s hydrophobic features and their distances to
the HBA features correlate with the distances between IIA’s ring aromatic features and
the corresponding HBA or negative ionisable group (Table 4).
Pharmacophore IIA further resembles the Chen et al. hypothesis in that it
contains two ring aromatic features and a hydrophobic region, which are three non-polar
features, thus correlating with their three hydrophobic features.

2.2.1.5 Comparisons between Human Type I and Type II Training sets and
Pharmacophores
There is a large degree of difference between training sets of the human 5AR
type I and type II pharmacophores presented in this thesis, the main difference being the
number of compounds in the training sets. This difference is reflected in the resultant
costs of the pharmacophores (-14 and ∼100 respectively). This large variation in
resultant costs is also a reflection of the difference in correlations between hIIA (0.88)
and hIIB (0.86), and hI (0.73). However, a similarity between the training sets is the
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presence of similar biphenyls 36 and 38 in the most active compound groups for each
set.
A large difference between the actual pharmacophores is that type I only has
three features, plus one pseudo-feature, while type II pharmacophores contain four.
The hI pharmacophore was more similar to pharmacophore IIB than IIA
(overlays in Figure 2.6), with both hI and IIB having a HBA feature and no negative
ionisable feature, while hypothesis hIIA for the type II isozyme contained both a HBA
and a negative ionisable feature. The distances between the HBA and hydrophobic
features in the hI and IIB pharmacophores were similar (within 0.5 Å; Figure 2.7). Also
the distances between the HBA and hydrophobic-aromatic feature in hI were similar to
the distances between the HBA and ring aromatic 1 in hIIB (within 0.8 Å), however this
is not apparent in the overlay shown in Figure 2.7 due to the perspective of the figure
(see Table 4 for actual distances). The distances between the negative ionisable feature
and the two ring aromatic features of hIIA also are similar to the distances between the
HBA feature and the hydrophobic and hydrophobic aromatic features in hI. Furthermore
the angle RA1-NI-RA2 in hIIA is very similar to the angle H-HBA-HA in the hI
pharmacophore (within 1.3°). However, the angle H-HBA-RA2 in the hIIB
pharmacophore is nearly double the angle HA-HBA-H in the hI pharmacophore.
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rIIB and hIIA

rIIA and hIIB

hI and hIIA

hI and hIIB

Figure 2.7: Overlays of the rat and human 5AR type II pharmacophores, and the
human 5AR types I and II pharmacophores; see figure 2.3 for details
of each pharmacophore

2.2.1.6 Rat Type II and Human Type II Pharmacophore Comparison
The training sets for these two sets of pharmacophores were quite different in
terms of the number of compounds included (Table 2), with the human type II training
set being much larger. This is reflected in the resultant cost, with the human
pharmacophores having a large resultant cost (∼100) and the rat pharmacophores
possessing a modest cost (∼32). The differences in resultant costs are not due to
differences in the correlations of the pharmacophores, with all pharmacophores having
correlations of about 0.9 (rIIA, 0.91; rIIB, 0.90; hIIA 0.88; hIIB, 0.86). The most active
compounds of the training sets are generally quite different, however, they both include
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indole compounds, specifically 39 and 40 for human type II and 41, 42, 44 and 45 for
rat type II (Figure 2.3).
Two categories of pharmacophores were produced, one of which had two HBA
/negative ionisable features, while the other category had only one HBA feature and no
negative ionisable feature. The corresponding rat and human type II pharmacophores
have been compared within these categories.
Pharmacophores hIIA and rIIB comprised the category of pharmacophores
which had two HBA/negative ionisable features, and they contained a HBA and a
negative ionisable feature. Although similar overall, the distance between the negative
ionisable group and the HBA group of rIIB is smaller than that of hIIA (Table 4), and
there is a good overlap between these two features (Figure 2.7). Furthermore they both
contain two additional non-polar features. For hIIA these features are ring aromatic
features and for rIIB they are a hydrophobic feature and a hydrophobic-aromatic feature
(Table 3). From the overlay of the two pharmacophores in Figure 2.7 it can be seen that
the orientations of these features are quite different in the rat and human
pharmacophores. It can also be seen that the distances between the two non-polar
groups from the negative ionisable group in rIIB and hIIA are very similar, but the angle
enclosed by the non-polar-negative ionisable/HBA-non-polar features is about four
times smaller in the hIIA pharmacophore than in the rIIB pharmacophore. The two nonpolarised (ring aromatic) features in hIIA are much closer together (4.0-6.0 Å) than the
non-polarised features in rIIB (9.1-11.1 Å).
Pharmacophores hIIB and rIIA are the pharmacophores which comprised the
category of rat and human 5AR type II pharmacophores containing only one HBA

58

feature. An additional similarity between these pharmacophores is that they both contain
three non-polarized features with some similarities in orientation (Figure 2.7). The ring
aromatic feature of rIIA and the ring aromatic feature 2 of hIIB are the same distance
away from the HBA feature in their respective pharmacophores. The ring aromatic
feature 1 in pharmacophore hIIB is also the same distance away from the HBA feature
in pharmacophore rIIA, however, as can be seen in Figure 2.7, the orientations of the
two groups are different.

2.2.2

Hypothesis Assessment by Flavonoids, Indoles and Naphthalene Inhibitors
Additional examination to ascertain the quality of pharmacophores can be

achieved by comparing estimated activities with real activities of non-training set
inhibitors. 5AR pharmacophores were analysed in this manner with 5AR inhibitors that
were published after the pharmacophores were generated. Chen et al161 identified
isoflavonoids from an NCI database as potential 5AR inhibitors 52-59 (Figure 2.8).
These isoflavonoids were assayed against rat 5AR type II, thereby enabling the rat type
II pharmacophore evaluation. This was especially valuable in the current investigation
as the development of isoflavonoid compounds was of concern within this project. Chen
et al used indolic carboxylic acids as part of their training set which were different to
the training set compounds in this investigation 47-48, 50 (Figure 2.6), 60-62 (Figure
2.8). These compounds were assayed for human 5AR type II inhibition. Baston et al162
have synthesized and evaluated 5AR activity of naphthalene carboxylic acids 63-64
(Figure 2.8). Compound 64 was tested against human type I facilitating the examination
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of hI. Compound 63 was assayed against human type II allowing the evaluation of the
hII pharmacophores. The results of all additional mappings are shown in Table 5.
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Figure 2.8: Structures of 5AR inhibitor compounds used to test the 5AR
pharmacophore. Compounds 52-59 are rat 5AR type II inhibitors. Compounds 60-63
are human 5AR type II. Compound 64 is a human 5AR type I inhibitor.
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Table 5: Estimated enzyme inhibitory activities (IC50 values) of compounds 50-62 on
various 5AR pharmacophores.

Compound
52
53
54
55
56
57
58
59
64
47
48 S
48 R
50
60
61
62
63

Pharmacophore
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
rIIA
rIIB
hI

Estimated activity (nM)
780
2200
250
280
280
490
320
10000
1200
46000
1600
19000
2000
3300
1600
33000
130

Actual Activity (nM)
48 700

hIIA
hIIB
hIIA
hIIB
hIIA
hIIB
hIIA
hIIB
hIIA
hIIB
hIIA
hIIB
hIIA
hIIB
hIIA
hIIB

180
64
480
220
600
170
62
88
600
190
600
28
740
910
910
16

10

31 000
27 400
30 100
15 700
23 100
26 200
6 900
810

4
69
40
1500
23
6300
200

As can be seen in Table 5, the experimental rat 5AR type II activity of six (5255, 57, 58) of the eight isoflavonoids 54-61 are better predicted by rIIB than rIIA.
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Therefore only rIIB will be discussed. Of all the Chen et al isoflavonoids, compounds
52-54 are predicted worst on the rIIB pharmacophore. Notably compounds 52-54 are
the least active of the isoflavonoid set. As the generation process of the pharmacophores
focuses heavily on the most active training molecules, less active molecules are less
accurately predicted. Pharmacophore rIIB generally overpredicted the activity of the
isoflavonoids 52-59, with the exceptions of 56 and 59. Compounds 53 and 54 were the
only compounds to be predicted to be more active than their experimental findings by
two orders of magnitude. It is also notable that these compounds possess two bulky
benzyloxy substituents on a phenyl moiety, where compounds 52 and 55 have smaller
methoxy groups in place (Figure 2.8). This indicated these compounds may have steric
issues. Compound 57 is the best predicted isoflavonoid of the set. Compound 59 is
predicted among the least active of compounds 52-59, however it is in fact the most
active. This is because the isoflavonoids 52-59 generally have low activity (Table 5)
compared to the rat training set compounds (Table 2).
In summary, of the pharmacophores rIIA and rIIB which were generated for
inhibitors of the rat type II enzyme, the rIIB pharmacophore predicted the activities of
the isoflavonoid compounds 52-59 better than the rIIA pharmacophore. Pharmacophore
rIIB generally predicted a compound to be more active than experimental findings and
accurate prediction was not consistent throughout the isoflavonoid testing group. Some
of these inaccuracies are suspected to be associated with inherent steric problems of the
isoflavonoid compounds 52-54 and the fact that all isoflavonoids 52-59 were less active
than the rat 5AR type II training set compounds.
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Compound 64 was mapped onto the human 5AR type I pharmacophore hI,
giving an estimated activity in the same order of magnitude as experimental findings,
albeit lower (Table 5). As there are no other compounds to compare this to it is not
possible to ascertain if this difference is due to steric reasons. The fact that estimated
and experimental IC50 values are in the same order of magnitude is a validating finding.

Compounds 47-48, 50 and 60-63 have experimental IC50 values for human 5AR
type II ranging from 4 to 6300 nM. This 4 order of magnitude range serves as an
excellent opportunity for the assessment of the human 5AR type II pharmacophores,
hIIA and hIIB. The experimental activity of six (47, 48S, 46R, 61-63) of the eight
compounds tested for human 5AR type II activity are predicted better by the hIIB
pharmacophore than the hIIA pharmacophore. Although hIIA has predicted the activity
of compound 50 better than hIIB, hIIB also predicts the activity of compound 50 very
closely (Table 5). Compound 62 was the least active compound of all tested against
human 5AR type II. Compound 62 was also predicted by the hIIB to be the least active
compound. It is evident for the reasons mentioned in this paragraph that the hIIB
pharmacophore is better than the hIIA pharmacophore. This confirms the findings in
Section 2.2.1.2. Therefore only the hIIB pharmacophore is discussed in the following
analysis.
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Figure 2.9: Mapping of compound 48S, the most active compound with an IC50
of 4nM on the hIIB pharmacophore.

The hIIB pharmacophore predicted the least active compound 60 as the least
active of the compounds 47-48, 50 and 60-63, however it also predicted the second least
active compound as compound 48S, which is experimentally found to be the most active
of the set of eight. There is no strong trend in the predictions for the compounds 47-48,
50 and 60-63 arising from their mappings on the hIIB pharmacophores. As there was a
large range of activities in this set of compounds, the hIIB pharmacophore is suspected
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to be of poor predictive value. Unfortunately the hIIB pharmacophore did not predict
the IC50 of the most active compound in the set of compounds, compound 48S well.
Compound 48S has an experimental IC50 value of 4nM, however hIIB predicted it with
an error of 50 (where error is defined as the factor by which a predicted activity and the
experimental activity are different). As the pharmacophore concentrated on molecules
with a low nM activity, this is a concern. As can be seen in Figure 2.9, compound 48S
is missing the aromatic feature of the hIIB pharmacophore.

In summary, the hIIB pharmacophore is a better pharmacophore compared to
hIIA as it predicted training set activities better (specifically 46). The main issue with
the hIIB pharmacophore is the mapping of compound 48S, which is the most active
compound of the 5AR type II assessment molecules.

2.2.3

Assessment of Novogen’s Isoflavonoids on 5AR Pharmacophores and

Design of Synthetic Targets
Assessment of other known isoflavonoids (available through Novogen) was
essential for the design of the new target ligands as they were to be based on the
isoflavonoid scaffold. The following compounds 30 and 32 were then mapped on the
human based 5AR pharmacophores, and on the α1A adrenoceptor, α1B adrenoceptor
and α1D adrenoceptor antagonist pharmacophores. Table 6 shows the predicted activities
from these mappings.
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Table 6:Predicted activities of the lead isoflavonoids 30 and 32.
1.1.1. Compound

OH

HO

920

α1A
Ki
(nM)
210

α1B
Ki
(nM)
36000

α1D
Ki
(nM)
2000

810

920

99

11000

200

1100

970

120

15000

190

hI
IC50

HIIA
IC50

HIIB
IC50

32

2000

2400

30
R

2200

2200

O
OH
O

HO

O
OH
O

HO

O

30 S
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Mapping the isoflavonoids onto the α1B adrenoceptor and α1D adrenoceptor
pharmacophores was needed to design α1A adrenoceptor specific antagonists.

Additional
aromatic feature

Additional
aromatic feature

Figure 2.10: Mappings of phenoxodiol 32 on the human 5AR type II
pharmacophores, hIIA and hIIB.
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The mappings of phenoxodiol 32 on the 5AR type II pharmacophores, hIIA and
hIIB were shown in Figure 2.10. These mappings call attention to a common feature
missed in all mappings, this being the additional aromatic feature. This indicated that
the presence of an additional aromatic group would be beneficial for 5AR activity.

Additional
positive
ionisable
feature
Figure 2.11: Mapping of phenoxodiol 32 on the α1A adrenoceptor pharmacophore

Figure 2.11 shows the mapping of phenoxodiol on the α1A adrenoceptor
pharmacophore. It is evident that the positive ionisable feature is missed in these
mappings and this calls for the addition of a protonatable nitrogen for adrenoceptor
activity. This moiety should be carefully placed as α1A adrenoceptor specificity is
needed over α1B and α1D activity so as to avoid unwanted side effects.
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2.2.4

Design of New Targets
All considered synthetic targets were based on the phenoxodiol lead. Positions 2

and 4 of the isoflavonoid nucleus were chosen as derivatisation centers as they were
predicted to be more amenable to synthetic manipulation.
Separate synthetic targets for 5AR activity and α1A adrenoceptor activity were
designed to facilitate a larger structure-activity knowledge base for these biological
targets. Structures which encompassed features for dual 5AR and α1A adrenoceptor
antagonism were also designed as possible dual action compounds through combining
moieties from the separate activities. Activities were then predicted utilizing the
CATALYST® program for conformer searching (best search, 20 kcal/mol limit) and
mapping onto the human 5AR and the α1 adrenoceptor pharmacophores (fast fit option).
Resulting predicted activities were then analysed for synthetic target selection.
From the analysis of isoflavonoid analogues mapped on the adrenoceptor
pharmacophores a protonatable nitrogen needed to be introduced into a phenoxodiollike structure. Targets designed for α1A adrenoceptor binding affinity incorporated a
protonatable nitrogen in the structure (Figure 2.12). Predicted activities are also shown
in Figure 2.12. Protonatable nitrogens were created as their protonated forms in
CATALYST®.
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Figure 2.12: Prospective synthetic targets for α1A selective antagonism and
their predicted α1 adrenoceptor binding Ki value(nM). R and S refer to the
absolute configuration of the enantiomers.
As can be seen in Figure 2.12 of the modelled compounds 65-70, compound 70
is predicted to be the most active α1A adrenoceptor antagonist. Due to its synthetic
accessibility (see Chapter 3 for more detail) it was chosen as a synthetic target.
Compound 67 was also predicted to be active and as it was thought to be synthetically
accessible (see Chapter 4 for more detail) it also was chosen as a synthetic target
Evaluating the biological activity of these isoflavenes was expected to aid in the
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determination of whether the α1A adrenoceptor pharmacophore was predictive for
isoflavonoid compounds.
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Figure 2.13: Prospective synthetic targets for human 5AR inhibition and their
predicted activity (IC50 nM). R and S refer to the absolute configuration of the
enantiomers. E and Z refer to the appropriate double bond geometries.
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There were three pharmacophores for 5AR generated in this study, hI and hIIA
and hIIB, which should be taken into account during the design of inhibitors. However,
due to the findings that hIIB was a better predictive pharmacophore than hIIA and that
hI was not a statistically valid pharmacophore, hIIB predictions are considered more
reliable than those from the other 5AR pharmacophores. It is for this reasons that only
hIIB predictions were considered.
Figure 2.13 contains compounds 71-77 which were considered as synthetic
targets. Pharmacophore hIIB predicts the 5AR type II activity of the lead isoflavene
compound 32, with an IC50 of 910 nM (Table 6). Pharmacophore hIIB predicts the most
active compound of all considered compounds to be compound 71 with a predicted IC50
activity of 43 nM. As this was thought to be synthetically accessible it became a
synthetic target. Compounds 74 and 75 were predicted to have similar 5AR type II IC50
values as the lead compound 32 by the hIIB pharmacophore. However, as these
compounds contained additional aromatic rings to the isoflavonoid core structure and
were expected to be synthetically accessible they also became synthetic targets.
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2.2.5

Target Compounds which Incorporate the 5AR and α1A Moieties
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α1B

α1D

hI

hIIA

hIIB
S

76R

2.8

3800

64

2100

860

110

76S

2.8

410

7.3

2400

810

72
HO

OH

O

NH2

78
Figure 2.14: Prospective synthetic target for a dual action anti-prostatic cancer
derivative. The dual actions are human 5AR inhibition (IC50 nM predicted) and α1A
adrenoceptor blockade (Ki nM predicted).

As it was desired to incorporate dual action into the isoflavonoid lead
compound, phenoxodiol 32, the synthetic target 78 incorporating both an aromatic ring
for 5AR activity and a basic nitrogen for α1A activity was proposed. The activities for
both biological actions are predicted to increase compared to the predicted activities of
the lead compound 32 (Figure 2.14). Predicted α1A adrenoceptor antagonism increased
due to the interaction of the basic nitrogen of 78 with the positive ionisable feature of
the pharmacophore. Selective α1A adrenoceptor antagonism was predicted especially for
the R enantiomer. The presence of the thienyl moiety increased the predicted 5AR
activities due to its interaction with the aromatic feature. Compound 78 was thus also
chosen (see Chapter 3 for more detail).

2.3

Summary and Conclusions
Human 5AR type I, human 5AR type II and rat 5AR type II inhibitory

pharmacophores were generated. The pharmacophore for the human 5AR type I

74

isozyme did not have a satisfactory cost analysis due to a small number of compounds
in the training set. The generation of the human 5AR type II inhibitory pharmacophore
resulted in two distinct pharmacophores each with excellent cost analysis. The rat 5AR
type II inhibitory pharmacophore possessed a moderate analysis. The human type II
pharmacophores were compared with a previously published pharmacophore.
Lead isoflavonoids were assessed on the human-based 5AR inhibition and
adrenoceptor antagonist pharmacophores. In order to increase predicted 5AR activities
of the lead isoflavonoid 32 an additional aromatic interaction was required and to
increase predicted α1A adrenoceptor antagonism a basic nitrogen was required. To this
end the aminomethyl derivatives 67 and 70, the phenyl hydrazone 76, the thienyl
compounds 71 and 78 and the thiazole 77 were designed as synthetic targets.
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Chapter 3
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Chapter 3

Substitution Reactions at the 2-Position
of Isoflavenes

3.1 Introduction

Soya products have been used in traditional Asian medicine for many centuries, and
these products are known to be beneficial in the prevention of prostate cancer.
Isoflavonoids are biologically active constituents of soya products. Isoflavonoids have
exhibited various anti-cancer activities, including against prostate cancer. The
isoflavonoids genistein, 4 and daidzein 5, which are contained in soya, have been shown
to have 5-α-reducatse (5AR) inhibitory activity.49 The 5AR enzyme is involved in the
early stages of prostate cancer.31 Novogen, an Australian pharmaceutical company,
currently has an isoflavonoid-derived isoflavene compound, phenoxodiol 32, in clinical
trials for prostate cancer in Australia and America.
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A symptom of prostate cancer is painful urination, caused by prostate enlargement
and consequent obstruction of the urethral path. In an effort to alleviate this symptom,
α1A adrenoceptor antagonists can be prescribed, since these antagonists result in urethral
smooth muscle relaxation and thus widening of the urethral path.
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In the current project, investigations were targeted at increasing the effectiveness of
the anti-prostatic cancer activity of phenoxodiol 32 derivatives. This was attempted
through a dual action design concept which involved, firstly, increasing 5-α-reductase
activity over that for phenoxodiol 32, thereby aiding the inhibition of prostate cancer
development; and, secondly, through α1A adrenoceptor antagonism alleviating the
urological symptoms of prostate cancer. While this dual action concept had not been
applied previously to isoflavonoids, some work by Sato et al.163 had shown proof the
general concept with indole-based derivatives. In order to aid the design of synthetic
targets, pharmacophores were generated for human 5AR type I and human 5AR type II
inhibitors. Pharmacophores for α1A antagonism generated by Bremner et al.145 were
utilized for the α1A antagonist target design. Computational pharmacophore studies
were carried out using the program CATALYST® version 4.5 from Accelrys (see
Chapter 2 for more detail).
Conformational models of feasible 2-substituted isoflavonoid derivatives were
generated as described in Chapter 2. Overlays of these derivatives onto the
pharmacophores were performed and their biological activities estimated. These studies
produced hypotheses indicating that an additional aromatic feature added to
phenoxodiol would increase 5-α-reductase activity and a basic nitrogen would introduce
α1A adrenoceptor antagonism.
The pyran ring contains a number of synthetically viable derivatisation centres, but
the 2-position of the pyran ring was the primary focus of this work to introduce a basic
nitrogen (and α1A adrenoceptor antagonism) in the phenoxodiol isoflavene framework.
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The main 2-substitiuted phenoxodiol target derivative indicated through the
computational studies to increase α1A adrenoceptor activity was an (R)-2-substituted
aminomethyl derivative 70 (Figure 3.1).

OH

HO

O

NH2

70

Figure 3.1: The amine synthetic target 70R overlayed onto the α1A pharmacophore.

The presence of the basic amine group in compound 70 facilitates a mapping of
the positive ionisable feature in the α1A adrenoceptor pharmacophore (Figure 3.1)
which is not possible in phenoxodiol. This should then introduce selective α1A
adrenoceptor antagonism, alleviating some of the pain associated with urination during
prostate cancer, assuming the pharmacophore is correct.
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Figure 3.2: Overlay of the 2S-thiazoyl synthetic target 77S on the hIIA
pharmacophore.

The 2-thiazolyl isoflavene 77 was predicted to have approximately the same
5AR type II inhibitory activity as phenoxodiol 32 (Figure 3.2), by the hIIB
pharmacophore, however, it was predicted to be more active then 32 by the hIIA
pharmacophore. The addition of the 2-thiazole ring in compound 77 increased the
predicted activity (IC50) from 2400nM to 880nM and 1200nM for the R and S
stereoisomers respectively. However, as this compound only possesses a weakly basic
nitrogen, binding to the α1A adrenoceptor was predicted to be weak. It was noted in the
overlay of 77 on the α1A pharmacophore in the modelling studies that there was no
positive ionisable feature interaction.
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As 2-substituted isoflavene derivatives such as 70 and 77 were desired for testing
against prostate cancer, approaches to the synthesis of 2-substituted isoflavene (2-aryl2H-1-benzopyran) derivatives were then investigated.

3.2 General Synthetic Approaches
There are various synthetic routes to 2-substituted 2H-1-benzopyrans. Most
commonly, 2-substituted compounds are synthesized with a putative 2-substituent
already in place prior to pyran ring construction (Schemes 3.1-3.3, Schemes 3.5-3.6).
This substituent may have a role as a good leaving group or be the final substituent. The
most common cyclisation procedures for the preparations of the pyran ring involve O1C2 bond formation or C3-C4 bond formation. These general approaches may also be
used to access 2-substituted analogues and details of these approaches are given in the
following sub-sections.

3.2.1

2-Substituted-2H-Benzopyran Synthesis via Ring Closure through O1-C2

Bond Formation
A recent synthesis of a 2-substituted benzopyran 80 was reported by Parker et
al164. They used an electrocyclic ring closure synthesis for the benzopyrans, with the
vinyl quinone 79 as a starting material (Scheme 3.1). The vinyl quinone 79 was
converted into its enol form 79a in situ, and subsequently was converted to the
benzopyran 80 by a thermal electrocyclic ring closure. This was done by heating 79 at
reflux in toluene with hexamethylphosphoric triamide for 2 hours, with 80 being
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obtained in 86% yield. It was found that the reaction could be accelerated (reaction time
45 minutes) by the addition of the Lewis acid FeCl3, however this reduced the yield of
80 to 76%.
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∆
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79
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Scheme 3.1: Electrocyclic cyclisation of the enol form of a vinyl quinone through O1C2 bond formation resulting in a 2-substituted benzopyran.164

A common route to 2-substituted isoflavenes is through a carbonyl group
addition and ring opening reaction with coumarins. One such synthesis of 2-substituted
isoflavenes starting from the coumarin 81 involved a Grignard reaction to give the
dihydroxy ring opened product 82 (Scheme 3.2). Compound 82 was then cyclised by
acid catalysed dehydration to give isoflavene 83 in 73% overall yield.165
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Scheme 3.2: Synthetic route to a 2-substituted isoflavene utilizing a coumarin as a
starting material.165
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Synthesis of the 2-substituted benzopyran 86 starting from the coumarin 84,
proceeded

initially

by

a

reductive

ring

opening

reaction

with

di-

isobutylaluminiumhydride (DIBAL-H) (Scheme 3.3). This produced the highly reactive
aldehyde intermediate 85, which was stabilized through aluminium co-ordination with
the phenolic oxygen. Subsequent in situ treatment with the Grignard reagent, methyl
magnesium bromide, and acid catalysed cyclisation then gave the 2-methyl substituted
isoflavenes 86 in 50% overall yield. 166
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Scheme 3.3: Synthetic route to a 2-substituted isoflavene utilizing coumarin as a
starting material and proceeding via a ring opened intermediate.167

A variation on the synthesis shown in Scheme 3.3 was developed by Grese et
al167 and led to the synthesis of 2-aryloxy derivatised isoflavenes for example 89
(Scheme 3.4). They used DIBAL-H reduction for the generation of the 2hydroxyisoflavene 88 from the coumarin 87 in 83% yield. The 2-hydroxy group was
then converted to the phenoxy group by heating with phenol. The resulting aryloxy
isoflavene 89 could then be used for further derivatisation though reaction with
Grignard reagents. This reaction involves the displacement of the phenoxy group in the
2-position by the R group from the Grignard reagent and is thought to proceed through
the magnesium co-ordinated intermediate 89a.
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Scheme 3.4: Synthetic route to 2-substituted isoflavenes utilizing coumarin as a
starting material.

A solvent free, microwave reaction has been developed for the ring construction
of a 2-amino substituted isoflavene (Scheme 3.5)168. The initial step in this synthesis
involved reaction of a secondary amine 92 with the aldehyde 91 to form the enamine 93
in solvent free conditions and assisted solely by microwave irradiation. The addition of
salicaldehyde 94 and ammonium acetate as a catalyst then formed the isoflavan 96 via
the intermediate 95. The key step of this reaction series is the isomerisation of 95
involving ring closure through O1-C2 bond formation to give the isoflavan 96. Under
the same conditions dehydration occurred yielding the isoflavene 97. The overall yield
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for the synthetic pathway was 80% using microwave irradiation, while with
conventional heating this pathway yielded the desired isoflavene 97 in only 55% yield.
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Scheme 3.5: A microwave assisted synthetic route to a 2-substituted isoflavene. 168

3.2.2

2-Substituted 2H-1-Benzopyran Synthesis through Ring Closure by C3-C4

Bond Formation
Doodeman et al169 have accessed the 2-benzyloxy substituted benzopyran 102
by way of C3-C4 formation (Scheme 3.6) through a ring-closing metathesis reaction.
This synthesis involved the generation of the allylic acetal 100 from a vinylic phenol 98
and benzyloxy-1,2-propadiene 99 through an oxypalladation reaction. Compound 100
then underwent a ruthenium-catalysed ring-closing metathesis reaction to afford the
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benzyloxy substituted benzopyran 102. Using the catalyst 101a the metathesis occurred
in a 77% yield at room temperature in DCM, however this reaction required a reaction
time of 4 hours due to problems encountered with catalyst decomposition. This
decomposition problem was overcome by using an alternative ruthenium-based catalyst,
101b, which reduced the reaction time to three hours and gave a similar yield (78%),
although heating to 80ºC in toluene was required. Doodeman et al169 utilized the
benzyloxy substituent as a good leaving group to form a benzopyrylium salt which
could then be converted to 2-substituted-2H-1-benzopyran derivatives by nucleophilic
addition (see section 3.2.3).
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dppp: 1,3-Bis(diphenylphosphino)propane
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Scheme 3.6: Synthesis of a 2-benzyloxy-2H-1-benzopyran through C3-C4 bond
formation by ring closing metathesis.

3.2.3

Synthesis of 2-Substituted Isoflavenes through Benzopyrylium-Based

Approaches
The isoflavylium salt is a versatile synthetic intermediate as it may undergo
various

reactions,

including

coumarin

formation

and

addition

reactions.170

Derivatisation at the 2-position has been achieved through nucleophilic addition to the
isoflavylium salt.
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An early synthesis of an unsubstituted isoflavylium salt was through an acid
catalysed condensation reaction of a 2-phenylethyl acetal 103 and salicaldehyde 94171
(Scheme 3.7). Initially this involves ethanol loss from the phenyl ethyl acetal forming
the 2-ethoxyphenylethene 104. The pyran ring in intermediate 105 is then formed by
acid catalysed addition of 94 to 104. Isoflavylium ion 106 then results from elimination
of ethanol and water from 105.
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Scheme 3.7: Acid catalysed synthesis of the isoflavylium cation.171

Doodeman et al169 have synthesised the 2-substituted benzopyrans 108 via
nucleophilic additions to the benzopyrylium ion 107 (Scheme 3.8). The generation of
107 was achieved by use of a Lewis acid (BF3-etherate) catalysed dissociation of the
benzyloxy leaving group in 102. Subsequent nucleophilic addition using TMS- or
tributyltin reagents provided the 2-substituted derivatives 108a-108d in moderate to
good yields.
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Scheme 3.8: Lewis acid dissociation of good leaving group to generate the
benzopyrylium ion and nucleophilic additions of silyl and tin-based nucleophiles.

An isoflavylium salt intermediate 110 was also accessed from the a 2-Nmorpholino substituted isoflavene 109 (Scheme 3.9). The morpholine serves as a good
leaving group and is removed by reaction with trityl perchlorate. The anion associated
with the salt is the non-nucleophilic perchlorate, which is commonly used as the counter
ion for the pyrylium, benzopyrylium or isoflavylium cation.172
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Scheme 3.9: Isoflavylium salt formation from an isoflavene with a nitrogen based
leaving group at the 2-position. 172

Trityl perchlorate has also been used to abstract a hydride from 4H-pyrene 111
forming the pyrylium salt 112173, and from the 3-ethoxycarbonyl benzopyran 113
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providing the benzopyrylium salt 114174 (Scheme 3.10). However this reagent has not,
to our knowledge, been used to oxidize a 2-unsubstituted isoflavene skeleton.
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-

O
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113
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Scheme 3.10: Pyrylium173 and benzopyrylium174 formation via hydride abstraction,
through the use of trityl perchlorate.

3.2.4

Synthetic Proposal for the 2-Substituted Isoflavene Derivatives
In our study, we wished to adopt an approach to the target 2-substituted

isoflavenes based on preformed 2-unsubstituted isoflavene derivatives available from
Novogen and then to introduce a variety of 2-substituents. A readily accessible route to
the 2-substituted isoflavonoid derivatives 115 and 116 utilizing preformed benzopyrans
was thus proposed via the isoflavylium salts 117 (Scheme 3.11). The addition of a
nucleophile would then produce the 2-substituted product 116. Previous methods of
acquiring 2-substituted isoflavonoid products from a preformed pyran ring through an
isoflavylium salt included a good leaving group, such as a morpholine (Scheme 3.9) in
the 2-position of the starting isoflavene. As the isoflavene starting material available to
us was phenoxodiol 32, with an unsubstituted 2-position, we required a synthesis where
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no prior leaving group was needed in the 2-position. Therefore we required a reagent
which would oxidise the pyran ring through hydride abstraction from the 2-position of
the isoflavene phenoxodiol 32.
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Scheme 3.11: Retrosynthetic route to 2-substituted phenoxodiol derivatives.

The phenolic hydroxyls of phenoxodiol 32 must be protected for the synthesis of
the isoflavylium salt 117, because of the nucleophilic properties of the hydroxyl group.
This protecting group (P) would then need to be removed ultimately to obtain the free
phenolic compound.
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An additional precursor to compound 118a which was readily available from
Novogen was the hydroxy compound 119 (P=Ac), which could be converted to the
former compound by dehydration.

3.3

Results and Discussion

3.3.1

Synthesis of Phenol-Protected Isoflavenes
The protection of the phenolic hydroxyls was essential for a successful synthetic

route involving an isoflavylium salt. The phenolic hydroxyl protecting groups chosen
for trial were the acetate group and the tert-butyldimethylsilyl group (t-BDMS group).
The acetate group was also considered as phenoxodiol was supplied in the acetate
protected form at the time. The t-BDMS group was chosen for trial as this group also
proved useful for reactions in the 4-position (see Chapter 4) and it was hoped to later
synthesize 2,4-disubstituted isoflavene target compounds.
There were two isoflavonoid precursors obtained from Novogen leading to the
protected phenoxodiol analogues. The first was the racemic 4-hydroxy isoflavan
analogue 119 and the other was phenoxodiol 32 itself. The 4-hydroxy isoflavan 119
was supplied as the diacetoxy protected form and was used to access the diacetoxy
protected derivative 118a of phenoxodiol.
Dehydration of the hydroxy compound 119 to the diacetoxy phenoxodiol
derivative 118a (Scheme 3.11) could be achieved by various reagents. A strong driving
force for this reaction is the creation of conjugation between the two aromatic rings.
There were numerous reagents available for such dehydration reactions. Two reagents
were trialled for the dehydration step (Scheme 3.12), phosphorus pentoxide (P2O5) and
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anhydrous copper sulfate (CuSO4). The former has long been a versatile dehydrating
reagent for the formation of double bonds for example in the preparation of aryl
substituted conjugated esters.175 Anhydrous CuSO4 has been used previously by various
groups for the dehydration of alcohols.176 The copper ion of copper sulfate typically
coordinates with five water molecules in a hydrated environment. Anhydrous copper
sulfate strongly coordinates to hydroxyl groups, thus increasing their leaving group
ability. Copper sulfate absorbed on silica gel has also been used for dehydration
reactions and the rate of these heterogeneous reactions are increased through the
increase in surface area.177
Treatment of compound 119 (P=Ac) with P2O5 gave the diacetoxy compound
118a as a cream coloured powder in 82% yield (Scheme 3.12). 1H NMR spectroscopy
provided evidence of double bond formation by the conversion of the multiplets
between 4.20 ppm and 4.49 ppm assigned to the H-2 protons 119 (P=Ac) to a singlet at
5.14 ppm. Additional 1H-NMR evidence for compound 118a was the appearance of a
singlet at 6.75 ppm which was assigned to the H-4 proton. MS (CI+) provided further
confirmation of the desired product via the presence of a molecular ion peak at m/z 325
(M+1).
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Scheme 3.12: Preparation of diacetoxy protected phenoxodiol from 119.

Finely ground anhydrous CuSO4 was also found to be a successful reagent for
the dehydration reaction producing the diacetoxy product 118a (Scheme 3.12). The
product was obtained in 97% yield as a white powder. Although hydrated CuSO4 is
blue, the gray colour of the reaction mixture did not change during the reaction as a
large excess of anhydrous CuSO4 was used. There were advantages in using anhydrous
CuSO4 over P2O5. Besides the fact that the anhydrous CuSO4 method afforded the
product in a higher yield, it also did not produce emulsions during the reaction workup
procedures; this was a problem with the P2O5 based reactions. Additionally, the reaction
with anhydrous CuSO4 took a shorter time, although it did require heating (Scheme
3.12).
The acetate 118a could also be obtained from phenoxodiol 32 through
acetylation with pyridine and acetic anhydride (Scheme 3.13). Evidence for product
formation was obtained from the 1H-NMR and MS spectroscopic data. The 1H-NMR
spectrum showed two singlet peaks at 2.29 ppm and 2.31 ppm, each with an integration
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of three. These peaks were assigned to the two acetate methyl groups. The CI-MS also
showed only one peak at m/z 325, corresponding to the M+1 peak for 118a.
Protection of the phenolic hydroxyls with the t-BDMS group was achieved by
stirring 32 with imidazole and t-butyldimethylsilyl chloride at room temperature for 32
hours (Scheme 3.13). This reaction is likely to proceed through a N- t-butyldimethylsilyl
imidazole intermediate.178 This reaction must be performed under rigorously anhydrous
conditions, and this was enabled through the use of powdered 3Å molecular sieves.
Evidence for the formation of the product 118b was obtained from the 1H-NMR and MS
data. The 1H-NMR spectrum showed singlet peaks at 0.78 and 0.77 ppm which could be
ascribed to the t-butyl groups of the t-BDMS group. There was also a singlet at 0.00
ppm due to the methyl groups in the silyl substituent of the t-BDMS group. The
presence of an M+1 peak at m/z 469 in the CI-MS was consistent with the formation of
the t-BDMS product.
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Scheme 3.13: Hydroxyl protection reactions of phenoxodiol 32.
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3.3.2

Synthesis of a Boc Protected TMS Amine.
In order to introduce aminomethyl functionality in the isoflavenes at the 2-

position by nucleophilic attack, the use of a protected amino trimethylsilyl derivative
was considered. Trimethylsilylmethylamine 120a was commercially available and it
was necessary to protect the amine group so that only attack on the isoflavylium salt by
the methylene group would occur. Protection of the amine by t-butyloxycarbonyl (boc)
groups was then investigated.
In this study, boc anhydride was used to synthesise the boc protected amine.
This method also required a base to deprotonate the primary amine 120a (and carbamate
intermediate 121a and the benzyl amine 121b to enable effective nucleophilic attack.
The base used here was 4-dimethylaminopyridine (DMAP) (Scheme 3.14).
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Scheme 3.14: Boc protection of TMS methylamines, 120a and 121b.
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Stirring of the TMS aminomethyl compound 120a, boc anhydride and DMAP at
room temperature for 48 hours gave the mono-boc protected carbamate 121a in 72%
yield. Evidence that the mono carbamate was formed was that the peak attributed to the
t-butyl group integrated for 9 protons in the 1H-NMR spectrum relative to the
integration for the methylene protons and the signals for the other groups. Additional
structural evidence arising from the 1H-NMR spectrum was the doublet signal at 2.70
ppm corresponding to the methylene protons, with coupling to the nitrogen proton. The
1

H-NMR spectrum exhibited a broad singlet at 3.10 ppm ascribed to the NH group.

Additional confirmation of the mono-boc product came from the ES+MS with an (M+1)
peak at m/z 204.2.
Attempts to produce the bis-boc compound by stirring the mono-boc product
121a at room temperature over four days gave some bis-boc product 122a, however
only in 20% yield. More severe reaction conditions were then investigated.
Heating 121a, boc anhydride and DMAP at reflux in THF for 48 hours produced
the bis-boc compound 122a in 84% yield. Also, heating the primary amine 120a with
the anhydride and DMAP for 48 hours gave 122a in 92% yield. Evidence for the bisboc protected product 122a came from the 1H-NMR spectrum which showed a singlet at
1.45 ppm and integrating for 18 protons which was consistent with the presence of two
equivalent t-butyl groups. Also the methylene protons could be assigned to a singlet at
3.10 ppm. The shift downfield of the methylene protons relative to the corresponding
signal in 121a is supportive of a further carbamate addition. An M+1 peak at m/z 304
was apparent in the CI-MS spectrum of 122a. The common t-butyl group loss also
occurred in this spectrum, with a fragment ion at m/z 248.
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The reaction between the benzyl boc amine 121b, boc anhydride and DMAP
afforded the boc protected amine 122b in 75% yield. The peak at 1.42 ppm in the 1HNMR spectrum integrated for 9 protons and was ascribed to the tert-butyl protons. In
the 13C-NMR spectrum the peak at 149.8 ppm was attributed to the carbamate carbonyl.
The tertiary carbon of the tert-butyl group was ascribed to the peak at 79.3 ppm and the
tert-butyl methyl carbons were credited to the peak at 28.5 ppm. Further confirmation
for the formation of 122b came from the mass spectral data where the molecular ion
peak appeared at m/z 294.

3.3.3

Generation of the Isoflavylium Ion and Nucleophilic Addition

OP

PO

O

116

R

PO

OP

O

117

PO

OP

O

118a (P=Ac) or 118b (P=t-BDMS)

Scheme 3.15: Retrosynthetic scheme of 2-substitution of phenoxodiol type compounds.

The use of isoflavylium salts as a synthetic pathway leading to 2-substituted
chromenes is well documented. This study explored the potential of both the diacetate
118a and t-BDMS 118b protected compounds as precursors of the stable isoflavylium
salts 117 (Scheme 3.15). The source of the isoflavylium ion stability is aromaticity,
which also provides the driving force for formation. To our knowledge, all previously
documented preparations of 2-substituted isoflavonoids via isoflavylium salts have used
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a good leaving group in the 2-position of the isoflavylium precursor.169 An example of
one such good leaving group is the morpholine group (Scheme 3.9). The leaving group
is eliminated from the pyran ring to form the salt. However, to form the isoflavylium
salt from the protected compounds 118a or 118b, a hydride must be abstracted from the
2-position, which is not considered to be a good leaving group. To our knowledge this
had not been attempted before on an isoflavonoid system.

The isoflavylium salt 117 is readily susceptible to addition by nucleophiles at the 2position and also, potentially, at the 4-position. However, nucleophilic addition occurs
selectively at the 2-position of the isoflavylium ion rather than the 4-position. There are
three reasons for this: firstly, the 2-position is more electrophilic than the 4-position;
secondly the 4 position is more sterically hindered; and thirdly, substitution at the 4position would break conjugation between the two aromatic rings. The conjugation is
broken during 4-position addition as it would cause double bond migration to the 2-3
position forming an sp3 carbon in the 4-position as can be seen in compound 123.
(Scheme 3.16)
OP

OP

δ+

Nu
2-addition

PO

O

Nu

116
OP

PO

δ+

O

117

X

Nu

Nu
4-addition
PO

123

O

Scheme 3.16: Products of 2 and 4 nucleophilic additions to the isoflavylium cation.

98

Similar nucleophilic attack in benzopyrylium salts, such as 124, has been observed
where the 2-position is preferred over the 4-position; steric factors may also favour
attack at the 2-position in this case. However, it is observed that the usual position for
nucleophilic attack is at the 2 position (Scheme 3.17)169. It should however be noted that
methanol addition to the 3-carboxyl benzopyrylium salt, 126174 gave the 4-methoxy
product 127 and not the 2-substituted product (Scheme 3.17). This is thought to be due
to the electron withdrawing ester substituent at the 3 position of the benzopyran making
the 4-position more electrophilic.

P(OEt)3, NaI
O

124

ClO4

PO3(Et)2

O

O

125

O
O

O

MeOH
O

O

126

O

ClO4

127

Scheme 3.17:Position of nucleophilic attack of the benzopyryliums 124169 and 126 174.

3.3.3.1 Optimisation of Isoflavylium Salt Formation
The formation of the isoflavylium salts 117 was a key step in the synthesis of the
2-substituted derivatives, and it required extremely anhydrous conditions to prevent
nucleophilic attack by water and formation of the 2-hydroxy compounds 128 (Scheme
3.18). For this reason freshly distilled anhydrous solvents and powdered 3Å molecular
sieves were used in the reactions.
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OP
OP

H2O
O

PO

PO

117

O

OH

128

Scheme 3.18: Addition of water to the isoflavylium 117.

Trityl (triphenyl carbenium) salts have been used previously to form the
isoflavylium system where a good leaving group was present in the 2-position.172 We
required the trityl reagent to abstract a hydride from isoflavene 118. Trityl salt reagents
have been used previously to abstract a hydride to form pyrylium 112 and
benzopyrylium 114 salts (Scheme 3.10). Trityl salts contain a highly electrophilic
positively charged carbon. It is this carbon which abstracts the hydride ion from the
pyran ring forming the pyrylium derivative and triphenylmethane 129. A notable
characteristic of benzopyrylium salts is that they are usually coloured red, orange or
yellow.179 This property may be used to assess whether isoflavylium salts have been
formed successfully.
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OP

O

PO

H

118

OP

O

PO

117

PF6

+

Ph3CH

129

PF6

Scheme 3.19: The use of the trityl hexafluorophosphate reagent for isoflavylium salt
formation.

Various trityl salts were trialled as reagents for the formation of the isoflavylium
salts 117. Non-nucleophilic counter anions were necessary so as to avoid their addition
to the isoflavylium salt. Previous studies using trityl salts have most commonly used the
perchlorate anion, but such salts are potentially explosive, and they were not used in the
current work. The PF6-, SnCl5- and BF4- salts were trialled on the diacetoxy protected
compound 118a. The trityl PF6- salt was trialled on bis-t-BDMS protected phenoxodiol
118b. (Table 7, Scheme 3.19)
In order to gauge the most suitable salt for the project syntheses, model reactions
with TMS-CN were undertaken and the yields of the nitrile products 116a assessed.
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Table 7: Yields of 2-nitrile substitution reactions trialing various trityl salts and
phenolic protecting groups involved in the isoflavylium (117) generation.
OP

OP

Ph3C+XPO

PO

O

OP

TMS-CN
PO

O

O

CN

X

118

117

116a

Protecting Group (P)

Counter Anion (X-)

Yield (%) of 116a

Ac

BF4-

43%

Ac

SnCl5-

76%

Ac

PF6-

80%

t-BDMS

PF6

-

0%

Isoflavylium salt formation proved to be a quick reaction as starting material
disappeared within 30 minutes (as determined by TLC analysis) for all the reactions
mentioned in Table 7. The use of the SnCl5- and the PF6- trityl salts proved to be the
better of the trialled salts and were equally successful with good percentage yields of
116a of 76% and 80 % respectively where the acetate group was in the starting material.
As tin has worse potential environmental and health effects and the PF6- salt produced a
slightly better percentage yield, the PF6- salt was chosen for the synthesis of other 2substituted phenoxodiol derivatives over the SnCl5- salt.
The use of the BF4- trityl salt with the diacetoxy compound 118a only gave 116a
in moderate yield. This was possibly due to degradation of the BF4- ion to BF3 and F-.
This is a problem because BF3 attacks acetate protected phenolic groups and deprotects
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them thereby allowing them to attack unreacted isoflavylium salts. This would lead to a
lower percentage yield. Also the F- ion could add to the 2-position of 116a.
The t-BDMS group was not suitable as a protecting group in the presence of the
trityl PF6- salt and no nitrile product could be detected. This may be because the PF6- ion
acted as a source of fluoride to remove the t-BDMS groups, and resulting in subsequent
intermolecular nucleophilic attack by phenoxide ion on the isoflavylium ion moiety
leading to polymeric products.

3.3.3.2 Synthesis of 2-Substituted Derivatives
The 2-substituted isoflavene derivatives 116a-d were synthesized from 118a
using the trityl hexafluorophosphate reagent forming the isoflavylium salt intermediate
117, followed by nucleophilic addition. Nucleophiles investigated included trimethyl
silyl (TMS) derivatives, a tributyl tin ((Bu)3Sn) derivative, alcohols and amines. Table 8
outlines the yields and NMR chemical shifts of the 2-substituted reaction products 116.
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Table 8: Yields, 1H and 13C chemical shifts (in ppm) of various 2-substituted products.
OAc

OAc

OAc

4
XR

trityl PF6
AcO

O

AcO

AcO

O

O

2 R

PF6

118a
Reagent (XR)
TMS-CN
S
TMS

117
Structure
116
a
b

R
CN
S

Yield
(%)
80
78

δH
H-2
6.01
6.44

δC
δH
C-2 H-4
64.3 6.97
74.7 6.89

N

N

TMS-acetylene
TMS-CH2N(BOC)2
TMSCH2NbenzylBOC
(Bu)3Sn allyl
HOCH3
HOCH2CH3
HOCH2CH2CH2Br

116

c
d
e

ethynyl
CH2NHBOC
-

7
32
0

6.19 91.7 6.91
5.15, 72.4 6.91
-

f
g
h
i
118a

allyl

68
63
46
66
-

5.34
5.85
5.98
6.00
5.14

OCH3
OCH2CH3
OCH2CH2CH2Br
H

75.6
98.3
64.1
97.5
67.4

6.71
6.98
6.98
7.01
6.75

The nitrile 116a was produced in 80% yield. 1H NMR spectroscopy showed the
peak representing the H-2 proton had shifted downfield from 5.14 ppm in the diacetate
118a to 6.01 ppm in the product 116a and the integration of the signal only corresponds
to 1 proton. Also a characteristic downfield shift of the peak ascribed to the H-4 proton
to 6.97 ppm was observed in the 1H-NMR spectrum, relative to the chemical shift of the
corresponding peak (5.14 ppm) in the 2-unsubstituted isoflavene 118. Attempts at
obtaining an infra red spectrum were made, however a reasonable spectrum was not
obtained. Further confirmation beyond the 1H-NMR spectrum was needed in order to
establish that the nitrile group had added and that it had in fact added at the 2 position.
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The

13

C-NMR spectrum of 116a revealed eight quaternary carbon signals,

corresponding to the number of such carbons expected in the nitrile product. The peak
at 116.0 ppm was assigned to the nitrile carbon. The CI mass spectrum showed a small
M+ peak at m/z 349 (8%) which substantiates nitrile addition. The base peak of the CI
mass spectrum was at m/z 323 (M+-CN) corresponding to the isoflavylium ion 117. The
isoflavylium ion is generated in the mass spectrometer during the ionization process as
this ion is stabilized by the aromatization of the pyran ring. Also elemental
microanalytical data was consistent with the formula of 116a. The ES+ MS for 116a
exhibited only one peak at m/z 367 corresponding to the desired product with the
addition of water, indicating possibly the formation of the corresponding amide. This
product was likely to have been formed in the mass spectrometer as an aqueous solution
was used to introduce the sample.

The thiazole derivative 116b was produced in 78% yield. Evidence for the
addition came from the ES+ MS showing the molecular ion at m/z 407.8. Additionally
the 1H NMR spectrum showed a singlet at 6.44 ppm which integrated for 1 proton and
was attributed to the H-2 proton. The shift of the H-2 proton downfield relative to the
diacetate 118 was expected in the thiazole compound 116b as the thiazole substituent
introduces an additional aromatic environment for the proton. The

13

C-NMR spectrum

also exhibited evidence for thiazole addition, through at 169.3 ppm, 143.3 ppm and
121.1 ppm which could be attributed to the C1”, C4” and C3” thiazole carbons
respectively. These chemical shifts are in accordance with literature values for the 13CNMR spectrum of thiazole.180
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The ethynyl compound 116c was produced in 7% yield. This product was only
seen when the reaction was stirred at room temperature for an hour. Elemental
microanalysis data concurred with the formation of the ethynyl derivative 116c. Further
evidence of ethynyl addition was provided by the 1H-NMR spectrum as the H-2 proton
was represented by a one-proton doublet at 6.19 ppm which had characteristically
shifted downfield relative to the corresponding H-2 proton peak at 5.14 ppm in 118a; a
doublet signal at 3.71 ppm was attributed to the ethynyl proton. The peak corresponding
to the H-2 proton is represented as a doublet and this is due to long range coupling with
the ethynyl proton (Figure 3.3). Long range coupling, with a coupling constant typically
of 2 Hz for the ethynyl proton has been reported previously in the literature,181,182
however the long range coupling in 116c was surprisingly found to be 7 Hz; the gCOSY
spectral data supported this coupling is shown in Figure 3.3.
C=CH

O
O
O
O

O
H
H

H-2

Figure 3.3: Long range coupling between the H-2 proton and the ethynyl proton of
the 2-ethynyl isoflavene 116c shown on the gCOSY spectrum.
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Another product formed in the reaction of 117 with TMS acetylene was the
dimeric compound 130. This was thought to arise via anion formation from the terminal
alkyne mediated by fluoride ion (from PF6-) as a base then attack on

another

isoflavylium group producing the dimeric compound 130 (Scheme 3.20). Evidence for
this mechanism came from the fact that the ethynyl product 116c was only produced
when the reaction mixture was stirred for 1 hour. When the reaction was extended to 12
hours only the dimeric product was isolated. The CI-MS and ES-MS spectra did not
provide firm evidence for 130, as each only exhibited a peak at m/z 323, corresponding
to the isoflavylium ion formed after elimination of the 2-substituent. The 1H-NMR
spectrum of 130 contained only the appropriate aromatic, H-2 and H-4 peaks and
notably no other peaks corresponding to an ethynyl proton. Evidence for the synthesis
of this dimeric compound came from the

13

C-NMR spectrum as all carbons in the

isoflavonoid skeleton were accounted for except for an additional peak at 92.5 ppm,
which corresponded to an ethynyl carbon. Elemental microanalysis data was also
consistent with the proposed dimeric structure.
OAc

AcO

OAc OAc

O

AcO
H

AcO

O

F
O

O

OAc

116c
Scheme 3.20: Dimer production.

OAc
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In an effort towards the synthesis of the target 2-aminomethyl isoflavene 70 the
bis-protected TMS methylamine 122 was reacted with the isoflavylium salt 117.
However, only the mono-boc protected amino methyl product 116d was obtained in
32% yield. This deprotection demonstrates that bis-boc protected amines are not stable
in the presence of good electrophiles. The ES+-MS spectrum exhibited the M+ ion at m/z
453 (33.3%) and a fragment ion corresponding to the loss of the t-butyl group at m/z
396 (9%), loss of the t-butyloxy group with a peak at m/z 379 (25%), and the loss of a
boc group with a peak at m/z 338 (100%), and the isoflavylium ion at m/z 323 (14.5%).
Integration data for the t-butyl protons (2.16 ppm) from the 1H-NMR spectrum
supported the production of the mono-boc protected amine 116d. The signal ascribed to
the methylene group protons appeared as a doublet of doublets at 2.59 ppm, resulting
from coupling with the H-2 proton and their diastereotopic nature. The proton on the
nitrogen was ascribed to 3 different peaks (integrating for 1 proton in total) in the 1HNMR spectrum, reflecting different rotamers and the diastereotopic nature of the 2substituent. The H-2 proton was also assigned to a doublet of doublet of doublets peak
at 5.15 ppm. This multiplicity can be explained by the coupling with the diastereotopic
methylene protons. The 13C-NMR spectrum confirmed the addition of the boc protected
methyl amine by the presence of peaks ascribed to the boc carbonyl, the t-butyl
quaternary carbon, the methylene carbon and the t-butyl methyl groups at 155.2 ppm,
75.5 ppm, 43.1 ppm and 30.7 ppm respectively.
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The boc and benzyl protected amino methyl compound 116e was not
synthesized successfully. Chromatography of the crude material gave no pure products.
The only material was baseline material which was assumed to be polymeric. This
reaction was thought to be unsuccessful due to hydride abstraction of the benzylic
carbon of the nucleophile. This would provide an opportunity for further reactions of the
isoflavylium ion.

The 2-allyl derivative 116f was produced in 68% yield. This yield was
acceptable for the purposes of this study, however this yield may be improved by the
use of molecular sieves. Allyl addition to the isoflavylium salt was established through
low resolution and high resolution CI-MS by observation of the M+1 at m/z 365 (46%
relative intensity). The base peak of the CI-MS spectrum was the isoflavylium ion at
m/z 323. However, the molecular ion peak was not seen at all in the CI-MS spectrum of
the 2-methoxy and 2-ethoxy derivatives 116g and 116h respectively and only just
detected in the nitrile and bromopropoxy derivatives 116a and 116i respectively.

The methoxy compound 116g was produced in 63% yield. Methoxy addition
was established through elemental microanalysis. The CI+-MS spectrum only contained
a peak at m/z 323 which is due to the isoflavylium ion fragment. The isoflavylium
fragment is generated through in situ elimination of the methoxy group in the mass
spectrometer. The 1H-NMR and

13

C-NMR spectra also contained evidence for the

methoxy compound 116g with the peaks at 3.58 ppm and 55.5 ppm assigned to the
methoxy protons and methoxy carbon respectively.
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The ethoxy compound 116h was produced in 46% yield. Elemental
microanalysis was consistent with the molecular formula for 116h. The CI-MS and ESMS spectra only contained the m/z 323 peak for the isoflavylium fragment, through
ready ion loss of the ethoxy group. Vul’fson et al.183 have also reported the loss of an
ethoxy group in the mass spectrum substituted from a dihydropyran.
In the 1H-NMR and

13

C-NMR spectra of 116a diagnostic triplet signal at 2.30

ppm was ascribed to the methyl protons of the ethoxy group. The diastereotopic
methylene protons of the ethoxy group gave two sets of multiplet signals in the 1HNMR spectrum, at 4.00 ppm and 3.78 ppm, which integrated for one proton each. A
similar signal pattern was observed for the ethoxy group methylene protons in the 1HNMR spectrum of the 2-ethoxybenzpyrene 131, where the methylene protons were
represented by signals at 3.50 ppm and 3.75 ppm in an ABX3 pattern (Figure 3.4).184
OCH2CH3

O

O

131

Figure 3.4: Section of the NMR spectrum of the 2-ethoxypyrene 131184, containing
the peaks corresponding to the diasterotopic methylene protons.

The bromopropoxy compound 116i was produced in 66% yield. Bromopropoxy
addition was indicated on the basis of the CI-MS spectral data by the

79

Br/81Br M+1

peaks at m/z 463/461. The presence of these molecular ion peaks is notable in this
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spectrum as there was no observable molecular ion in the CI-MS spectra of the other
alkoxy substituted analogues. This molecular ion appearance may possibly be due to the
protonation of bromine instead of the acetal oxygen and the increased size of the
substituent. The isoflavylium ion fragment again appeared as the base peak in this
spectrum. Notably, this CI-MS spectrum also exhibited peaks corresponding to the
deprotected compound, however deprotection must have occurred within the mass
spectrometer as the 1H-NMR spectrum showed both acetoxy groups were present.

For all the nucleophilic addition products, establishment of 2-substitution and
the exclusion of 4-substitution was facilitated by the analysis of the gHMBC spectra of
the derivatives. Typically in the gHMBC spectrum the H-5 proton correlated with the
C4 carbon, and the H-4 proton likewise with the C5 carbon, while none of the protons
or carbons of the added substituents correlated with the H-4 proton or the C4 carbon.
For the purposes of establishing the C2 substitution by a gHMBC analysis, the products
were divided into three categories as noted in Figure 3.5A, 3.5B and 3.5C.
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H
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O
H
HCc

Hc

(C)

Figure 3.5: Correlations observed in the gHMBC spectra of the nucleophilic addition
products. See text for details.
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Derivatives containing substituents attached by a tertiary carbon include the
nitrile 116a, the thiazole 116b and the ethynyl product 116c. The H-2 proton of these
compounds was correlated in the gHMBC spectrum, with the directly attached tertiary
carbons (Ca) of the 2-substituents (Figure 3.5A).
Derivatives with 2-substituents attached to the isoflavene skeleton through a
methylene carbon were the boc protected methyl amine 116d and the allyl derivative
116f. In the gHMBC spectrum of these compounds the expected Cb-H2 and Hb-C2
correlations were observed (Figure 3.5B).
The alkoxy isoflavene derivatives were the methoxy 116g, the ethoxy 116h, and
the bromopropoxy 116i, and in these cases Cc-H2 and Hc-C2 gHMBC correlations were
seen (Figure 3.5C).

3.3.4

Reactions of 2-Substituted Products

3.3.4.1 Attempted Triazole Synthesis
From the pharmacophore studies, increased inhibitory activity was also
predicted with a triazole in the isoflavene 2-position. A triazole in the 2 position would
provide an additional aromatic ring which could to increase 5AR binding. Triazoles are
accessible from acetylene precursors and they are commonly synthesized by an azide
1,3-cycloaddition to the acetylene.
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Scheme 3.21: Attempted synthesis of the 2-triazole compound 132.

Balle et al185 have described a method for triazole synthesis by heating a mixture
of the acetylene starting material and neat azidotrimethylsilane at 170°C in a sealed
tube. Katritzky et al186 have used a milder method of heating an azide with an acetylene
at reflux in diethyl ether for seven days. Rostovtsev et al187 have also avoided heating
azidotrimethylsilane to potentially explosive high temperatures, by using sodium
ascorbate and copper (I) sulfate and stirring the reaction mixture at room temperature.
However, in the current study an attempt to utilize the milder Rostovtsev et al187 method
was unsuccessful and only starting material was recovered.

3.3.4.2 Attempted Reduction of Nitrile Compound 116a to Form 70
The target amino methyl compound 70 incorporated a basic nitrogen in an effort
to introduce α1A adrenoceptor antagonism. It was planned that this amine could be made
by reduction of the nitrile in 116a, with concomitant acetate cleavage. There are many
reducing agents available, including numerous hydrides. A very common reagent is
lithium aluminium hydride (LiAlH4). This reagent has previously been used by Pierre et
al188 to reduce a nitrile to an aminomethyl group. Mayer et al189 have also used LiAlH4
to a reduce a phenolic acetate to a phenol.
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a) r.t or 43°C
Scheme 3.22: A reductive synthetic pathway to the target 2-aminomethyl isoflavene
70.

Attempts to synthesise the compound 70 through reduction of 116a were
performed at two temperatures, diethyl ether at reflux and at room temperature (Scheme
3.22). The CI+-MS data showed a M+2 peak at m/z 271, signifying 70 formation.
Analysis by 1H-NMR spectrometry of the crude reaction mixture of both reactions
revealed a diagnostic triplet at 4.34 ppm which was assigned to H-2 and no H-2 peak at
5.14 ppm, also indicating the synthesis of 70. Purification of the desired product was
difficult as it remained on the base line of silica and alumina TLC plates, reflecting the
highly polar nature of the compound. As a result crude material recovery was poor and
attempts at further extractions were unsuccessful at producing more material; this was
thought to be due to strong product coordination with aluminium hydroxide produced
on addition of water during the workup. In an attempt to overcome this by cleaving the
amine-aluminium bond, ethylene diamine was added to the extractions. It was hoped
that the ethylene diamine would preferentially coordinate to aluminium over the
product. However, this approach was unsuccessful at obtaining further material, even
when the ethylene diamine extraction mixture was heated overnight.
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3.3.4.3 Deprotection of the Acetoxy Isoflavene Derivatives
In order to obtain the free phenolic compounds from the diacetoxy isoflavenes
two common methods were used. One involved heating with imidazole in absolute
ethanol at reflux, and the other, milder, method of stirring with sodium hydroxide
solution at room temperature.
Table 9: Yield and method of various 2-substituted isoflavene phenolic acetate
deprotections.

O

OH
O

O

a or b
O

O

R

HO

O

116

R

115
a) 5M imidazole, abs. ethanol, ∆
b) NaOH, rt

Starting
material
116a

Product

R

Method

115a

CN

116f
116h
116i

115f
115h
115i

Allyl
Ethoxy
bromopropoxy

Imidazole
NaOH
Imidazole
NaOH
NaOH

Yield (%) of
115
0
65
97
53
65

Heating imidazole with the 2-nitrile compound 116a did not produce the desired
free phenolic product. The 1H-NMR spectrum of the crude reaction product showed no
observable H-2 proton between 5 and 6 ppm and a messy aromatic section, indicating
degradation of the starting material 116a. There was also no peak in the CI-MS
spectrum indicative of the formation of the desired phenolic product. The reason for the
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failure of this method is attributed to the harsh reaction conditions, which may have lead
to imidazole attacking an isoflavylium salt formed after imidazole based elimination of
the nitrile group.
The desired nitrile product was formed successfully by using a milder method
which involved stirring the isoflavene 116a in a dilute aqueous sodium hydroxide
solution. Evidence for acetate loss is found in the 1H-NMR spectrum by the loss of the
two singlet signals previously attributed to the acetate methyl protons at 2.31 and 2.29
ppm. The

13

C-NMR spectrum also indicated the loss of the acetate groups by the

disappearance of the carbonyl peaks and the methyl peaks of the acetate at 169.1 ppm,
168.9 ppm and 21.1 ppm respectively. Additional structural evidence came from the
absence of methyl proton signals in the DEPT NMR experiment. Confirmation of the
free phenolic form of the product came from the ES-MS which established a small
molecular ion peak at m/z 266.

The deprotection of the allyl isoflavene 116f with imidazole was achieved in a
near quantitative yield of 97%. In the 1H-NMR spectrum of the product 115f no peaks
were present which could be ascribed to the acetate methyl protons while two other
signals at 8.33 ppm and 8.27 ppm, each integrating for 1 proton, were attributed to the
phenolic hydroxyls. Confirmation of the desired product also came from the ES-MS
spectrum which exhibited an M+1 peak at m/z 281. The imidazole method was
successful in this case presumably because elimination of the 2-allyl group would not be
a favourable process. This provides evidence that the C2-CH2(allyl) bond is a
chemically robust carbon-carbon bond.
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Deprotection of the two alkoxy isoflavenes, 115h and 115i to give 115h (53% yield)
to 115i (65% yield) respectively was successfully achieved using sodium hydroxide in
53% and 65% yield respectively. However, the solution of NaOH (0.1M) was less
concentrated compared to that used with the nitrile (1M). The CI-MS spectrum of the
deprotected ethoxy product only exhibited the isoflavylium ion peak at m/z 239 with no
molecular ion, however supportive evidence for 115h was provided by elemental
microanalysis. The CI-MS spectrum of the deprotected bromopropoxy product 115i did
have M+1 peaks at m/z 379/377 (9/10%) and the isoflavylium ion at m/z 239 (100%).
The 1H-NMR and

13

C-NMR spectra of the deprotected compounds lacked peaks

attributable to acetate groups.

3.4

Summary and Conclusions
A new convenient procedure for the synthesis of 2-substituted isoflavenes was

developed using trityl salts and isoflavene precursors. This involved nucleophilic attack
on the isoflavylium ion 117. A range of nucleophiles were utilised, including TMS, tin
and alcohol based nucleophiles. Phenolic acetate protection was found to be compatible
with this procedure, while t-BDMS protection was not. The ethynyl compound 116c
was found to undergo further reaction with an isoflavylium ion to for a dimerised side
product. Acetate deprotection was carried out successfully to produce the new free
phenolic compounds.
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Chapter 4

Derivatisation of the 4-Position of
Isoflavonoids

4.1

Introduction

Many naturally occurring isoflavonoids possess a keto group in the 4-position.
Examples include genistein 4 and daidzein 5. As ketones are synthetically useful
moieties, derivatisation at the 4-position was expected to provide access to a variety of
isoflavonoid derivatives. As ketones are such versatile moieties, it was surprising to find
that there were only 26 publications based on the derivatisation at the 4-keto position in
isoflavonoids (Scifinder Scholar, Nov 2004).
OH
OH

HO

OH

O

4

O

O

HO

5

O

Computational studies contained in this thesis (Chapter 2), identified three target
isoflavonoid-based compounds with new functionalities at the C4 position which could
incorporate the biological activities required. These compounds included the amine 67,
the phenyl hydrazone 76 and the thienyl derivative 71. Compound 67 incorporated a
basic nitrogen desired for α1A adrenoceptor activity. Compounds 76 and 71 incorporated
an aromatic moiety which was predicted to increase 5AR type II activity. Figure 4.1
shows compounds 71 and 76 superimposed on the human 5AR type II pharmacophores
hIIA and hIIB.
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71 on hIIA

Phenylhydraone 76 on hIIA

67 on α1A adrenoceptor

Phenylhydrazone 76 on hIIB

Figure 4.1: Compounds 71 and 76 on the hIIA and hIIb pharmacophores and
compound 67 on the α1A pharmacophore.
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4.2

General synthetic approach
4.2.1

Approach to the Amine 67

It was proposed that an aminomethyl derivative at the 4-position could be
accessed through reduction of a nitrile group, this latter group being introduced in turn
by nucleophilic addition to the C4 carbonyl group (Scheme 4.1). The retrosynthetic
sequence proposed thus involved the key nitrile intermediate 133, which could be
accessed from 134a.
N
H2N

HO

OH

O

O

67

OAc

OAc

AcO

O

AcO

133

O

134a

Scheme 4.1: Retrosynthetic scheme for the synthesis of the 4-amino compound 67.

In the case of the isoflavone 134a, the ketone at the 4-position is an aryl ketone.
This type of ketone is less reactive than an alkyl ketone, and hence for addition to these
types of ketones, the ketone must be activated. For example, Jacobs et al190 have added
a nitrile group (from trimethylsilyl cyanide) to the aryl keto moiety in 135 through
ketone activation by the use of a Lewis acid, BF3 (Scheme 4.2); this resulted in the
cyano ether 136 in good yield. Elimination of the ether group with phosphorus
oxychloride and pyridine then gave the α,β-unsaturated nitrile 137 (Scheme 4.2). In the
case of 134a, acetate protecting groups were incorporated to prevent any competitive
attack on the BF3-activated ketone group by phenolic groups.
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N
N

O

TMSO

TMS cyanide
BF3-etherate

POCl5

135

136

137

Scheme 4.2: Nitrile addition to the benzylic ketone 136 and elimination to the α,β
unsaturated nitrile 137.190

4.2.2 Aryl Hydrazones
Further C4 derivatised isoflavonoid targets included the aryl hydrazone 76.
Hydrazones are easily accessible moieties, with their formation involving a
condensation reaction between a hydrazine and a ketone. For example, with the ketone
138 and phenyl hydrazine 139, the mechanism of formation involves an initial attack on
the ketone 138 by the primary amine 139 and loss of a proton forming the hydroxy
amine 140. Elimination of water then results in the phenyl hydrazone 141 (Scheme 4.3).
H
H
O

O

OH

OH

O

O
NH

N

H

H

138

HN
H2N
HN

HN

140

139

O

N
HN

Scheme 4.3: Mechanism of hydrazone formation.
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The oxime 142 (Figure 4.2) was also a desired target in the current studies in
order to assist with structure-activity relationship (SAR) studies. Oxime formation
proceeds via a similar mechanism to hydrazone formation, with hydroxylamine as the
attacking nucleophile. An isoflavanone 4-oxime has previously been synthesized by
Yamaguchi et al191.

HO

OH
N

HO

O

142
Figure 4.2: The oxime synthetic target 142.

4.2.3

Thienyl Derivatives

The synthetic target 71 (Scheme 4.4) contains an additional thienyl group on the
isoflavonoid skeleton. The formation of a carbon-carbon bond between a thiophene and
the isoflavonoid is required for the synthesis of compound 71.
The carbon-carbon bond formation was required in the 4-position. As the
isoflavone 134 was readily available from Novogen, it was decided that the 4-keto
group was a synthetic handle appropriate for accessing the desired thienyl compound
71.
Addition of the thienyl group was attempted via three distinct synthetic
approaches. The first approach was through direct nucleophilic addition to the 4-keto
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group of 134 with an organozinc bromide reagent, generating the hydroxy intermediate
144 and subsequent dehydration to introduce the double bond. This approach would
involve a common Grignard-type addition to the carbonyl moiety. The second approach
considered was through the synthesis of a triflate intermediate 145 and subsequent
Negishi type coupling with a thienyl moiety through a palladium-mediated reaction. The
triflate intermediate 145 could be obtained through the generation of the enolate ion 146
(Scheme 4.4). This general approach had previously been carried out by Ishizuka et
al192, where they produced a 4-phenylbenzopyran derivative 151 in 99% yield from the
corresponding ketone 147 via 150 (Scheme 4.5).

124

S

HO

S

OH

O

PO

71

OP

O

OP

143
S

OP

PO

PO

OH

S

O

144

O

143

OP
O

OP
OLG

PO
PO

O

134

O

145
OP

LG= leaving group

O

(methoxy or triflate)
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O
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OP
O

PO

O

134
Scheme 4.4: Retrosynthetic analysis of thienyl addition.

The variation of this second approach was based on a precedent reported in a
patent by Ishizuka et al193. In this case the 4-methoxy substituent of the benzopyran
carboxylic ester 148 was substituted with a thienyl group to afford 149 (Scheme 4.5).
This approach was also taken for the synthesis of other 4-alkyl and 4-phenyl
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benzopyran derivatives in good yields. The reagents used for these substitution reactions
were Grignard and organozinc reagents. The substitution was activated through
magnesium and zinc coordination with the ether and carboxylate oxygens.
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Scheme 4.5: Synthetic steps used by Ishizuka et al193 to access 4-substituted
benzopyran derivatives.
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All of these approaches would require protection of the phenolic hydroxyl
groups and this aspect is discussed in the following sections.

4.3

Results and Discussion

4.3.1

Free Phenolic Compound
The 4-ketone derivative 134a was supplied by Novogen. While the acetoxy

protecting groups were expected to be viable ones for the phenyl hydrazone and oxime
reactions, for the projected thienyl bromide reactions, alternative phenolic protective
functionality would be required. In order to protect the ketone isoflavonoid with other
protecting groups, the free phenolic compound 30 had to be made. The most facile
method to the free phenolic compound from the phenolic ester was by reaction with
imidazole. The known phenolic compound 30 was obtained in 93% yield194 (Scheme
4.6). With the phenol 30 in hand, other ether-based protection for the hydroxy groups
was investigated as noted in the following sections.
OH

O
O

O
O
O

5M imidazole
∆
O

O

HO

134a

O

30

Scheme 4.6: Acetate hydrolysis in 134a forming the free phenolic isoflavone 30.

4.3.2

Attempted Cyclohexyl Ether Protection
The cyclohexyl protecting group is not a common phenolic protecting group,

however it has been used previously by Engelhard et al195 for the protection of tyrosine
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152 to produce 153. Ether formation was achieved using cyclohexene and BF3-etherate
(Scheme 4.7) 195

OH

O

BF3-etherate
COOH

152

COOH

153 NH2

NH2

Scheme 4.7: Protection of a phenolic hydroxyls as a cyclohexyl ether.

In order to protect the phenolic hydroxyls of compound 30 with the chemically
sturdy cyclohexyl protecting group, the phenolic compound 30 was treated with
cyclohexene and BF3-etherate (Scheme 4.8). However 134b was not observed and only
starting material was recovered. The reason for the lack of success in this case is not
clear.

OH

O

O

O

BF3.etherate
cyclohexene
HO

O

30

O

O

134b

Scheme 4.8: Attempted cyclohexyl ether protection of the isoflavone 30.
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4.3.1.2 t-BDMS Protection
The t-BDMS group is a common protecting group for hydroxyl groups,
including phenolic hydroxyl groups, and it is stable in Grignard-type reactions.196
Protection of the phenolic hydroxyls in 30 with the t-BDMS group was achieved
by stirring imidazole and t-butyldimethylsilyl chloride at room temperature for 32
hours. This reaction is likely to proceed through an N-t-butyldimethylsilyl imidazole
intermediate.178 This reaction must be performed under rigorously anhydrous conditions
and powdered 3Å molecular sieves were used to assist this. Evidence for formation of
the product 134c was obtained through 1H-NMR and MS data. The 1H-NMR showed
singlet peaks at 0.78 and 0.77 ppm ascribed to the t-butyl groups in the two t-BDMS
groups. There was also a singlet at 0.00 ppm which was ascribed to the trimethyl silyl
groups. The mass spectrum (CI+) of 134c had an M+1 ion peak at m/z 485. A fragment
peak corresponding to t-butyl loss in the mass spectrum, a characteristic of t-BDMS
compounds, was also observed.

4.3.2

Amine Formation
In order to prepare the target amine 67, a facile route involving the reduction of

the 4-nitrile isoflavene 133 was devised (Scheme 4.9). The synthesis of this intermediate
was enabled by TMS nitrile addition to the ketone 134a, resulting in the TMS ether 154
which then underwent an elimination reaction forming the nitrile intermediate 133.
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N

N

OAc
O

OAc

a
AcO

OAc

TMSO

b

O

AcO

134a

H2N

154

OH

O

AcO

133

O

a: p-TsOH/TMSCN, BF3/TMSCN
b: POCl3/pyridine

c
HO

67

O

c: LiAlH4

Scheme 4.9: Synthesis of the 4- aminomethyl target 67.

4.3.2.1 Attempted Acid Catalysed Nitrile Addition
The first step in the proposed synthesis of the isoflavene 67 involved the
addition of the nitrile. This process required the activation of the ketone group and the
first attempts involved the use of a Brönsted acid to do this. The acid, p-toluenesulfonic
acid (p-TsOH) was employed to protonate the carbonyl oxygen.
When the isoflavone 134a was allowed to react with TMS cyanide in the
presence of p-TsOH (Scheme 4.9a) the desired ketone addition was unsuccessful,
yielding only starting material. The reason for the failure of this reaction is probably due
to insufficient protonation of the ketone.
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4.3.2.2 Lewis Acid-Catalysed Addition
Lewis acid activation of ketones for the addition of nucleophiles is a commonly
used method. For example, this approach has been utilized by Jacobs et al190 for the
addition of TMS cyanide to the p-TsOH activated benzylic ketone 155 (Scheme 4.10).
The resulting TMS ether 156 then underwent an elimination reaction using phosphorus
oxychloride and pyridine, producing the double bond nitrile compound 157 in 79%
overall yield.

O

NC

TMSCN
BF3
O

POCl3
pyridine
O

155

CN

OTMS

O

156

157

Scheme 4.10: Nitrile addition to the p-TsOH activated ketone 156 by Jacobs et al and
subsequent elimination to form the α,β -unsaturated nitrile 157.190

In the present work, ketone activation by BF3-etherate was employed for the
synthesis of the nitrile TMS ether 154. The reaction mixture turned a dark brown colour
and compound 154 was produced in ca 5 % yield, however the purity was not high. The
evidence for the synthesis of 154 came from a signal representing the trimethylsilyl
methyls at 0.07 ppm in the 1H-NMR spectrum. A peak at 117.3 ppm in the

13

C-NMR

spectrum corresponds to the nitrile carbon and confirms its addition, along with the
TMS methyl peaks at 0.02 ppm. The low yield observed in this reaction is attributed to
attack on the acetate protecting groups by BF3.
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Ketone activation by BF3-etherate, TMS nitrile addition and subsequent TMS
ether elimination by phosphorus oxychloride did however give the desired 4-nitrile
isoflavene 133 in 12% yield.

13

C-NMR spectral data confirmed the nitrile group

incorporation with the appearance of a new peak at 126.4 ppm. The low yield of this
reaction is probably caused by the deprotection of the phenolic acetates during the TMS
nitrile addition.
Due to time constraints an attempt at the synthesis of the target compound 67 by
LiAlH4 reduction of 133 was not performed.

4.3.3

Oxime and Aryl Hydrazone Formations
The oxime 142 was prepared in 64% yield from the isoflavone 134a on reaction

with hydroxylamine. Evidence for oxime formation came from the CI-MS spectrum,
which exhibited an M+1 peak at m/z 272 as the base peak. Notably this spectrum also
exhibited a fragment peak at m/z 257, corresponding to the ketone 30; this probably
resulted from oxime cleavage during the acquisition of the CI-mass spectrum.
Additional evidence for oxime formation was forthcoming from a comparison of the 1HNMR spectrum of the ketone 30 and the oxime 142. Due to the higher electron
withdrawing properties of the carbonyl moiety compared to the oxime it would be
expected that the H-3 proton, α to the carbonyl carbon (C4) of the ketone 30 would be
further downfield in the 1H-NMR spectrum than the H-3 signal in the oxime 142.
However this was not observed in the 1H-NMR spectrum with the H-3 of the ketone 30
represented by the peak at 3.83ppm and the H-3 proton of the oxime represented by the
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peak further downfield at 4.51 ppm (Table 10). The reason for the H-3 proton appearing
more downfield in the oxime in the 1H-NMR spectrum can be explained by taking into
consideration intra-molecular electronic interactions between the benzylic H-3 proton
and the oxime oxygen, when 142 has an E configuration. This configuration would be
favoured due to this electronic interaction; also the Z conformation would encounter
steric clashes between the oxime hydrogen and the H-5 proton. The 1H-NMR spectrum
contains further evidence for oxime formation when examining the peaks attributed to
the H-2 protons and comparing them to the isoflavone 30 peaks. The peaks for the H-2
protons in the oxime appear at 4.39 and 4.21 ppm as doublets of doublets. As the H-2
protons appear as doublets of doublets and appear at two different places in the 1HNMR spectrum it is apparent that they are non-equivalent. This non-equivalence arises
from the lack of rotation due to the rigidity of the pyran ring.

H
N

O
H
OH

HO

O

H
H

142
Figure 4.3: Structure of the oxime 142.

The two phenolic acetate groups were removed during the oxime formation as a
result of the nucleophilic attack by the nitrogen of the free amine on the carbonyl of the
acetate group (Scheme 4.11). CI-MS spectral analysis of the crude reaction mixture at
2hr revealed the mass of the mono-deprotected 158 (m/z 299) and the fully deprotected
ketone 30 (m/z 341) and no 142. From this CI-MS spectrum it was apparent that the
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acetate groups were removed prior to oxime formation (Scheme 4.11). As the C4 ketone
is electron withdrawing rendering the para C7 pyran oxygen delta positive and therefore
more electrophilic the C7 acetate group would then be attacked first before the C4’
acetate group (Scheme 4.11).
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Scheme 4.11: Stepwise acetate deprotection and Oxime/Hydrazone formation.

Reacting aryl hydrazines with the isoflavone 134a produced the aryl hydrazones
76 and 159a-g in 34%-82% yield (Table 10). Where the aryl hydrazine was supplied as
the hydrochloride or hydrobromide salt, sodium acetate was used to generate the free
hydrazine.
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Table 10: Tabulation of the yields, proton and carbon NMR chemical shifts for H-2,
H-3, C2 and C4 for the ketone 30, oxime 142 and aryl hydrazone 76 and 159a-g
compounds synthesised.
R
NH

OH

N

HO

O

159
Compound
Number
30

R
-

Yield
(%)
N/A

142

-

64

4.39, 4.21
(d of d)
4.36 (d of
q)
4.42, 4.33
(d of d)
4.46, 4.37
(d of d)
4.39, 4.35
(d of d)

70.9

H-3
H-NMR
3.83 (d of
d)
4.51 (bd)

71.5

4.20 (bs)

38.7

71.4

4.29 (bs)

38.7

71.4

4.34 (bs)

38.7

71.9

4.23 (t)

40.5

71.3

4.25 (bs)

39.0

73.1

4.18 (bs)

39.8

59

4.48, 4.35
(d of d)
4.37 (d of
q)
4.37 (m)

76.5

43.9

34

4.41 (bs)

71.8

4.49 (d of
d)
4.39 (bs)

82

76
Cl

159a

64
56

159b
Cl

159c

62

Cl

NO2

159d

67

159e
CN

159f
159g

69

N

H-2
H-NMR
4.53 (d)

1

13

C2
C-NMR
72.0

1

13

C3
C-NMR
51.1
60.8

39.3

b, broad; s, singlet ; d, doublet; t, triplet; q, quartet; m, multiplet.

It was noted that during the synthesis of the oxime the phenolic acetate
protecting groups were lost. CI-MS analysis during the formation of the unsubstituted
phenyl and p-chlorophenyl hydrazones at two hours revealed that the acetate groups
were lost before the formation of the hydrazone. The benzopyran phenolic acetate
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would be removed before the 3-phenyl phenolic acetate for the same reasons as
mentioned for the oxime.
Evidence of aryl hydrazone formation came from the CI-MS data for the
products 76 and 159a-g. MS spectra supplied the molecular ion peaks (M+1) with
intensities between 22% and 100%, with the exception of the p-nitrile phenyl hydrazone
160f which gave a M-1 peak (7%). For CI-MS spectra the base peak corresponded to
the ketone compound 30. This peak arises from the hydrolysis of the hydrazone
products. This hydrolysis occurs as all the steps of the reaction mechanism for the
formation of the hydrazones are reversible (Scheme 4.3).
Additional evidence for the formation of the hydrazone products came from the
1

H-NMR spectra. It was expected that the peak representing the H-3 proton of the

hydrazone products 76 and 159a-h would be further up-field than in the ketone 30, as
oxygen is more electronegative than nitrogen. However, this was not the case as can be
seen in Table 10. All H-3 protons produced peaks in the 1H-NMR spectrum between the
range of 4.20 ppm and 4.48 ppm, while the H-3 proton of the ketone appeared further
up-field at 3.83 ppm. This result is attributed to electronic interactions between the
nitrogen of the hydrazone bond and the H-3 proton similar to the oxime (Figure 4.3).
The 13C-NMR provided further evidence for the formation of the aryl hydrazones from
the up-field shifting of the C3 carbon signal from 51.1 ppm in the ketone 30 to a range
of 38.7 ppm to 43.9 ppm in the aryl hydrazones 76 and 159a-g.
Two doublets of doublets in the 1H-NMR spectra provide additional evidence
for the formation of the hydrazone products. These peaks were ascribed to the H-2
protons. This pattern was found in all hydrazone products with the exception of the
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hydrazones 160e-g. This pattern in the 1H-NMR spectrum is caused by the H-2 protons
becoming non-equivalent upon hydrazone formation. The H-2 protons in the 1H-NMR
spectrum of the p-CH3 compound 159e appeared as a doublet of quartets at 4.37 ppm.
The doublet splitting was due to non-equivalent H-2 protons and provides evidence for
the formation of the hydrazone 159e. The H-2 protons of the p-nitrile phenyl hydrazone
compound 159f appeared as a multiplet at 4.37ppm and integrated for two protons. In
the 1H-NMR spectrum of the pyridyl hydrazone, the signal for the H-2 protons was
ascribed to a broad singlet at 4.41 ppm and integrated for two protons.
In the 13C-NMR spectrum of the aryl hydrazone products the peaks attributed to
the C4 carbon were observed between 140.3 ppm and 154.5 ppm, consistent with
hydrazone formation. The C4 carbon in the ketone appeared at 191.4 ppm. The peaks
attributed to the C4 carbon were shifted up-field in the 13C-NMR spectrums of the aryl
hydrazone products 76 and 159a-g due to the weaker electron withdrawing properties of
the hydrazone nitrogen compared to the carbonyl oxygen, providing substantiation for
hydrazone formation.
Interestingly the p-nitrophenyl hydrazone synthesis also produced the diacetate
protected phenyl hydrazone 160 (Figure 4.4).
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Figure 4.4: Structure of the diacetate protected phenyl hydrazone 160.

Attempted Synthesis of the Diphenyl Hydrazone 161
In order to increase structural diversity in the aryl hydrazone derivatives, the
diphenyl hydrazone derivative was considered as a synthetic target. As the diphenyl
hydrazone isoflavonoid possessed an extra phenyl ring compared to the aryl hydrazones
in Table 10, it was thought that this would increase 5AR inhibition. Diphenyl hydrazone
synthesis was attempted through hydrazone formation from the diphenyl hydrazine and
ketone 134a. As the diphenyl hydrazine was supplied as the hydrochloride salt, sodium
acetate was added to the reaction to create the free hydrazine in situ (Scheme 4.12).
However no diphenyl hydrazone product was observed even after heating at reflux
overnight. The only compound isolated from this reaction was the free phenolic ketone
intermediate 30. The failure of this synthesis is most likely due to the high steric bulk of
the diphenyl hydrazine.
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Scheme 4.12: Attempted synthesis of the diphenyl hydrazone 161.

Attempted Imidazolyl Hydrazone and Pyrimidyl Hydrazone Synthesis
In an attempt to synthesise the imidazolyl hydrazone 162 and the pyrimidyl
hydrazone 164, the isoflavone 134a was reacted with the respective hydrazines. As the
imidazole was supplied as the hydrobromide salt sodium acetate was added to the
reaction to create the hydrazine in situ. These attempts were unsuccessful at producing
the desired products. The attempted imidazolyl hydrazone synthesis unexpectedly
produced the benzofuran 163 (Scheme 4.12). The formation of this compound was
confirmed by CI-MS,

1

H-NMR and

13

C-NMR. The endeavour to synthesis the

pyrimidine hydrazone 164 by reacting the isoflavone 134a with p-trifluoromethane
pyrimidyl hydrazine, did not return any identifiable product.
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Scheme 4.13: Attempted synthesis of the imidazolyl hydrazone 162 and the pyrimidyl
hydrazone 164.

The possible mechanism for the formation of the benzopyran 163 during the
attempted synthesis of the imidazole hydrazone 162 could involve an initial enamine
tautomerisation forming 165. As the imidazole nitrogen is quite basic, the 2-amino
substituent becomes a good leaving group and the pyran oxygen then attacks C3
facilitating the construction of an imine. This would give the short lived oxiranium
intermediate 166. As this reaction was not performed in an anhydrous manner, water
could attack the oxirane 166 giving the benzofuran 167. The loss of formaldehyde
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provides the benzofuran 168, which could then undergo imine hydrolysis provide the
benzofuran 163.
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Scheme 4.14: Proposed mechanism for the production of the benzofuran 163 from
the attempted imidazole hydrazone synthesis.
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4.3.4

Thienyl Group Addition

4.3.4.1 Attempted Direct Addition
Additions of Grignard reagents to isoflavones 169 has been performed by
Irmscher et al197, producing the aryl alcohols 170 in good yield. (Scheme 4.15). The aryl
alcohols 170 then underwent acid-catalysed dehydration to form the respective
isoflavenes 171.

H

H

O

R4

OH

R4MgBr
R7

O

R2

R7

169

O

R2

170
R4

H+
R7

O

R2

171
R2=H/ethyl, R4=Ph/cyclohexyl/ethyl/p-OCH3Ph, R7=H/CH3O
Scheme 4.15: Grignard addition to the isoflavones 169 and subsequent acid catalysed
dehydration producing the isoflavenes 171.

It was noted that reactions with some aryl alcohols produced ring opened
products. Irmscher et al197 also noted the formation of two ring opened side products
174 and 175 in the Grignard reaction. They proposed a mechanism for the ring opening
(Scheme 4.16). This involved α-proton abstraction and the initial formation of the
enolate anion 172. Electron distribution then ring opening resulted in the restoration of

142

the ketone and the migration of the negative charge to the former pyran oxygen,
affording a stabilized phenoxide anion 173. The Grignard reagent then may react with
the β-unsaturated carbon or to the ketone of 173, producing the ring opened products
174 and 175 respectively.
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Scheme 4.16: Mechanism proposed by Irmscher et al197 for the ring opened products
174 and 175 produced during the Grignard additions with isoflavones 169.

In order to explore this chemistry further, the synthesis of the hydroxy
methylthienyl isoflavonoid 144 through a direct Grignard-type addition to the
isoflavone and subsequent dehydration was undertaken. In an attempt to achieve dual
α1A adrenoceptor antagonism and 5AR inhibition in the one molecule, the ultimate 2,4disubstituted isoflavene target 78, was thought to be accessible by first synthesising the
4-thienyl isoflavene 144 then executing 2-substitution giving 176, it was desirable that a
protecting group be stable during both reactions (Scheme 4.17). During this project the
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t-BDMS and acetate protected isoflavones 134 were readily accessible. Even though the
t-BDMS protecting group would be stable to a Grignard reagent, the thienyl zinc
bromide reagent was used because it was not expected to react with either t-BDMS or
acetate protecting groups, and the latter would also be suitable for later 2-substitution of
the isoflavene (see Section 3.3.3.1 for more detail).
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Scheme 4.17: Synthetic route to achieve the 2,4-disubstituted isoflavene 78.

Reaction of the isoflavone 134c with the thienyl zinc bromide reagent 177, was
undertaken at room temperature (Scheme 4.18). This reaction provided the
corresponding thienyl alcohol 144 in 40% yield, as estimated by 1H-NMR analysis of
the crude material. It also unexpectedly provided a benzofuran compound 178 which
possessed an exocyclic double bond in 60% yield, as ascertained by 1H-NMR analysis.
Purification of these compounds from the reaction mixture through silica gel
chromatography was successful, although it was not reproducible under all conditions.

144

When the chromatography was performed rapidly (25 minutes), the thienyl alcohol 144
was obtained in only 8% yield, while the benzofuran compound 178 was obtained in
80% yield. Notably when the chromatography was performed more slowly (1 hour)
only double bond compound 178 in 91% yield and no thienyl alcohol 144 was
recovered. This indicated that silica gel is converting the thienyl alcohol 144 into the
double bond compound 178. Attempts to purify products by chromatography using
alumina was surprisingly also unsuccessful and none of the product 144 or side-product
178 was isolated.
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Scheme 4.18: Products from reaction with the isoflavone 134c with the thienyl zinc
bromide reagent 177.
In the 1H-NMR spectrum of the desired thienyl alcohol compound 144 a triplet
at 4.65ppm was ascribed to the H-3 proton. Two doublet of doublets signals at 4.44ppm
and 3.16ppm each integrating for one proton were ascribed to the H-2 protons. The fact
that the peaks for the H-2 protons had separated into two positions and that they
appeared as doublets of doublets, indicated that these protons were not chemically
equivalent and were in fact diastereotopic. The 1H-NMR spectrum also provided further
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evidence for the methyl thienyl compound 144 with the presence of doublet peaks
corresponding to the H-3” and H-4” protons at 6.68 ppm and 6.98 ppm respectively and
the methyl group was assigned to a singlet at 1.96 ppm with an integration of 3 protons.
The singlet peak at 12.69 ppm was attributed to the hydroxy proton. The

13

C-NMR

spectrum also confirmed the synthesis of the thienyl alcohol by the thienyl carbons C3”
and C4” appearing as peaks at 129.9 ppm and 122.4 ppm. The peak at 22.8 ppm was
ascribed to the methyl carbon. Confirmation of the thienyl alcohol 144 was also
provided by ES+-MS with an M+1 peak appearent at m/z 583 and an M-1 peak from ES-MS at m/z 581. The base peak (m/z 313) in the ES+-MS spectrum corresponded to that
for the ketone 134c consistent with the loss of a methyl thienyl fragment. This indicated
that the methylthienyl fragment was a better leaving group than the hydroxy moiety.
Elemental microanalytical data for the thienyl alcohol 144 was also consistent with this
formula.
The benzofuran side-product 178 produced by the thienyl zinc bromide addition
was identified through ES-MS, 1H-NMR and

13

C-NMR spectroscopy and elemental

microanalysis. The ES+-MS contained a base peak at m/z 485 corresponding to either
the benzofuran 178 or the ketone starting material 134c, as did the elemental
microanalysis results. However the ketone starting material 134c was ruled out as the
1

H-NMR spectrum did not correspond with previous

1

H-NMR spectra of this

compound. The 1H-NMR spectrum contained diagnostic singlets for the five-membered
ring compound 178 at 5.66 ppm and 5.16 ppm integrating for one proton each. The gHSQC spectrum revealed that the proton associated with these peaks was attached to the
same carbon, substantiating the presence of the exocyclic double bond. Comparable
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exocyclic vinylic protons from a benzofuran have been reported at 4.2 and 4.6 ppm.198
Additional evidence that the side product 179 also contained a benzylic hydroxyl group
came from the 1H-NMR spectrum which contained a singlet at 12.30 ppm. This
hydroxyl peak appeared in a similar position in the thienyl alcohol 144 (12.69 ppm).
The proposed mechanism for the formation of the unusual product 178 in acidic
environments such as silica gel involves the loss of the H-3 hydrogen as a proton
resulting in the loss of the thienyl group and the formation of the 4-hydroxyisoflavene
179. An indication that the thienyl group is a better leaving group than the hydroxy
group under acidic conditions is contained in the ES-MS spectrum of the thienyl alcohol
144 as the base peak observed corresponded with a fragment without the thienyl group.
Ring opening could then occur through isomerisation of the enol 179 to the α,βunsaturated ketone 180. Attack of the phenolic anion (or the phenol itself) at the keto-α
carbon, aryl group migration and keto group attack could then form the benzofuran
compound 178. (Scheme 4.19) Such a rearrangement and ring contraction does not
appear to have been reported previously in the literature.
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Scheme 4.19: Proposed mechanism for the formation of benzofuran 178.

The next stage in the synthesis of the thienyl isoflavene 71 involved the
dehydration of the thienyl alcohol 144. As the thienyl alcohol 144 was isolated in poor
yield, it was decided to attempt subsequent dehydration reactions on crude material. 1HNMR spectroscopic analysis of the crude material revealed that 40% of it was the
thienyl alcohol 144, and this was taken into account when yields were calculated. There
are numerous reagents facilitating dehydration reactions, but only CuSO4, P2O5 and the
Burgess reagent were trialled here.

Anhydrous CuSO4 has previously been used for the dehydration of various
primary, secondary and tertiary alcohols176. These alcohols were dehydrated at
temperatures between 95ºC and 180ºC, over 0.5h to 15 h, with yields in the range of 495%.
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An attempt to use CuSO4 for the dehydration of the thienyl alcohol 144 was
unsuccessful as this only returned starting material. As this reagent was successful for
the dehydration forming the 4-unsubstituted isoflavene 118, a plausible reason for the
dehydration failure for compound 144 is due to steric hindrance caused by the thienyl
group, hindering copper complexation to the tertiary hydroxyl group.
An attempt to dehydrate the thienyl alcohol 144 using P2O5 was then performed
on crude reaction material from the thienyl addition, as there were problems associated
with the purification of the thienyl alcohol 144. Unfortunately dehydration did not occur
with P2O5 and unexpectedly only returned the initial ketone starting material 134c in
31% yield; no other products were obtained. Assuming that the ketone came from the
thienyl alcohol 144, a proposed mechanism is presented in Scheme 4.20.

This

mechanism initially involves the formation of the phosphoric ester 181 and subsequent
attack on the P=O bond to afford the intermediate 182. Elimination of the
methylthiophene would then form the ketone 134c.
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Scheme 4.20: Generation of the ketone 134c starting material from the thienyl
alcohol during the attempted P2O5 dehydration.
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A further attempt at dehydration was carried out utilizing the Burgess reagent
((methoxycarbonylsulfamoyl)triethylammonium hydroxide inner salt). Since Burgess et
al 199 described their mild method for the dehydration of secondary and tertiary alcohols
in the 1970s, a number of applications have been described in the literature, especially
towards the synthesis of natural products. For example, the formation of the exocyclic
double bond in 184 from 183, which then facilitated the synthesis of the oxygencontaining four membered ring in taxol 185200 (Scheme 4.21). Another example of the
use of the Burgess reagent is in the synthesis of the anti-tumour

alkaloid (+)-

narciclasine 188201, an alkaloid from the Amaryllidaceae. The Burgess reagent was used
for the formation of the endocyclic double bond in the narciclasine precursor 187 from
186 (Scheme 4.21).
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Scheme 4.21: Examples of the use of Burgess reagent in the synthesis of Taxol 185
and (+)-narciclasine 188 for the formation of exocyclic and endocyclic double bonds.

A reaction mechanism for dehydration of alcohols using the Burgess reagent has
been proposed by Rinner et al202. This involves initial attack by the hydroxyl oxygen of
189 on the sulfur displacing the tertiary amine of 190. The negatively charged nitrogen
is then able to act as a base for the β-proton, resulting in syn-elimination of the
intermediate sulfamate 190 and formation of the alkene 191 (Scheme 4.22).
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Scheme 4.22: Reaction mechanism for the Burgess reagent alcohol dehydration
reaction.202

The Burgess reagent was trialled on a sample of the crude mixture of the thienyl
alcohol 143 and the benzofuran 178,. Although the Burgess reagent was successful for
the examples in the previous paragraph, it did not form the desired dehydrated product
from 143 and gave a mixture of unidentified compounds. As a result attention was
turned to an alternative approach to the 4-thienyl isoflavene 78 via an enolate anion.

4.3.4.2 Attempted 4-Thienyl Isoflavene Synthesis through Enolisation and Negishi
Type Couplings
An alternative route to isoflavenes starting from an isoflavone is through αproton abstraction and enolate anion formation. Enolisation produces the isoflavene
double bond and the anionic 4-oxygen is then able to attack an electrophile. OAlkylation or O-acylation would then give isoflavenes such as 148 or 150 respectively
(Scheme 4.5). This general approach has been used successfully by Isizuka et al192
(Scheme 4.5).
In an attempt to synthesise the thienyl isoflavene 71 it was decided to explore
the potential enolate anion route (Scheme 4.23). It was planned that once the enolate
anion 146 was generated, reaction with either of the electrophiles methyl iodide or N-
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phenyl bis(trifluoromethane) sulfonimide would produce the intermediates 145a
(R=CH3) and 145b (R=SO2CF3) respectively. A Negishi type coupling with the
methylthienylzinc bromide would then provide the methylthienyl isoflavene 143.
Deprotection would then afford 71.
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Scheme 4.23: Synthetic route resulting in the 4-thienyl isoflavene 143 through the
enolate anion 146.

Negishi couplings typically use a nickel or palladium-based catalyst to couple a
zinc halide with a halide, triflate or phosphine. Corley et al203 have combined
Cl2Pd(dppf) and CuI to catalyse the coupling between the triflate 192 and the zinc
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iodide 193 to give 194 in 41% yield (Scheme 4.24). A nickel based catalysis was
involved in the Negishi coupling of the coumarin phosphate 195 and a thienyl zinc
bromide to produce the 4-thienyl coumarin 196 in 90% yield. 204

IZn

OTf

+

HOOC

N
Boc

3mol% Cl2Pd(dppf)
6mol% CuI

N

HOOC

192
193
dppf=[1,1’-bis(diphenylphosphino)-ferrocene]

Boc

194

S
OPO(OEt)2

BrZn

S

1mol% NiCl2(dppe)

+
O

O

O

195

O

196

dppe=(diphos)1,2-Bis(diphenylphosphino)ethane
Scheme 4.24: Examples of a palladium catalysed Negishi coupling between the
triflate 192 and the zinc halide 193203 and a nickel based coupling to achieve the 4thienyl coumarin 196204.

In order to determine the stability of the enolate anion 146 the t-BDMS
protected isoflavone 134c was treated with the strong base sodium hydride. This
abstracted a proton from the 3-position of the isoflavone 134c and generated the enolate
anion 146. This produced a characteristic yellow colour in the reaction mixture for the
anion. The reaction mixture was then treated with an aqueous work up. When this was
performed at room temperature the ketone 134c was produced in 85% yield and the
benzofuran side product 178 was produced in 15% yield. The formation of 178 suggests

154

the partial instability of the enolate anion which must proceed via a ring opening and
aryl migration reaction in order to produce 178 (Scheme 4.25).
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Scheme 4.25: Addition of water to the enol tautomer 146 which gave a mixture of the
starting ketone 134c the benzofuran 178.

One pot generation of 146, triflation and a subsequent Negishi coupling attempt
between the triflate 145a (R=SO2CF3) and methylthienyl zinc bromide was attempted.
Unfortunately the desired 4-methylthienylisoflavene 143 (Scheme 4.23) was not
observed in the 1H-NMR spectrum of the crude final reaction product. In an attempt to
determine whether the failure of this reaction was associated with the Negishi coupling
step or the synthesis of the triflate intermediate 145a, an effort to isolate or observe the
triflate intermediate 145a was made. This attempt was unsuccessful as no material was
returned after purification and it could not be verified whether the triflate intermediate
145a was synthesised.

A trial reaction to produce the 4-methoxy isoflavene 145b (R=CH3) was
performed to investigate the reactivity of the enolate 146 in view of the failure to isolate
the triflate intermediate 145a (R=SO2CF3). It was also hoped that the 4-
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methoxyisoflavene 145b would serve as alternative Negishi coupling agent (Scheme
4.4). Upon generation of this anion at -48ºC with sodium hydride, methyl iodide was
added (Scheme 4.23), forming the 4-methoxy isoflavene 145b (R=CH3) in 63% yield.

1

H-NMR spectrum provided evidence for the synthesis of the 145b (R=CH3).

No signal was present which could be ascribed to the H-3 proton, while a singlet
ascribed to the H-2 protons appeared at 4.57 ppm. The 3-proton singlet at 3.85 ppm was
assigned to the protons from the methoxy substituent. Also the carbon of this substituent
was attributed to the peak at 30.9 ppm in the 13C-NMR spectrum. A peak assigned to the
C4 carbon was present at 133.4 ppm in the

13

C-NMR spectrum. An M+ ion was

observed in the ES+ mass spectrum at m/z 498.

Ishizuka et al192 have utilised 4-methoxy benzopyran 148 (Scheme 4.5) in a
Grignard coupling with a methylthienyl magnesium bromide to afford the 4-thienyl
benzopyran. Attempts to utilise the 4-methoxy isoflavene 145b (R=CH3) in a similar
Negishi-type reaction were carried out, however this reaction returned 90% of the
starting material and a small amount of an unknown compound. A further attempt to the
4-methoxy isoflavene 145b (R=CH3) utilizing NiCl2 as a catalyst in this type of
coupling returned only the same unknown compound in good yield and no starting
material was recovered. Due to time constraints of this project further attempts to
synthesise the 4-thienyl compound 71 were not carried out.
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4.3 Summary and Conclusions
Nitrile addition to the isoflavone 134a was achieved through BF3 activation of
the isoflavone 134a, however in poor yield, subsequent reduction was achieved
however purification of the desired product was not accomplished. Eight aryl
hydrazones were obtained through reaction of the isoflavene 134a with the
corresponding hydrazine. A rearranged benzofuran product 163 was obtained from the
attempt to synthesise the imidazole hydrazone in a similar manner. Efforts to achieve a
4-methylthienyl isoflavene were undertaken, however unsuccessfully. These also efforts
uncovered a new rearrangement producing the novel benzofuran 178.
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Chapter 5 Development of the 5-α-reductase type I assay
5.1

Introduction
As mentioned in Chapter 1, the 5-α-reductase (5AR) enzyme plays a role in

many disorders and diseases, including some prostate cancers. The 5AR enzyme
catalyses the synthesis of dihydrotestosterone (DHT) 2 from testosterone (T) 1 (Scheme
5.1). The 5AR enzyme employs NADPH as a hydride source for the reaction. There are
two isozymes of 5AR, type 1 and type 2, which are encoded by from two different
genes and, other synthesis are distributed differently throughout the body. The 5AR type
1 is the dominant isozyme in the skin, while 5AR type 2 is the dominant isozyme in the
prostate. They also bind inhibitor molecules with different affinities. The isozymes also
differ between species.
OH
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5-α-reductase
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1 (T)

2 (DHT)

O

Aldosterone
Synthase

O

(A)

Scheme 5.1: The conversion of testosterone (T) 1 to dihydrotestosterone (DHT) 2 and
androstenedione (A) by the 5-α-reductase enzyme and the metabolism of T by
aldosterone synthase to androstenedione.
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Both hormones T and DHT act individually as growth promoters upon
binding to the androgen receptor, however DHT is forty times more potent as a growth
promoter than T. This conversion can be upregulated in some prostate cancers and in
such cases inhibiting this conversion is a beneficial treatment. It should be noted that
androstenedione (A) is another metabolite of T, and this conversion is carried out by the
aldosterone synthase enzyme.

There is currently only one drug clinically available as a selective 5AR type 2
inhibitor, namely Finasteride 7 (Figure 5.1). Finasteride 7 has a steroidal structure and
therefore patients may suffer from steroidal side effects including sterility. The dualisozyme 5AR inhibitor, Dutasteride 8, is currently in clinical trials which also has a
steroidal structure and therefore will also produce steroidal side effects. As there is only
these two steroidal compounds which are available for 5AR inhibition there is a great
need for new compounds, and, preferably, ones not based on a steroidal core.
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Figure 5.1: The structures of Finasteride and Dutasteride.

As 5AR is a nuclear membrane enzyme, there is no crystal structure available
and therefore small molecule inhibitor design must rely on other methods. Chapter 2 of
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this thesis has detailed ligand-based pharmacophore generation for human 5AR type 1
and type 2 isozymes. The 5AR type 1 pharmacophore (Figure 5.2) generated contained
three features (HBA, hydrophobic and hydrophobic-aromatic) and one pseudo-feature
(HBA). The presence of the pseudo-feature in a pharmacophore is considered to render
the pharmacophore non-valid. The statistics of the pharmacophore also rendered the
pharmacophore non-valid. The reason for the non-validity of the pharmacpohore is that
the training set used for the generation was too small, with only fifteen compounds
included, where 14 compounds is normally considered to be the minimum number of
compounds in a training set for a quality pharmacophore generation. As the number of
non-steroidal compounds assessed for their 5AR type 1 inhibitory activity is limited, it
was decided that additional compound testing for 5AR type1 activity was required.

N

O

R
R

37
N

Figure 5.2: The 5AR type 1 pharmacophore hI with the most active molecule in the
training set mapped onto it.
The wire cage spheres represent the pharmacophore features. For hydrogen bond
acceptor (HBA) the smaller sphere represents the area where the feature of the
molecule lies during the mapping, and the larger sphere represents the interaction point
of the enzyme. The coloured circles on the two dimensional chemical structures show
where a feature has been mapped onto a compound.
Colour coding: blue, hydrophobic aromatic; light blue, hydrophobic; green, HBA.
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5.2

5AR Type I Testing
There are various ways of performing a 5AR inhibitory assay. These include

whole cells assays, extracted protein assays, partially purified protein assays and
enzyme expressed assays.
While there are a variety of 5AR sources, they can be categorised into one of
two classifications: tissue sources or cell cultures. Obtaining 5AR from a tissue source
involves collecting from an animal an organ or tissue and homogenising it until there is
no structure on the tissue level. This method is more likely to afford the native 5AR
enzyme, than materials from a cell culture. Human 5AR tissue sources include human
scalp tissue and prostate tissue for the 5AR type 1 and type II isozymes
respectively.205,206 Cell culture sourcing involves the source of a cell culture which
produces the required enzyme protein. Many prostate cancer cell lines are available
including the LNCaP (androgen-dependent, 5AR type I)207, PC3 (androgen independent,
5AR type I)208, Du145 (5AR type I209 and type II208) cell lines. This method involves an
increased risk of mutation as cell cultures are cancerous cells which are known to have a
higher probability of mutation than non-cancerous cells.

5.2.1

Whole Cell Assays
5AR whole cell assays have been carried out by Picard et al210 and Kaefer et

al206 on DU145 cells and by Kaefer et al206 from human scalp homogenates. This
method involves incubation of T and inhibitor with the whole intact cell and subsequent
analysis of the percentage conversion to DHT.
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The advantage of this method lies in its simplicity. However the disadvantage
lies in the accuracy of the results. The results here are dependent on a number of
interfering factors. One of these factors originates from the inhibitor diffusing into the
cell, as different may have different hydrophobicities, therefore their diffusion rates will
be different and as the 5AR enzyme is a nuclear membrane protein the actual
concentration of inhibitor will differ in the vicinity of the enzyme, producing inaccurate
results. Another source of inaccuracy comes from other proteins within the cell which
may bind or modify the inhibitor, hence changing the concentration at the enzyme.

5.2.2

Extracted Protein Assays
Negri-Cesi et al207 have performed a 5AR assay using LNCaP cells as the 5AR

source. Protein extraction assays involve lysing a cell, discarding all the cell debris and
extracting the protein contents of the cell. The protein contents are then incubated with
T and inhibitor and subsequent analysis of percentage conversion of T into DHT affords
an estimate of enzyme inhibition.
The advantage of using this method over the whole cell assay method arises
from the lack of a cell membrane through which the inhibitor has to diffuse. This results
in a more accurate assay as the concentration of inhibitors in the region of the enzyme is
kept constant. However, as the 5AR protein is not purified and there other proteins
which may bind or modify the inhibitor.
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5.2.3

Enzyme Expressed Assays
Relatively recent technology has allowed enzyme assays to be performed in an

extremely accurate manner. This technology is based on enzyme expression assays.
These assays entail the expression of a particular enzyme DNA on the cellular
membrane of CHO cells. The DNA of the enzyme has been transfected into these cells.
This enables the assay to be executed with the highest purity of the enzyme and no other
protein expression to interfere inhibitor metabolism or binding and without diffusion
factors which produce inaccuracies. Difficulties can be encountered with the method as
a result of the high level of accuracy required by the method. This method, has
previously been used by Guarna et al205 for the 5AR type I enzyme.

5.3

Methodology for Assay Development
In the current work, an in-house assay was developed based on the requirement

for data on a greater number of training set inhibitors for the refinement of the 5AR type
I pharmacophore. The source of 5AR type I used for the assay was the prostate cancer
cell line, LNCaP. This cell line has been shown to contain 5AR type I and not 5AR type
II isozymes by Negri-Cesi et al.207 LNCaP cells are known to grow in an androgen
dependant manner.211 As it was not known whether the 5AR enzyme is up- or downregulated in the presence of androgen during cell culture, the assay was performed on
protein extracted from both testosterone treated and untreated cells.
Protein concentration determinations were carried out according to Pearsons
method.212 Protein extraction assays were chosen as the most appropriate and
manageable assay type to undertake. Tritiated testosterone was used to trace
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testosterone metabolism. With tritium radiation, the β particle (an electron) may be
detected in various ways, including scintillation counting and development of a
photosensitive film.
Tritiated T was used and two methods were trialled for T and DHT detection:
TLC

photo-development

and

scintillation

counting.

Photo-development

was

unsuccessful as it required over two weeks for development which was not an
acceptable time frame. Scintillation counting was successful as it was sensitive enough
to detect a dilution series of tritiated testosterone (Figure 5.3).
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Figure 5.3: Scintillation counts of various amounts of β particles from tritiated
testosterone.

5.4

Results and Discussion of the 5AR Assay
The method chosen for separating T and DHT was by TLC on silica gel with a

mobile phase of 15% ether in DCM (Scheme 5.4).157 As the tritiated testosterone and
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tritiated metabolite concentrations on the TLC were too low to view by UV light the
TLC plates were spiked with additional untritiated T, A and DHT. T and A were
detected under UV light at 254nM, however DHT was detected by the heat-assisted
development of a molybdate dip. Each spot was then scraped off the TLC plate and βradiation counts obtained. As molybdate dip was contained in the assay samples,
scintillation from controls with varying concentrations of tritiated testosterone from a
molybdate stained TLC plate were compared to counts from a non-stained sample with
the same concentration of tritiated testosterone to determine whether the molybdate dip
affected the scintillation counts. The molybdate dip samples were found produce the
same scintillation counts as the corresponding samples from the non-molybdate dip
treated set.

Androstenedione
Dihydrotestosterone

Testosterone

Figure 5.4: TLC plate for the separation of testosterone and its metabolites
Androstenedione and dihydrotestosterone.
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As can be seen in Figure 5.5, it was quite clear that at 500nM assay activities
using protein extracts from both testosterone treated and untreated decline with
increased inhibitor concentration. It was noted that for the assay which used protein
from testosterone treated cells the activity dropped to about half when incubated with
500nM Finasteride. Since the human 5AR type I IC50 for Finasteride 7 has been
reported as 410 nM,213 this assay was considered to be consistent with IC50 data
reported for this compound in the literature.
Published assays have used various concentrations of testosterone. During the
development of the 5AR assay the concentration of testosterone was adjusted so that the
experimental IC50 value of Finasteride 7 matched the literature value. Figure 5.5 shows
the results of an assay determining the optimal concentrations for the assay. It can be
seen from Figure 5.5b that testosterone concentrations of 10nM to 100nM using
extracts from both testosterone treated and untreated cells had no real decline in activity
as the amount of inhibitor (Finasteride) increased.
These results indicated there may be a negative feedback mechanism with
testosterone incubation of the cells since in the assays where no Finasteride was used
there was significantly more enzyme activity when the cells had not been treated with
testosterone.
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Figure 5.5: Graphical results of the assays containing different concentrations of
testosterone on T treated (T) and untreated (U) cellular protein extracts (a), with an
expansion (b) of the results of the 500nM T assays for T treated and untreated cells.
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Unfortunately, further assays did not reproduce these initial encouraging results.
This appeared to be due to the fact that the LNCaP cell line has mutated and changed its
characteristics. The modified cell line produced less protein, grew more slowly, and
gave decreased 5AR activity and produced increased IC50’s for standard inhibitors in
whole cells assays.
In order to overcome this problem a new batch of LNCaP cells were obtained
from the NCI, however these cells also exhibited signs of contamination. In a further
effort to over come this contamination problem LNCaP cells were obtained from Gillian
Lehrbach at the Garvan Institute, Sydney and the assay was carried out in the School of
Biology, University of Wollongong. The results from this assay are displayed in Figure
5.6. While these results showed a decrease in DHT production as the Finasteride
inhibitor concentration increased, the IC50 value did not match the literature data.
Optimisation to correlate the experimental and literature IC50 values was required to
gain meaningful results from the assay. Due to time constraints it was decided that any
further effort to develop the assay was not possible and that the assay should be
outsourced.
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New Batch Assay
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Figure 5.6: Graphical assay results from the 5AR assay sourcing cells from the
Garvan institute.
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Chapter 6
Cell Based Biological Testing of Isoflavonoids
and COX, Thromboxane Synthase Inhibition Studies.
6.1

Introduction
While it is important to test compounds on specific enzymes and receptors to aid

their design, it is just as important if not more so, to assess their activity on the whole
cell. Whole cell assays provide information pertaining to a more complex cellular
environment and may indicate other biological targets which were not contemplated
before.
This Chapter includes testing results of the isoflavonoids on eight different
cancer cell lines. The testing was performed by Novogen in Sydney. Among these cell
lines are prostate cancer, breast cancer, ovarian cancer, lung cancer and leukaemia cell
lines.
Cyclooxygenases (COX) and thromboxane synthase are important enzymes in
cancer development. Cancer initiation and progression facilitation by excess
prostaglandins in inflamed tissue has been suggested.214 Cyclooxygenases (COX)
produce prostaglandins from arachidonic acid.25 Strong evidence exists that the COX
inhibitor Celecoxib reduces the risk of colon cancer215, also that many metatheses
contain elevated COX-2 expression. COX-2 has been shown to drive angiogenesis and
halt cellular apoptosis.216 Thromboxane is related to prostaglandins and is derived from
arachidonic acid by thromboxane synthase. It has been found that prostate cancer cells
have elevated levels of thromboxane synthase compared to normal prostate cells. An
increase in cellular motility of these prostate cancer cells is associated with the elevated
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levels of this enzyme.217 Testing of various compounds against these enzymes was also
performed by Novogen and the results are included in this Chapter.

6.2

Cell Line Descriptions
Isoflavonoids were tested on three different prostate cancer cell lines, namely the

LNCaP, PC3 and DU-145 cell lines. The LNCaP cell line is an androgen dependent cell
line which only contains 5AR type I and not 5AR type II.207 The PC3 and DU-145 cell
lines are androgen independent prostate cancer cell lines.208
The MDA-MB-468 cell line is an estrogen receptor negative (estrogen
independent) breast cancer cell line,218 MCF-7 is an estrogen receptor positive breast
cancer cell line219. The NCI-H460 cell line is a large cell lung cancer cell line.220 A2780
and CP70 are cis-platin resistant ovarian cancer cell lines.220 HPAC is a pancreatic
cancer cell line.221 CCRF-CEM is a leukaemia cell line which readily becomes resistant
to methoxtrexate.222 RMPI-8226 is a myeloma cell line.223 HTB-138 is an astroglioma
cell line.224

6.3

Results and Discussion

6.3.1

Cell Line Inhibition Results (Cytotoxicity)
Cell line cytotoxicity assays were performed according to the methods of Alley

et al.225 Optimal seeding densities were determined over five days. Cells were
trypsinised, resuspended in culture medium and seeded at appropriate densities, then
incubated at 37ºC under 5% CO2. After a predetermined lag time the cells were
incubated with the test compound (performed in serial dilutions and with a negative
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control) for five days. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium
bromide)(0.5 mg/mL) in buffer was then added and incubated at 37ºC with the cell
cultures for an additional 3 hours. DMSO was added and absorbance was read at
570nm.
Table 11 outlines the results from the cell line cytotoxicity assays. The results of
this assay represent the concentration required to kill half the population of the cell line
and is presented in µM.

Table 11: LD50 (µM) values of various isoflavonoid compounds against a panel of
cancer cell lines. Where there is more than one entry in a cell the assay has been run a
second time. Results which have a standard deviation have been run in triplicate, if
there is no standard deviation shown the assay was run once. A blue cell denotes active
results and the yellow cell denotes very active results.
Compound
/ cell line
Cell type
116a

LNCaP

PC3

DU-145

MCF-7

Prostate
35.0±6.4

MDA-MB468
Breast
48.4±23.2

Prostate
57.3±26.8

Prostate
71.1±43.8

115a

87.4±37.2

23.2±1.5

34.8

18.4

53.1±4.7

142

>150

>150

>150

>150

76
159a

16.3
30.6±43.2
29.9±2.8

33.9
16.8±1.5
16.8±3.5

13.8
13.4
19.1

34.9
7.9
8.8

159b

32.2±0.0

18.3±6.1

25.2

14.6

159c

47.9±16.4

19.7±10.6

25.4

23.8

159d

51.0
54.7±4.8
16.3
34.4±19.6

44.8
51.3±34.7
28.0
38.4±29.7

46.0
46.0±0.7
19.2
19.2±1.6

26.2
25.0±2.3
22.40
22.5±3.9

159e

Breast
9.1

HTB138
Glioma
65.8

>150

27.9
39.5
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Table 11 (cont.): LD50 (µM) values of various isoflavonoid compounds against a
panel of cancer cell lines. Where there is more than one entry in a cell the assay has
been run a second time. Results which have a standard deviation have been run in
triplicate, if there is no standard deviation shown the assay was run once. A blue cell
denotes active results and the yellow cell denotes very active results.

Compound/ CP70
Cell line
Cell type
Ovar
17.4
116a

A2780

HPAC

Ovarian
31.0±5.3

Pancreatic
121.4±9.5

CCRF- RPMI- NCI-H460
CEM
8226
Leukem Leukem Lung
100.7±19.8
15.7
30.5

115a

39.4

59.4±33.7

142

111.2

81.3±60.7

76

33.3

29.8±8.4

159a

13.7

23.5±5.2

27.7
25.5
14.1

159b

18.0

27.2±1.5

21.7

159c

22.0

31.6±5.7

18.7

159d
159e

38.9

>150

13.4

>150

38.2±11.1

34.3±20.5

12.0

31.5

53.3±12.5

35.5±28.0

5.7

29.8

>150

32.7
40.6±14.1
13.3±
19.4±9.9

Most compounds revealed moderate activity against cancer cell lines (between
20 and 120 µM). This is especially true for the phenyl hydrazones 76, 159a-e which
generally exhibited an increase in activity relative to the oxime 142, demonstrating the
benefit of the additional aromatic group. The most active compound against any cell
line was the phenyl hydrazone 159e against the leukaemia cell line CCRF-CEM with an
LD50 of 5.71µM. The most active compound against a prostate cancer cell line was the
unsubstituted phenyl hydrazone 76, against the DU-145 cell line. The most active
compounds against the LNCaP cell line were the phenyl hydrazones 76 and 159c. The
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most active compounds against the PC3 cell line were 76, 159a, 159b and 159c, all
within 16µM and 20µM. The most active compounds against the DU145 cell line were
76, 159a and 159e. The acetate protected cyano isoflavene 116a was the most active
compound tested against the MCF-7 breast cancer cell line.
Compounds which were revealed to be active against the CR70 ovarian cancer
cell line were the acetate protected 116a and the phenyl hydrazones 159a and 159b. No
compounds tested were highly active against the A2780 ovarian cancer cell line. This
was also the case for the HPAC pancreatic cancer cell line. The four compounds which
showed activity against the RPMI-8226 leukaemia cell line were 116a, 142, 159e and
the 159d. Three compounds were active against the lung cancer cell line NCI-H460,
these being the phenyl hydrazones 159a, 159c and 159e.

Table 12: Concentrations found to inhibit 50% of testosterone induced proliferation
for three phenyl hydrazone derivatives.
NO2

Compound /Cell Line

LNCaP IC50 (µM)

76

2.25

159e

0.68

159d

Less than 0.035

NH
N

HO

O

159d

Table 12 outlines the result from a testosterone induced LNCaP proliferation
assay. These results are the concentrations in µM required at which 50% of testosterone
induced proliferation is inhibited. This assay is an indication 5AR activity as LNCaP

OH
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cells are androgen dependent. As can be seen in table 12, all three phenyl hydrazones
assayed were very active in the proliferation assay, especially the p-nitro 159d. This
provides support that an aromatic ring is beneficial for 5AR activity (see Chapter 2 for
more details).

6.3.2

COX Assay Results
Buffy coats obtained from the Red Cross Blood Bank and diluted with buffer,

were overlayed onto Lymphoprep density gradient medium. A mononuclear cell layer
was obtained through centrifugation and monocyte enriched cells obtained through
counter-current centrifugal elutriation. Monocytes were resuspended in RPMI tissue
culture medium with foetal calf serum and incubated at 37ºC with test compound (in
DMSO) for 30 min. Bacterial lipopolysaccaride (LPS) was added and incubated at 37°C
in 5% CO2 for 18 hours. Cell free supernatants obtained through centrifugation were
then assayed for prostaglandin production by radioimmunoassay.

Table 13: Percentage COX inhibition by various isoflavonoid phenyl hydrazones.
Compound

%Inhibition at 10µM

76

100

159e

77

159d

100

The three phenyl hydrazones tested showed significant COX inhibitory activity
(Table 13), with 100% inhibition at 10µM for the unsubstituted phenyl hydrazone 76

177

and the p-tolyl hydrazone 159e. The p-nitro phenyl hydrazone 159d followed with 77%
inhibition at 10µM concentration.

6.3.3

Thromboxane Synthase Assay Results

Cell free supernatants obtained through centrifugation as described in section
6.3.2, were then assayed for thromboxane production by radioimmunoassay. (As the
direct thromboxane synthase product, Thromboxane 1 (TXA1), is labile in aqueous
media the metabolite of TXA1, Thromboxane 2 (TXB2), the stable hydrolysis product of
TXA1, was measured).

Table 14: Percentage thromboxane synthase inhibition by various isoflavonoid
phenyl hydrazones at 10 µM.
Compound

% Inhibition at 10µM

76

33

159e

27

159d

60

The three phenyl hydrazones showed thromboxane synthase inhibitory activity
(Table 14), with the p-tolyl hydrazone 159e exhibiting the greatest activity with 60%
inhibition at 10µM concentration. The unsubstituted phenyl hydrazone 76 followed with
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33% inhibition at 10µM concentration and the p-nitro phenyl hydrazone 159d had a
similar inhibitory activity with 27% inhibition at 10µM.

6.3.4

Activity at α1 Adrenoceptors
Unfortunately, as the target amines were not synthesised, the α1 adrenoceptor

results were not obtained. One compound, the pyridyl hydrazone 159g was tested (at the
Victor Chang Cardiac Research Institute, Sydney) but was shown to be inactive.

6.4

Summary and Conclusions
As a general trend the phenyl hydrazones exhibited more cytotoxic activity

against a battery of cancer cell lines than the other isoflavone derivatives tested. When
comparing this trend with the oxime derivative 143, it can be concluded that an extra
aromatic ring was beneficial to activity, as had been suggested by the pharmacophore
modelling (see Chapter 2). Generally, both the acetate protected and deprotected 2cyano isoflavenes 116a and 115a, displayed moderate cytotoxicity activities against a
panel of cancer cell lines. Of notable activity was the acetate protected 2-cyano
isoflavene against the breast cancer cell line, MCF-7. Three phenyl hydrazones, 76,
159d and 159e were tested for proliferation inhibition of the LNCaP prostate cancer cell
line, and all three exhibited good proliferation inhibition, especially the p-nitro
derivative 159d. These three phenyl hydrazones also were good COX inhibitors.
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Chapter 7 Conclusions and Future Directions
Computer aided techniques were employed to facilitate the synthetic target
design process. Pharmacophores for inhibitors of human 5AR type I, human 5AR type
II and rat 5AR type II enzymes were generated. The human 5AR type I enzyme training
set provided pharmacophores with a poor statistical analysis. This was due to a small
number of compounds comprising the training set, and, as there were a limited number
of compounds in the literature, it was decided that additional training set molecules
could be generated by setting up an in house 5AR type I assay. Two pharmacophores
were produced for the human 5AR type II enzyme, each with excellent statistical
analysis. For the rat 5AR type II isozyme two pharmacophores were also generated,
both with moderately good statistical analysis. Multiple generations for a randomized
variation of this training set produced different pharmacophores with less consistent
correlation values compared to the non-randomized pharmacophore thus increasing our
confidence in the statistical relevance of the rat 5AR type II enzyme. The isoflavanone
30 and phenoxodiol 32 were mapped onto the human 5AR pharmacophores and these
mappings indicated that addition of an aromatic ring to these types of compounds would
increase 5AR inhibitory activity. Mappings of these compounds on to α1 adrenoceptor
pharmacophores revealed that the inclusion of a basic nitrogen could introduce α1A
adrenoceptor antagonism. In light of these findings 2- and 4- substituted isoflavonoids
were designed as potential dual action agents for the treatment of prostate cancer and its
symptoms. Future work should ensure that additional inhibitors of 5AR type I are used
in the training set of the next 5AR type I pharmacophore, in particular, isoflavonoid
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5AR inhibitors. These latter should be assessed on all the pharmacophores, and
correlations between them examined.
A versatile route to 2-substituted isoflavenes was developed through utilizing an
isoflavylium salt 117. It was found that this salt could be synthesised through oxidation
of the 2-unsubstituted isoflavene 118a by the use of various trityl salts. The trityl
hexafluorophosphate salt and the trityl pentachlorostannate salt were found to be the
most successful. Acetate protecting groups were found to be stable under these
conditions, while tBDMS groups were found to be labile. Subsequent nucleophilic
addition to the salt gave 2-substitited derivatives. Eight new 2-substituted isoflavene
derivatives were synthesized from the acetate protected isoflavene 118a. These
derivatives included compounds with heteroaryl, cyano, allyl, ethynyl and alkoxy
substituents in the 2-position. The 2-ethynylisoflavene 116c was found to undergo a
dimerisation process involving further nucleophilic attack on the isoflavylium salt
intermediate. A deprotected 2-aminomethylisoflavene 70 was synthesized through
reduction of the 2-cyano derivative 116a but it could not be purified. A boc and acetate
protected 2-aminomethyl derivative 116d was synthesised, however due to problems
with purification and degradation on silica of 116d, removal of the boc and acetate
protecting groups was not carried out. In order to achieve a stable protected form of the
2-aminomethylisoflavene 70, investigations into various amine protecting groups should
be included in future projects. Deprotections of 2-substituted isoflavenes, including the
cyano, allyl and two alkoxy derivatives, were carried out using either imidazole or
NaOH.
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Synthesis of the 4-cyano isoflavene 133 was achieved, however in poor yield.
Attempts to reduce 133 to the target amine 67 were not performed due to time
restrictions, however this should be included in future work. Eight new 4-aryl
hydrazones 76, 159a-g were synthesized by reaction of the isoflavone 134a with the
respective hydrazines Another new rearrangement involving the imidazolyl hydrazone
162 and affording the benzo[b]furan derivative 163 was also found. Approaches toward
the 4-thienyl isoflavene 71 derivative were also undertaken. One approach employed a
direct addition of the thienyl substituent to the isoflavanone 134c producing the
corresponding hydroxy isoflavan 144. This compound was difficult to isolate as it was
found to rearrange to a novel benzofuran 178. Numerous attempts to form the 2-thienyl
isoflavene 143 by dehydration of the alcohol 144 were unsuccessful. An alternative
route involving enolisation and the formation of an isoflavene 4-triflate or 4-methoxy
isoflavene intermediate which would then undergo a Negishi type coupling to achieve
the 4-thienyl isoflavene 71 was devised. Attempts at synthesis of 143 through a triflate
intermediate were unsuccessful and it is in fact not certain whether a triflate
intermediate was generated as isolation of the triflate was not possible. Reaction of the
enol isoflavene 146 with methyl iodide gave the 4-methoxy isoflavene 145b.
Subsequent attempts at coupling the methoxy isoflavene with the thienyl zinc bromide
reagent 177 were unsuccessful with an unidentified compound being formed; this
reaction was found to be catalysed by NiCl2. Further investigation into the elucidation
of the unidentified compound, as well as the synthesis of the thienyl isoflavene 71 is
required. Regarding further attempts to synthesise the 4-thienyl compound through the
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Negishi route, trials with various appropriate catalysts, possibly nickel-based, are
recommended.
In order to provide additional isoflavonoid and non-isoflavonoid 5AR type I
inhibitors for an iterative pharmacophore generation process, a 5AR type I assay was
developed. A crude protein assay was successfully developed using LNCaP cell lines as
the enzyme source. The assay was standardised through the use of Finasteride.
Unfortunately the LNCaP cells were contaminated shortly after the set up of the assay,
altering the activity of the 5AR type I enzyme. Attempts to overcome this by obtaining a
new batch of the cell line were unsuccessful. The assay needs to be re-developed with a
new batch of LNCaP cells and compounds tested for their inhibition.
Cell based cytotoxicity testing of various synthesised isoflavonoids was carried
out at Novogen, Sydney using numerous cancer cell lines. The compound which
showed the most cytotoxicity was the p-tolyl hydrazone 159e against the CCRF-8226
leukaemia cell line with an LD50 of 5.71 µM. The phenyl hydrazone derivatives were
generally moderately cytotoxic against most cancer cell lines.
Three phenylhydrazones, 76, 159e and 159d were tested for proliferation
inhibition in the androgen dependent prostate cancer cell line LNCaP. Notable growth
inhibitory activity was shown by all three of the phenyl hydrazones and especially by
the p-nitrophenylhydrazone 159d against LNCaP cells with an IC50 of less than 0.35
µM. This indicates that the 5AR pharmacophores are predictive. These three phenyl
hydrazones were also tested for COX inhibition and thromboxane synthase inhibition.
Significant COX inhibition was exhibited, while moderate thromboxane synthase
inhibition was revealed.
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Further cell based testing of all synthesised derivatives is required. Also testing
of the amine-based derivatives for α1A adrenoceptor binding should be included in
future projects. Future projects should consider the phenyl hydrazones as lead
compounds due to their very encouraging results in the cell-based anti-cancer testing.
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Chapter 8 Experimental
8.1

Molecular Modelling
Molecular modelling was undertaken using CATALYST version 4.5 (Accelrys)

on a Silicon Graphics work station.

8.2

Chemistry Experimental Section

8.2.1

General Experimental for Synthesis
Masses were measured using an OHAUS Analytical Standard Balance. Melting

point determinations were carried out on a Reichert hot stage melting point apparatus
and are uncorrected.

Low Resolution chemical ionization (isobutene, CI+) and electron impact (EI+)
mass spectra were obtained on a Shimadzu QP-5000 mass spectrometer by a direct
insertion technique with an electron beam of 70eV. High resolution mass spectra
(HRMS) (methane, CI+, EI+) were determined on a Fisons/VG Autospec spectrometer
using PFK (perfluorokerosene) as the internal standard. Low resolution electrospray
(ES+/ES-) spectra were obtained on a quattro triple quadrapole mass spectrometer. High
resolution electrospray mass spectrometry (HRMS) (ES+/ES-) was carried out on a GTof mass spectrometer. The m/z values are stated with their peak intensities as a
percentage in parentheses.

Microanalysis was carried out by George Blazak at the University of Queensland.
Microanalysis results are expressed in elemental percentages based on atomic weights.
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Proton, carbon, two-dimensional and one-dimensional NMR experiments were
carried out on a Varian Mercury 300 MHz or a Varian Innova 500MHz spectrometer.
Spectra were recorded in deuterated solvent denoted in parentheses, and referenced to
the residual non-deutertated solvent signal. Chemical shifts (δ) in parts per million
(ppm) were measured relative to the internal standard.

Analytical thin layer chromatography (TLC) was carried out on Merck silica gel
60 F254 pre-coated aluminium plates with a thickness of 0.2 mm.

Chromatography refers to column chromatography, performed under ‘flash’
conditions on Merck Silica gel 60 (230-400 mesh), unless otherwise stated. Sigma
Aldrich aluminium oxide (58 Å mesh) was used when alumina chromatography was
performed and alumina TLC was performed using Merck neutral aluminium oxide 60
F254 pre-coated aluminium plates with a thickness of 0.2mm. Chromatography solvent
mixtures were measured by volume and are reported in parentheses. Compound spots
on the TLC plates were detected by UV (λ 254 nm) or by reaction with ammonium
molybdate226.

Solvent removal was carried out under reduced pressure (in vacuo) with a Büchi
rotary evaporator. The temperature for solvent removal was 50°C unless otherwise
stated. Solvent extracts were dried with anhydrous sodium sulphate or magnesium
sulphate as indicated.
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Anhydrous solvents were purified and dried according to the method described
in Perrin and Amarego227 and distilled immediately before use. Other solvents were
analytical reagent grade and were used as received, with the exception of
dichloromethane (DCM) which was laboratory reagent grade and was distilled before
use. Pet. Spirit refers to the fraction with boiling points between 40°C and 60°C.
Starting materials and reagents were purchased from Sigma Aldrich Pty Ltd, or
Lancaster Chemicals and used as received. The diacetoxy isoflavonoid precursors 118a,
119a and 135a were obtained from Novogen, Sydney, and were recrystallised from
absolute ethanol. The isoflavene 32 was obtained from Novogen and used as received.
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8.2.2

Experimental Relating to Chapter 3

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from 7hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran
OAc

(32)using P2O5
5
6

The diol 32 (4.062 g, 11.88 mmol) was heated at reflux

4a

4
3

7

in acetic anhydride (20mL) and pyridine (5mL) for 2.5 h.

AcO

8

4'

O

1'

3'
2'

2

1

The cooled reaction mixture was then added to water (200mL). The crude material was
then extracted with DCM (2x100 mL). The DCM extract was dried (Na2SO4), the
solvent removed and the residue recrystallised from ethanol to give 118a (3.387 g,
10.45 mmol) as a cream powder in 88% yield; mp 177-178 °C.

1

H-NMR (300MHz, d6-acetone): δ 7.42 (d of d, 2H, J=8.4, 1.5, H-2’), 7.11 (d of d, 2H,

J=9.0, 2.1, H-3’), 7.06 (d, 1H, J=7.8, H-5), 6.75 (s, 1H, H-4), 6.65 (d of d, 1H, J=8.1,
2.1), 6.61 (d, 1H, J=1.5, H-8), 5.14 (s, 2H, H-2), 2.31 (s, 3H, CH3CO), 2.29 (s, 3H,
CH3CO). 13C-NMR (75MHz, CDCl3): δ 169.6 (C=O), 169.6 (C=O), 154.1 (C8a), 151.3
(C7), 150.6 (C4’), 134.5 (C1’), 130.6 (C3), 127.6 (C5), 126.1 (C2’), 122.2 (C3’), 120.9
(C4a), 119.8 (C4), 115.0 (C6), 109.6 (C8), 67.4 (C2), 21.3 (CH3). MS (CI+): m/z 325
(M+1, 100%).

190

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from the
isoflavanol (119)
The alcohol (119) (1.500 g, 4.385 mmol) was stirred with P2O5 (12.46 g, 87.78 mmol)
in dry DCM at rt for 2 h. The suspension was then added to water (100mL). Ethyl
acetate (50 ml) was added and the organic layer was collected, and then washed
successively with water, and then brine, before being dried over sodium sulfate. The
solution was then filtered and evaporated to dryness. The resulting solid was then
passed through a short silica column using 100% DCM as the eluting solvent, to afford
118a as a white amorphous solid (1.193 g, 3.683mmol) in 84% yield.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2H-1-benzopyran (118a) from the
isoflavanol (119) using CuSO4
The alcohol (119) (0.846 g, 2.474 mmol) was heated at reflux in a suspension of
anhydrous CuSO4 (2.645 g, 15.44 mmol) in dry toluene (5mL) for 30min. The
suspension was then filtered. The resulting filtrate was then evaporated to dryness under
reduced pressure, affording 118a as a powder (0.777 g, 2.399 mmol) in 97% yield.

Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-2H1-benzopyran (119b) from 7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (32)
A mixture of 32 (1.365 g, 5.686 mmol),
O

4'

imidazole

(3.986

g,

58.555

mmol),

t-

5
6

butyldimethylsilyl chloride (3.996 g, 26.515
mmol) and powdered 3Å molecular sieves in

4a

4

7

Si
O

8

8a O
1

3
2

1'

3'
2'

Si
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DMF (25 mL) was stirred at rt for 30 h. The reaction mixture was then filtered. Icewater (50 mL) was added to the filtrate resulting in precipitate formation. The product
was extracted from the mixture with DCM (2 x 50 mL), washed with water (3 x 50 mL),
then brine (50 mL) and then dried over MgSO4. The solution was then filtered. The
filtrate was evaporated under reduced pressure. The resulting solid was recrystallised
from absolute ethanol and to give 119b in 67% yield (1.785 g, 3.810 mmol) as
colourless crystals mp 54-55ºC.

1

H-NMR (300MHz, CDCl3): δ 7.08 (d, 2H, J=8.7, H-2’), 6.71 (d, 1H, J=7.8, H-5), 6.63

(d, 2H, J=8.7, H-3’), 6.46 (s, 1H, H-4), 6.20 (d of d, 1H, J=8.1, 2.4, H-6), 6.16 (d, 1H,
J=2.4, H-8), 4.89 (s, 2H, H-2), 0.78 (s, 9H, SiC(CH3)3), 0.77 (s, 9H, SiC(CH3)3), 0.00 (s
6H, SiCH3). 13C-NMR (75MHz, CDCl3): δ 156.3 (C8a), 155.4 (C7), 154.0 (C4’), 130.1
(C1’), 128.6 (C3), 127.2 (C5), 125.7 (C2’), 120.2 (C3’), 118.3 (C4), 117.0 (C4a), 113.4
(C6), 107.5 (C8), 67.2 (C2), 25.7 (SiCCH3), 18.3 (SiCCH3), -4.4 (SiCH3). MS (ES+):
m/z 469.4 (M+1, 100%). HR (ES+) MS: m/z calcd for [MH+] C9H21NO2Si: 469.2589,
found: 469.2592.

Preparation of t-butyl N-(trimethylsilyl)methylcarbamate (121a)
O

A solution of DMAP (0.091 g, 0.8446 mmol) and (BOC)2O (3.402 g,
15.588

mmol)

in

acetonitrile

(6

mL)

was

added

to

Si

N
H

O

trimethylsilylmethyamine 120a (0.703 g, 6.805 mmol) with ice cooling. The reaction
mixture was then stirred at rt (30°C) for 48 h. The reaction mixture was added to water
(150 mL) and extracted with DCM (2 x 75 mL). The DCM was dried over Na2SO4 and
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filtered. The DCM was evaporated under reduced pressure. The residue was redissolved
in DCM (2 mL) and applied to a silica column. A column was then run with 100%
DCM as the mobile phase, with TLC monitoring of the fractions using a molybdate dip.
The product (121a) was obtained as a colourless oil in 72% yield (0.991 g, 4.873
mmol).

1

H-NMR (300MHz, CDCl3): δ 3.10 (bs, 1H, NH), 2.70 (d, 2H,J=5.1, CH2), 1.46

(s, 9H, C(CH3)3) 0.00 (s, 9H, Si(CH3)3). 13C-NMR (75MHz, CDCl3): 152.9 (C=0), 81.8
(C(CH3)3), 37.1 (SiCH2), 28.0 (C(CH3)3), -2.9 (Si(CH3)3). MS (ES+): m/z 203 (M+1,
14%), 147 (M+-C(CH3)3+2, 32%), 132 (M+-O-C(CH3)3+2, 100%). HR (ES+) MS: m/z
calcd for [M+] C9H21NO2Si: 203.1432, found: 203.1429.

BOC protection of tert-butyl N-(trimethylsilyl)methylcarbamate (120a).
A solution of DMAP (0.175 g, 1.624 mmol) and (BOC)2O (4.775 g, 21.879 mmol) in
acetonitrile (8 mL) was added to trimethylsilylmethylamine 120a (0.957 g, 9.269 mmol)
at 0°C and the mixture then stirred at rt (30°C) for 100 h. The reaction mixture was
added to water (150 mL) and extracted with DCM (2 x 75 mL). The DCM was dried
over Na2SO4 and filtered. The DCM was evaporated under reduced pressure. The
residue was redissolved in DCM (2 mL) and applied to a silica column. A column was
then run with 100% DCM as the mobile phase to afford (121a) in 69% yield (1.302 g,
6.400 mmol) and the bis boc protected product (122a) in 20% yield (0.563 g, 1.854
mmol).
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Synthesis

of

tert-butyl

N-(tert-butyloxycarbonyl)-N-

(trimethylsilyl)methylcarbamate (122a)
A solution of DMAP (0.081 g, 0.757 mmol) and (BOC)2O (0.253 g,
1.159 mmol) in THF (2 mL) was added to t-butyl N-

O
Si

N
O

O
O

(trimethylsilyl)methylcarbamate (120a) (0.086 g, 0.422 mmol) with
ice cooling and then the reaction mixture was heated at reflux for 48 h. The reaction
mixture was then added to water (150 mL) and extracted with DCM (2 x 75 mL). The
DCM was dried over Na2SO4 and filtered. The DCM was evaporated under reduced
pressure. The residue was redissolved in DCM (2 mL) and applied to a silica column. A
column was then run with 100% DCM as the mobile phase. This gave the product
(122a) as a clear solid in 92 % yield (0.123 g, 0.388 mmol), mp 52-53 °C.

1

H-NMR (300MHz, CDCl3): δ 3.10 (s, 2H, CH2), 1.45 (s, 18H, C(CH3)3), 0.00 (s, 9H,

Si(CH3)3).

13

C-NMR (75MHz, CDCl3): δ 155.8 (C=O), 155.4 (C=O), 82.3 (C(CH3)3),

37.1 (SiCH2), 28.0 (C(CH3)3), -2.9 (Si(CH3)3). MS (ES+): m/z 304 (M+1, 12%), 248
(M+- C(CH3)3+2, 27%), 233 (M+-O- C(CH3)3+2, 100%), 175 (M+-C(CH3)3-O-C(CH3)3,
54%), 131 (M+-COO-C(CH3)3-O-C(CH3)3, 38%). HR (ES+)MS: m/z calcd for [MH+]
C14H29NO4Si: 304.1953, found: 304.1975.
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Synthesis of tert-butyl N-benzyl-N-(trimethylsilyl)methylcarbamate (122b)
A solution of DMAP (0.088 g, 0.8185 mmol) and (BOC)2O (1.972
Si

N

g, 9.037 mmol) in acetonitrile (3 mL) was added to TMS methyl
O

O

benzyl amine 121b (0. 403 g, 2.082 mmol) on ice and stirred at rt.
The reaction mixture was added to water (150 mL) and extracted with DCM (2x 75
mL). The DCM was dried over Na2SO4 and filtered. The DCM was evaporated under
reduced pressure. The residue was redissolved in DCM (2 mL) and applied to a silica
column. A column was then run with 100% DCM as the mobile phase. This provided
122b as a clear oil in 75% yield (0.459 g, 1.562 mmol).

1

H-NMR (300MHz, CDCl3): δ 7.19-7.35 (m, 5H, ArH), 4.42 (s, 2H, PhCH2), 2.69 (s,

2H, SiCH2), 1.42 (s, 9H, C(CH3)3), 0.04 (s, 9H, Si(CH3)3). 13C-NMR (75MHz, CDCl3):
δ 149.8 (C=O), 128.5 (ArCH), 127.2 (ArCCH2), 79.3 (C(CH3)3), 52.8 (PhCH2), 37.9
(SiCH2), 28.5 (C(CH3)3), -1.4 (Si(CH3)3). MS (ES+): m/z 294 (M+1, 38%), 238 (M+1-tBu, 92%), 222 (M+1-TMS, 100%). HR (ES+) MS: m/z calcd for [MH+] C16H27NO2Si:
294.1901, found: 294.1903.

Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using
trityl tetrafluoroborate
O

Freshly distilled anhydrous DCM (50 mL) was
added to 118a (0.504 g, 1.554 mmol), trityl

4'
5
6

O

4

3

1'

3'

O

2'

2

7
O

tetrafluoroborate (0.768 g, 2.296 mmol) and

4a

8a O
8
1

CN

powdered 3Å molecular sieves. The murky brown solution was stirred at room
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temperature for 30 min. Trimethylsilyl cyanide (0.318 g, 3.215 mmol) was then injected
into the reaction mixture and left to stir at room temperature overnight. The solution
was filtered. The filtrate was then dried (Na2SO4) and dissolved in DCM (4 mL) and
applied to a silica column. Elution with DCM gave the product 116a as a white solid
(0.233 g, 0.668 mmol, 43%), mp156 -158°C.

1

H-NMR (500MHz, CDCl3): δ 7.49 (d, 2H, J=8.7, H-2’/6’), 7.23 (d, 1H, J=8.0, H-5),

7.18 (d, 2H, J=8.6, H-3’/5’), 6.97 (s, 1H, H-4), 6.85 (d of d, 1H, J=2.5, 8.1, H-6), 6.84
(s, 1H, H-8), 6.01 (s, 1H, H-2), 2.32 (s, 3H, CH3), 2.30 (s, 3H, CH3).

13

C-NMR

(75MHz, CDCl3): δ 169.1 (C=O), 168.9 (C=O), 151.9 (C8a’), 151.1 (C7), 150.3 (C4’),
131.9 (C3), 128.3 (C5), 126.2 (C2’), 125.9 (C1’), 122.4 (C3’), 122.3 (C4), 119.1 (C4a),
117.0 (C6), 116.0 (CN), 110.5 (C8), 64.3 (C2), 21.1 (CH3). MS (CI+): m/z 323 (-CN,
100%), 349 (M+, 8%). MS (ES+): m/z 367 (M++H2O, 100%). Microanalysis: Found:
C=69.20%; H=4.34, 4.35%; N= 3.67%; C20H15NO5 requires: C=68.76%; H=4.33%,
N=4.01%.

Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using
trityl hexafluorophosphate salt
Freshly distilled anhydrous DCM (50 mL) was

O

4'
5

added to (118a) (0.503 mg, 1.550 mmol), trityl

6

O

hexafluorophosphate (0.879 g, 2.265 mmol) and

4a

4

3 1'

3'

O

2'

7
O

8

8a O 2 CN
1

powdered 3Å molecular sieves. The murky
brown solution was stirred at room temperature for 30 min. Trimethylsilyl cyanide
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(0.480 g, 485 mmol) was then injected into the reaction mixture and left to stir at rt
overnight. The solution was filtered. The filtrate was then dried and dissolved in DCM
(4 mL) and applied to a silica column. A gradient column was then run starting with 5%
hexane in DCM then run using 100% DCM. The product 116a was collected in 80%
yield as a white solid (0.431 g, 1.235 mmol), mp 156-158°C.

Synthesis of 7-acetxoy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (116a) using
trityl pentachlorostannate
Freshly distilled anhydrous DCM (50 mL) was added to 118a (0.499 g, 1.5398 mmol),
trityl pentachlorostannate (1.273 g, 1.834 mmol) and powdered 3Å molecular sieves.
The murky brown solution was stirred at room temperature for 30 min. Trimethylsilyl
cyanide (0.550 g, 556 mmol) was then injected into the reaction mixture and left to stir
at rt overnight. The solution was filtered. The filtrate was then dried and dissolved in
DCM (4 mL) and applied to a silica column. The column was then run starting with
100% in DCM, then 5% ethyl acetate in DCM. The product 116a was collected in 76%
yield as a white solid (0.408 g, 1.170 mmol), mp 164-165ºC.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-(2-thiazoyl)-2H-1-benzopyran (116b)
Anhydrous DCM (50 mL) was added to 118a

O

4'

(0.451 g, 1.390 mmol), trityl hexafluorophosphate

5
6

O

4a

4

3

7

(0.849 g, 2.188 mmol) and powdered 3Å molecular
sieves. The murky brown solution was stirred at

O

8

8a O 2
1

1'

3'

O

2'

1" S 2"
3"
N

5"

4"

room temperature for 30 min. TMS thiazole (0.4025 g, 2.564 mmol) was then injected

197

into the reaction mixture and the mixture left to stir at room temperature for 2h. The
solution was filtered. The filtrate was then dried (MgSO4) and dissolved in DCM (4
mL) and applied to a silica column. A gradient column was then run starting with 100%
DCM increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl
acetate in DCM. The product 116b was collected in 78% yield as a creamy white solid
(0.695 g 1.707 mmol), mp 136-138ºC.

1

H-NMR (300MHz, CDCl3): δ 7.60 (bd, 1H, J=2.7, H-2”), 7.37 (d, 2H, J=8.7, H-2’/6’),

7.23 (d, 1H, J=6.3, H-5), 7.08 (d, 1H, J=2.7, H-3”), 6.93 (d, 2H, J=8.4, H-3’/5’), 6.89
(s, 1H, H-4), 6.57 (d of d, 1H, J=8.4, 2.7, H-6), 6.53 (d, 1H, J=2.4, H-8), 6.44 (bs, 1H,
H-2), 2.13 (s, 3H, CH3), 2.10 (s, 3H, CH3). 13C-NMR (75MHz, CDCl3): δ 169.5 (C=O),
169.3 (C=O), 169.3 (C1”), 151.8 (C8a), 151.7 (C7), 150.8 (C4’) 143.3 (C4”), 134.0
(C3), 131.5 (C1’), 127.9 (C5), 126.9 (C2’), 122.2 (C3’), 121.1 (C3”), 120.9 (C4), 120.2
(C4a), 115.7 (C6), 110.6 (C8), 74.7 (C2), 21.3 (CH3CO). MS (CI+): m/z 407.8 (M+1,
100%). HR (CI+) MS: m/z calcd for [M+] C22H17NO5S: 408.0906, found: 408.0887.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-ethynyl-2H-1-benzopyran-2 (116c)
Anhydrous DCM (50 mL) was added to 118a (0.646 g, 1.995 mmol), trityl
hexafluorophosphate (1.159 g, 2.987 mmol) and powdered 3Å molecular sieves. The
brown-yellow solution was stirred at room temperature for 1 h. TMS acetylene (1.4 mL)
was then injected into the reaction mixture and the mixture left to stir at room
temperature for 1 h. The solution was filtered. The filtrate was then dried (MgSO4) and
dissolved in DCM (4 mL) and applied to a silica column. A gradient column was then
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run starting with 100% DCM increasing polarity by 5% ethyl acetate increments and
ending with 10% ethyl acetate in DCM. The product 116c was collected in 7% yield as
a creamy white solid (0.047 g, 0.1397 mmol), mp 179-181 °C decomp., and the dimeric
compound 122 was produced in 67% yield (0.4478g, 0.6683mmol), mp 237-238 °C
decomp.

(116c):
1

H-NMR (300MHz, CDCl3): δ 7.56 (d, 2H, J=8.7,

O

5
6
7

O

H-2’), 7.19 (d, 1H, J=8.1, H-5), 7.10 (d, 2H, J=8.7,

O

H-3’), 6.91 (s, 1H, H-4), 6.80 (d, 1H, J=2.4, H-8),

8

4a

4

4'
3

3'

1'

O

2'

8a O 2
1

6.75 (d of d, 1H, J=8.4, 2.4, H-6), 6.19 (d, 1H, J=7.5, H-2), 3.71 (d, 1H, J=7.8, C≡CH),
2.30 (s, 3H, COCH3), 2.29 (s, 3H, COCH3).13C-NMR (75MHz, CDCl3): δ 169.8 (C=O),
169.7 (C=O), 134.2 (C7), 131.0 (C8a), 128.0 (C4’), 127.0 (C3), 127.0 (C1’), 122.2
(C5), 122.1 (C2’), 120.8 (C4), 119.0 (C3’), 115.6 (C6), 110.8 (C8), 91.7 (C2), 21.4
(COCH3). MS (CI+): m/z 323 (isoflavylium, M-C≡CH, 100%). Microanalysis: Found:
C=72.39%; H=4.66%; C20H16O5 requires: C=72.41%; H=4.63%.

O

(130):
5
1

H-NMR (300MHz, d6-DMF): δ 7.11 (d,

6

O

4a

4

7

2H, J=9.0, H-2’), 7.02 (d, 1H, J=8.4, H-5),
6.98 (s, 1H, H-4), 6.73 (d of d, 1H, J=2.4,

O

8

8a O

4'
3

1'

O
O

O

3'
2'

2

1
O

0.3, H-8), 6.66 (d, 2H, J=9.0, H-3’), 6.53
O

O
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(s, 1H, H-2), 6.51 (d of d, 1H, J=8.4, 2.4, H-6), 1.94 (s, 3H, COCH3), 1.88 (s, 3H,
COCH3).

13

C-NMR (75MHz, d6-DMSO): δ 169.2 (C=O), 169.1 (C=O), 151.8 (C7),

150.8 (C8a), 150.2 (C4”), 133.0 (C3), 128.4 (C1’), 128.2 (C5), 126.4 (C2’), 122.2 (C4),
121.5 (C3’), 119.4 (C6), 116.3 (C4a), 110.7 (C8), 92.5 (C≡), 91.7 (C2), 20.4 (COCH3),
20.3 (COCH3). MS (ES+): m/z 323 (M+1, 100%). Microanalysis: Found: C=69.27%,
H=4.62%; C41H34O10 requires: C=69.28%, H=4.60%,

Synthesis of the dimeric compound 130
Anhydrous DCM (50 mL) was added to 118a (0.646 g, 1.995 mmol), trityl
hexafluorophosphate (1.159 g, 2.987 mmol) and powdered 3Å molecular sieves. The
brown-yellow solution was stirred at rt overnight. TMS acetylene (1.4 mL) was then
injected into the reaction mixture and the mixture left to stir at rt for 1 hr. The solution
was filtered. The filtrate was then dried (MgSO4) and dissolved into DCM (4 mL) and
applied to a silica column. A gradient column was then run starting with 100% DCM
increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl acetate in
DCM. The dimeric compound 130 was produced in 91% yield (0.608 g, 0.9077 mmol).

Synthesis

of

7-acetxoy-3-p-acetoxyphenyl-2-tert-butyloxycarbonylaminomethyl-

2H-1-benzopyran (116d)
O

Anhydrous DCM (50 mL) was added to 118a
(0.404 g, 1.246 mmol), trityl hexafluorophosphate

5
6
7

O
O

(0.612 g, 1.576 mmol) and powdered 3Å molecular

8

4a

4

4'
3

1'

3'
2'

8a O 2
1
O

N
H
O

O
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sieves. The orange-yellow solution was stirred at rt for 30 min. Anhydrous methanol (3
mL) was then injected into the reaction mixture and the mixture stirred at room
temperature overnight. The solution was filtered. The filtrate was then dried (MgSO4)
and dissolved in DCM (4 mL) and applied to a silica column. A gradient column was
then run starting with 100% DCM increasing polarity by 5% ethyl acetate increments
and ending with 10% ethyl acetate in DCM. The product 116d was collected in 45%
yield as a creamy white solid (0. 255 g, 0.5612 mmol), mp 52-54 °C.

1

H-NMR (300MHz, CDCl3): δ 7.64 (d, 1H, J=8.7, H-5), 7.52 (d, 1H, J=8.7, H-2’), 7.48

(d, 1H, J=8.7, H-2’), 7.13 (d, 2H, H=8.7), 6.98 (d of d, 1H, J=8.7, 2.4, H-6), 6.91 (d,
1H, J=2.8, H-4), 6.67 (d, 0.6H, J=2.1, H-8), 6.66 (d, 0.4H, J=2.1, H-8), 5.44 (d of d,
0.4H, J=11.0, 2.4, NH), 5.15 (d of d of d, 1H, J=11.1, 6.0, 2.4, H-2), 4.86 (bt, 0.3H,
J=1.5, NH), 4.76 (bd, 0.3H, J=1.2, NH), 2.59 (d of d, 1H, J=15.0, 10.0, CH2), 2.20 (d,
1H, J=15.0, CH2), 2.31 (s, 3H, COCH3), 2.23 (s, 3H, COCH3), 2.16 (s 9H,C(CH3)3).
13

C-NMR (75MHz, CDCl3): δ 169.5 (COCH3),155.2 (CONH), 150.1 (C8a), 147.0 (C7),

143.7 (C4’), 134.7 (C3), 130.7 (C1’), 127.5 (C5), 125.2 (C2’), 122.2 (C2’), 121.9 (C4),
120.2 (C3’), 116.1 (C6), 114.9 (C4a), 109.5 (C8), 75.5 (C(CH3)), 72.4 (C2), 43.1 (CH2),
30.7 (C(CH3)3), 21.3 (COCH3). MS (ES+): m/z 453.2 (M+, 33.3%), 396.2 (M-C(CH3)3,
9.2%), 379.2 (M-O-C(CH3)3, 25.3%), 338 (M+1-2xboc, 100%), 323.0 (Isoflavylium,
14.5%). HR (ES+) MS: m/z calcd for [M+] C25H27NO7: 454.1876, found: 454.1872.
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Attempted synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-tert-butyloxycarbonyl(Nbenzyl)aminomethyl-2H-1-benzopyran (116e)
Freshly distilled anhydrous DCM (50 mL) was added to 118a (0.524 g, 1.617 mmol),
trityl hexafluorophosphate (0.799 g, 2.059 mmol) and powdered 3Å molecular sieves.
The reaction mixture was stirred at room temperature for 30 min. tert-butyl N-benzyl-N(trimethylsilyl)methylcarbamate (122b) (0.750 g, 2.557 mmol) was then injected into
the flask and the mixture left to stir at rt for 3 hours. The solution was filtered. The
filtrate was then dried (MgSO4) and dissolved in DCM (4 mL) and applied to a silica
column. A gradient column was then run starting with 5% hexane in DCM as the mobile
phase, then 100% DCM. No product was isolated, with material remaining on the base
line.

Synthesis 7-acetoxy-3-p-acetoxyphenyl-2-allyl-2H-2-allyl-1-benzopyran (116f)
Freshly distilled anhydrous DCM (50 mL) was
O

added to 118a (0.492 g, 1.517 mmol) and trityl

5
6

O

hexafluorophosphate (0.865 g, 2.228 mmol). The

4
3

7
O

4a

4'

8

murky brown solution was stirred at room

1'

8a O 2
1"
1

3'

O

2'
2"

3" H3"b
H

3"a

temperature for 25 min. Allyl tributyltin (1.053 g,
3.180 mmol) was then injected into the flask and the mixture left to stir at rt overnight.
The solution was filtered. The filtrate was then dried (MgSO4) and dissolved in DCM (4
mL) and applied to a silica column. A gradient column was then run starting with 5%
hexane in DCM as the mobile phase, then 100% DCM. The product 116f was collected
as a white solid (0.375 g, 1.032 mmol), mp 90-91°C in 68% yield.

202

1

H-NMR (300MHz, CDCl3): δ 7.45 (d, 2H, J=9.0, H-2’), 7.11 (d, 2H, J=8.7, H-3’),

7.06 (d, 1H, J=8.0, H-5), 6.71 (s, 1H, H-4), 6.67 (d, 1H, J=2.4, H-8), 6.64 (d of d, 1H,
J=2.4,1.5, H-6), 5.94-5.80 (m, 1H, H-2”), 5.34 (d of d, 1H, J=3.0, 12.0, H-2), 5.07 (d,
1H, J=0.9, H-3”b), 5.04 (d, 1H, J=12.0, H-3”a), 2.62-2.51 (m, 1H, H-1”), 2.31 (s, 3H,
CH3CO), 2.27 (s, 4H, CH3CO, H-1”).

13

C-NMR (75MHz, CDCl3): δ 169.5 (C=O),

169.3(C=O), 152.4 (C8a), 151.5 (C7), 150.5 (C4’), 134.7 (C1’), 134.4 (2”), 133.8 (C5),
127.4 (2’), 126.6 (C3), 122.2 (C3’), 120.8 (C4), 119.5 (4a), 118.1 (6), 114.8 (C3”),
110.4 (C8), 75.6 (C2), 38.0 (C1”), 21.5 (CH3CO). MS (CI+): m/z 365.0 (M+1, 34%),
323 (M+-allyl, 100%). HR (CI+) MS: m/z calcd for [MH+] C22H20NO5: 365.1384,
found: 365.1380.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-methoxy-2H-1-benzopyran (116g)
Anhydrous DCM (50 mL) was added to 118a

O

5

(0.376 mg, 1.159 mmol), trityl hexafluorophosphate

6

O

(0.956 g, 2.4647 mmol) and powdered 3Å

4'
4a

4

3

1'

7
O

O
8 8a 1

3'

O

2'

2 O

molecular sieves. The brown-yellow solution was stirred at room temperature for 30
min. Anhydrous methanol (3 mL) was then injected into the reaction mixture and the
mixture stirred at rt overnight. The solution was filtered. The filtrate was then dried
(MgSO4) and dissolved into DCM (4 mL) and applied to a silica column. A gradient
column was then run starting with 100% DCM increasing polarity by 5% ethyl acetate
increments and ending with 10% ethyl acetate in DCM. The product 116g was collected
in 63% yield as a creamy white solid (0.258 g, 0.731 mmol), mp 149-151 °C.
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1

H-NMR (300MHz, CDCl3): δ 7.53 (d, 2H, J=9.0, H-2’), 7.24 (d, 1H, J=8.4, H-5), 7.13

(d, 2H, J=8.4, H-3’), 6.98 (s, 1H, H-4), 6.85 (d, 1H, J=2.1, H-8), 6.77 (d of d, 1H,
J=8.4, 2.1, H-6), 5.85 (s, 1H, H-2), 3.58 (s, 3H, OCH3), 2.32 (s, 3H, CH3CO), 2.30 (s,
3H, CH3CO).

13

C-NMR (75MHz, CDCl3): δ 169.5 (C=O), 169.3(C=O), 151.6 (C7),

150.7 (C8a), 150.4 (C4’), 133.7 (Ca), 128.3 (Ca), 128.1(C5), 127.0 (C2’), 122.1(C3’),
121.6 (C4), 119.6 (C4a), 115.6 (C6), 110.5 (C8), 98.3 (C2), 55.5 (OCH3), 21.3
(CH3CO).
Ca: C3 or C1’
MS (CI+): m/z 323 (100%, M-OCH3). Microanalysis: Found: C=67.82%; H=5.13,
4.35%; C20H18O6 requires: C=67.79%; H=5.12 %.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-ethoxy-2H-1-benzopyran (116h)
Anhydrous DCM (50 mL) was added to 118a
(0.502 g, 1.549 mmol), trityl hexafluorophosphate

O

5
6

O

4a

4

4'
3

1'

7

(0.872 g, 2.247 mmol) and powdered 3Å molecular

O
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O

2'

O 2 O
8 8a 1

sieves. The murky brown solution was stirred at rt for 30 min. Anhydrous ethanol (3
mL) was then injected into the reaction mixture and left to stir at rt overnight. The
solution was filtered. The filtrate was then dried (MgSO4) and dissolved into DCM (4
mL) and applied to a silica column. A gradient column was then run starting with 100%
DCM increasing polarity by 5% ethyl acetate increments and ending with 10% ethyl
acetate in DCM. The product 116h was obtained in 63% yield as a creamy white solid
(0.359 g, 0.9759 mmol), mp 134-136 °C.
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1

H-NMR (300MHz, CDCl3): δ 7.53 (d, 2H, J=9.0, H-2’), 7.23 (d, 1H, J=8.4, H-5), 7.12

(d, 2H, J=8.4, H-3’), 6.98 (s, 1H, H-4), 6.82 (d, 1H, J=2.1, H-8), 6.76 (d of d, 1H,
J=8.4, 2.1, H-6), 5.95 (s, 1H, H-2), 4.00 (m, 1H, OCH2CH3), 3.78 (m, 1H, OCH2CH3)
2.32 (s, 3H, CH3CO), 2.30 (s, 3H, CH3CO), 1.25 (t, 3H, J=7.2, CH2CH3). 13C-NMR
(75MHz, CDCl3): δ 169.5 (C=O), 169.3 (C=O), 151.4 (C7), 151.1 (C8a), 150.6 (C4’),
134.6 (Ca), 129.7 (Ca), 128.0 (C5), 126.9 (C2’), 122.1 (C3’), 121.5 (C4), 119.6 (C4a),
115.4 (C6), 110.4 (C8), 97.2 (C2), 64.1 (CH2CH3), 21.5 (CH3CO), 15.7 (CH3CH2).
Ca: C3 or C1’
MS (CI+): m/z 323 (isoflavylium, 100%). Microanalysis: Found: C=68.49%;
H=5.53%; C21H20O6 requires: C=68.40%; H=5.48 %.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2-(3-bromopropoxy)-2H-1-benzopyran
synthesis (116i)
Freshly distilled anhydrous DCM (50 mL) was

O

5

added to 118a (0.434 g, 1.338 mmol), trityl

6

O

4a

4

hexaflurorphosphate (0.9910 g, 2.570 mmol) and

3

1'

2

7
O

4'

8a O
8
1

O

3'

O

2'
Br

powdered 3Å molecular sieves under argon. The
murky brown solution was stirred at room temperature for 1 h. 3-Bromopropanol (1.2
mL) was then injected into the reaction mixture and the mixture stirred for 1.5 h. The
solution was filtered. The filtrate was then concentrated by evaporation under reduced
pressure and the residue applied to a silica column. A column was then run in 100%
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DCM. The product 116i was collected in 66% yield as a white solid (0.407 g, 0.8831
mmol), mp 123-125 °C.

1

H-NMR (300MHz, CDCl3): δ 7.54 (d, 2H, J=8.7, H-2’), 7.23 (d, 1H, J=8.4, H-5), 7.14

(d, 2H, J=8.7, H-3’), 7.00 (s, 1H, H-4), 6.85 (d, 1H, J=2.4, H-8), 6.78 (d of d, 1H,
J=2.1, 8.1, H-6), 5.97 (s, 1H, H-2), 4.11 (m, 1H, OCH2), 3.88 (m, 1H, OCH2), 3.41 (m,
2H, BrCH2), 2.31 (s, 3H, CH3CO), 2.30 (s, 3H, CH3CO), 2.11 (m, 2H,
OCH2CH2CH2Br).

13

C-NMR (75MHz, CDCl3): δ 169.6 (C=O), 169.4 (C=O), 151.5

(C7), 151.0 (C8a), 150.7 (C4’), 134.3 (Ca), 129.5 (Ca), 128.1 (C5), 126.8 (C2’), 122.2
(C3’), 121.4 (C4), 119.5 (C4a), 115.6 (C6), 110.4 (C8), 97.6 (C2), 65.6 (OCH2), 32.7
(OCH2CH2), 30.8 (CH2Br), 21.4 (COCH3), 21.4 (COCH3).
Ca: C3 or C1’
MS (CI+): m/z 463/461 (M+1, 13/17%), 462/460 (M+, 14/13%), 418/420 (M+1-COCH3,
4/4%), 323 (M-OCH2CH2CH2Br, 100%), 281 (M-OCH2CH2CH2Br-COCH3, 75%), 239
(M-OCH2CH2CH2Br-2xCOCH3, 38%). HR (CI+) MS: m/z calcd for [MH+]
C22H21BrO6: 461.0594, found: 461.0590.

Attempted

Synthesis

of

7-actetoxy-3-p-acetoxyphenyl-2-(5-triazoyl)-2H-1-

benzopyran (132)
The isoflavene 116c (0.024 g, 0.0688 mmol) was stirred with CuSO4.5H2O (0.003 g,
0.00120 mmol), sodium ascorbate (0.008 g, 0.0404 mmol) and TMS azide (0.154 g,
1.337 mmol) in a 1:1 mixture of ethanol and water (2mL) for 48 hours. Water was
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added and the precipitate collected, 1H-NMR analysis only showed the starting
isoflavene 116c.

Attempted

synthesis

of

aminomethyl

7-hydroxy-3-p-hydroxyphenyl-2H-1-

benzopyran (70)
The diacetoxy protected nitrile compound 116a (0.100 g, 0.2871 mmol) in anhydrous
THF (0.9 mL) was added dropwise to a suspension of LiAlH4 (0.026 g, 0.6772 mmol) at
0ºC. Upon the nitrile addition gelatinisation of the mixture began and thus an additional
amount of anhydrous THF (1 mL) was added. This stopped the gelatinisation process
and dissolved the gel that had already formed. The resulting suspension was stirred at
0ºC for 10 min, then at rt for 2.75 h. Water (25mL) was added to the reaction mixture
and the mixture filtered. The filtrate was evaporated to dryness. Attempts to purify the
product 70 were unsuccessful, as recrystallisation proved difficult and product absorbed
strongly to the base line on PLC (silica gel). Attempts to extract further product from
the aluminium hydroxide precipitate with DCM, ether and ethyl acetate were
unsuccessful.

Attempted deprotection of 7-acetoxy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran
(115a)
Compound 116a (0.300 g, 0.8602 mmol) in a 5M imidazole in methanol solution
(10ml) was heated at reflux for 1.5 h. The solution was then cooled to rt and the
methanol was evaporated off under reduced pressure. Water (25 ml) was added,
resulting in a milky precipitate. This suspension was stored in the refrigerator for 13 h,

207

resulting in a more coarse precipitate. The off white precipitate was collected by suction
filtration. 1H-NMR analysis of this product revealed it only containing aromatic
hydrogens, and no characteristic signal between 6.0-6.2ppm (for H2).

Synthesis of 2-cyano-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115a)
The nitrile 116a (0.0845 g, 0.243 mmol) was stirred at

OH

5

room temperature in THF (3mL) and 50% methanol/water

6

4a

4

4'
3

7

1M NaOH (9mL) for 4 h. The solution was then

HO

8

8a O 2
1

1'

3'
2'

CN

neutralized with 5M HCl and extracted with DCM (2x50mL). The DCM extract was the
concentrated, and then applied to a silica plug (short column). 15% Diethyl ether in
DCM was passed through the plug to give the product 115a as a red glass (0.061 g,
0.233mmol) in 96% yield.

1

H-NMR (300MHz, d6-acetone): δ 8.79 (bs, H, OH), 7.52 (d, 2H, J=8.7, H-2’), 7.19 (d,

1H, J=8.1, H-5), 7.09 (s, 1H, H-4), 6.93 (d, 2H, J=8.7, H-3’), 6.59 (d of d, 1H, J=8.4,
2.4, H-6), 6.55 (d, of d, J=2.1, 0.3, H-8), 6.46 (s, 1H, H-2). 13C-NMR (75MHz, d6acetone): δ 160.0 (C8a), 158.1 (C7), 156.6 (C4), 142.8 (C3), 139.7 (C1’), 128.9 (C2’),
125.8 (C5), 115.4 (C3’), 113.4 (C4), 110.3 (CN), 105.0 (C6), 103.5 (C4a), 102.8 (C8),
61.2 (C2). MS (CI+): m/z 266 (M+1, 3%), 239 (isoflavylium, 100%). Microanalysis:
Found: C=72.43%; H=4.21, N=5.25%; C21H20O6 requires: C=72.45%; H=4.18%,
N=5.28%.
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Synthesis of 2-allyl-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115f)
Compound 116f (0.095 g, 2.61 mmol) was stirred at

OH

5

room temperature in a 1M NaOH, 50% methanol/50%

6

4a

4

4'
3

1'

3'
2'

7

water solution (12 mL) for 7h. The solution was

HO

8

8a O 2
2"
1"
1

3"

neutralised with 5M HCl and extracted with DCM (2x50mL). The DCM extract was
concentrated, then applied to a silica plug. 15% Diethyl ether in DCM was passed
through the plug to give the product 115f as a red glass (0.071 g, 0.253 mmol) in 97%
yield.

1

H-NMR (300MHz, d6-acetone): δ 8.33 (s, 1H, OH), 8.27 (s, 1H, OH), 7.41 (d, 2H,

J=8.7, H-2’), 6.98 (d, 1H, J=7.8, H-5), 6.87 (d, 2H, J=8.7, H-3’), 6.75 (s, 1H, H-4), 6.42
(d of d, 1H, J=8.1, 2.4, H-6), 6.35 (d, 1H, J=2.4, H-8), 5.94 (m, 1H, H-2”), 5.35 (d of d,
1H, J=9.3, 3.3, H-2), 5.04 (d of d, 1H, J=6.0, 1.2, H-3”), 5.0 (d, 1H, J=1.2, H-3”), 2.52
(m, 1H, H-1”), 2.25 (m, 1H, H-1”).

13

C-NMR (75MHz, d3-acetone): δ 158.6 (C7),

157.3 (C4’), 152.8 (C8a), 134.8 (C3), 132.0 (C2”), 128.7 (C1’), 127.6 (C5), 126.5
(C2’), 117.2 (C4), 116.8 (C3”), 115.8 (C3’), 108.7 (C6), 107.6 (C4a) 103.7 (C8), 76.0
(C2), 37.9 (C1”). MS (CI+): m/z 281.1 (M+1, 22%), 239.3 (M+1-allyl, 100%). HR
(CI+) MS: m/z calcd for [MH+] C18H16O3: 281.1172, found: 281.1176.
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Synthesis of 2-ethoxy-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran (115h)
The 2-ethoxy compound 116h (0.011 g, 0.03013 mmol)

OH

5

was stirred at rt in a 0.1M NaOH, 50% methanol/50%

6

4'

4
4a

3

1'

7

water solution (0.6 mL) and THF (4.5 mL) for 2h. The

HO

O
8 8a 1

2

3'
2'

O

solution was neutralised with 5M HCl and extracted with DCM (2 x 25mL). The DCM
layers were then combined, dried with MgSO4 and concentrated, then applied to a silica
plug. 15% Diethyl ether in DCM was passed through the plug to give the product 115h
as a red glass (0.005 g, 0.016 mmol) in 53% yield.

1

H-NMR (300MHz, d4-methanol): δ 7.08 (d, 2H, J=8.4, H-2’), 7.00 (d, 1H, J=7.8, H-

5), 6.81 (s, 1H, H-4), 6.48 (d, 2H, J=8.4, H-3’), 6.44 (d of d, 1H, J=7.8, 2.4, H-6), 6.35
(d, 1H, J=2.1, H-8), 6.13 (s, 1H, H-2), 4.80 (m, 1H, OCH2CH3), 3.63 (m, 1H,
OCH2CH3). 13C-NMR (75MHz, d4-methanol): δ 158.7 (C8a), 156.9 (C7), 150.9 (C4’),
127.7 (C*), 126.8 (C*), 126.6 (C2’), 126.3 (C5), 119.5 (C4), 115.3 (C4a), 115.3 (C3’),
109.7 (C6), 103.6 (C8), 92.0 (C2), 67.8 (CH2CH3), 20.5 (CH3CH2).
Ca: C3 or C1’
MS (CI+): m/z 239.3 (isoflavylium, 100%). Microanalysis: Found: C=71.78%; H=4.21,
N=5.25%; C17H16O4requires: C=71.82%; H=5.67%.
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Synthesis of 2-(3-bromopropoxy)-7-hydroxy-3-p-hydroxyphenyl-2H-1-benzopyran
(115i)
The diacetoxy 2-bromopropoxy compound 116i (0.106 g,

OH

4'
5

0.231 mmol) was stirred at room temperature in a 0.1M

6

4a

4

3

1'

7

NaOH, 50% methanol/50% water solution (1 mL) and

HO

8

8a O 2 O
1

3'
2'
Br

THF (9 mL) for 20h. An additional portion of aqueous 5M NaOH was added (0.2mL)
The solution was neutralised with 5M HClaq and extracted with DCM (2x50mL). The
DCM layers were then combined, dried with MgSO4 and concentrated, then the residue
applied to a silica plug. 15% Diethyl ether in DCM was passed through the plug to give
the product 115i as a red glass (0. 057 g, 0.1507 mmol) in 65% yield.

1

H-NMR (300MHz, d6-acetonitrile): δ 7.53 (d, 2H, J=8.7, H-2’), 7.23 (d, 1H, J=9.0, H-

5), 7.08 (s, 1H, H-4), 6.96 (d, 2H, J=8.7, H-3’), 6.62 (m, 2H, H6, H-8), 6.11 (s, 1H, H2), 4.16 (d of t, 1H, J=10.2, 5, OCH2), 3.96 (d of d of d, 1H, J=12.3, 6.9, 5.7, OCH2),
3.52 (t, 2H, J=6.6, OCH2CH2CH2Br), 2.18 (t of d, 2H, J=6.5, 4.8, OCH2CH2CH2Br).
13

C-NMR (75MHz, d6-acetonitrile): δ 158.4 (C8a), 157.2 (C7), 151.7 (C4’), 129.0 (C3),

128.4 (C1’), 127.9 (C5), 127.1 (C2’), 119.5 (C4), 116.0 (C3’), 115.3 (C4a), 109.8 (C6),
103.8 (C8), 97.8 (C2), 65.7 (OCH2), 33.1 (CH2CH2Br), 31.2 (CH2Br). (CI+) MS: m/z
379.3/377.1 (M+1, 9/10%), 239 (M-O(CH2)3Br, 100%). HR (CI+) MS: m/z calcd for
[MH+] C18H17BrO4: 377.0383, found: 377.0387.

211

8.2.3

Chemistry Experimental Relating to Chapter 4

Deprotection of 7-acetoxy-3-p-acetoxyphenyl-2,3-dihydrobenzopyran-4-one (134a)
The acetate protected ketone 127a (0.910 g, 2.668 mmol) was

OH
O

5

heated at reflux in a 5M solution of imidazole in methanol (10

4

6
7

mL) for 4 h. The solution was concentrated by evaporation

HO

8

4'

O

3
2

1'

3'
2'

1

under reduced pressure and was poured into water (50mL). The
resulting precipitate was then filtered. The residue was collected by suction filtration
and dried under reduced atmosphere providing the desired free phenolic product 30 in a
93% yield (0.635 g, 2.481 mmol) mp over 270ºC, as a pale pink powder.

1

H-NMR (300MHz, d6-acetone): δ 7.74 (d, 1H, J=8.7, H-5), 7.07 (d, 2H, J=8.4, H-2’),

6.74 (d, 2H, J=8.4, H-3’), 6.50 (d of d, 1H, J=8.7, 2.1, H-6), 6.33 (d, 1H, J=2.7, H-8),
4.55 (d, 1H, J=2.4, H-2), 4.53 (d, 1H, J=2.7, H-2), 3.83 (d of d, 1H, J=6.2, 1.2, H-3).
13

C-NMR (75MHz, d6-acetone): δ 190.4 (CO), 164.4 (C7), 163.8 (C8a), 156.9 (C4’),

129.9 (C2’), 129.5 (C5), 127.3 (C1’), 115.5 (C3’), 114.6 (C4a), 110.7 (C6), 102.7 (C8),
72.0 (C2), 51.1 (C3). MS (CI+): m/z 341 (M+1 100%).

Attempted synthesis of 7-cyclohexyloxy-3-p-cyclohexyloxyphenyl-2,3-dihydro-4H1-benzopyran-4-one (134b)
A solution of 1M BF3-etherate (0.1 mL) was added to a stirred solution of 30 (0.495 g,
1.457 mmol) in cyclohexene (3 mL). The reaction mixture was stirred at rt for 48 h.
TLC analysis showed only starting material present. The solution was then heated at
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reflux overnight. TLC analysis again showed only starting material present. The
reaction mixture was evaporated to dryness under reduced pressure. 1H-NMR and MS
(CI+) analysis of the residue confirmed the sole presence of the starting ketone 30.

Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-2,3dihydro-4H-1-benzopyran-4-one (134c)
A mixture of 30 (1.978 g, 7.750 mmol),

O
O

imidazole

(5.429

t-butyldimethylsilyl

g,

79.74

5

mmol),

chloride (5.875

g,

6

4a 4

7

Si
O

8

8a O
1

4'
3

1'

Si

3'
2'

2

mmol) and powdered 3Å molecular sieves in DMF (45 mL) was stirred at rt for 30 h.
The reaction mixture was then filtered. Ice-water (50 mL) was added to the filtrate
resulting in precipitate formation. The product was extracted with DCM (2 x 50mL),
washed with water (50 mL), brine (50 mL) and dried over MgSO4. The solution was
then filtered. The filtrate was evaporated under reduced pressure. The resulting solid
(2.820 g, 5.829 mmol, 75% yield) was recrystallised from ethanol to afford 127b as a
white powder, mp103-104ºC.

1

H-NMR (500MHz, CDCl3): δ 7.88 (d, 1H, J=9.0, H-5), 7.12 (d, 2H, J=8.0, H-2’), 8.50

(d, 2H, J=8.5, H-3’), 6.52 (d, 1H, J=8.5, H-6), 6.41 (s, 1H, H-8), 4.60 (m, 2H, H-2),
3.86 (d of d, 1H, J=8.0, 5.0, H-3), 0.97 (s, 18H, SiC(CH3)3), 0.18 (s, 6H, SiCH3), 0.00
(s, 6H, SiCH3).

13

C-NMR (75MHz, CDCl3): δ 191.4 (CO), 163.2 (C*), 162.8 (C*),

155.2 (C4’), .129.6 (C2’), 129.5 (C1’), 127.9 (C5), 120.3 (C3’), 115.6 (C4a), 115.0
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(C6), 107.6 (C8), 72.0 (C2), 51.3 (C3), 25.6 (SiC(CH3)3), 25.5 (SiC(CH3)3), 18.2
(SiC(CH3)3), 18.2 (SiC(CH3)3), -4.4 (SiCH3), -4.3 (SiCH3).
C*: C7 or C8a
MS (CI+): m/z 485 (M+1, 100%), 371 (M+1- t-BDMS, 9%), 257 (M+2- 2x t-BDMS,
9%).

Attempted reaction of 134a with trimethylsilylcyanide
A mixture of 134a (0.552 g, 1.624 mmol), trimethylsilyl cyanide (0.383 g, 3.870 mmol)
and p-toluenesulfonic acid (ca. 2 mg) was heated at reflux in acetonitrile (50 mL) for 27
h. The solution was then evaporated to dryness. The resulting solid showed only the
presence of the 134a starting material by TLC, CI-MS and 1H-NMR analysis.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-4-cyano-4-trimethylsilyloxy-3,4-dihydro2H-1-benzopyran (154)
The ketone 134a (0.317 g, 0.9323 mmol) and
Si

trimethylsilyl cyanide (0.38mL) in dry toluene
(3mL) was heated at reflux for 3.5 h. The reaction

NC

5
6

O

7
O

mixture was then poured into ice water (15mL) and

4a

8

8a O

O

4'

O

4
3
2

1'

3'

O

2'

extracted with ether (2x50mL). The ether extracts were combined, the solvent
evaporated and the residue chromatographed on a silica column using 2% hexane in
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DCM as the mobile phase. This produced the TMS ether nitrile 154 in 5% yield (0.0205
g, 0.0466 mmol), mp 161-162ºC.

1

H-NMR (300MHz, CDCl3): δ 7.60 (d, 1H, J=8.7, H-5), 7.71 (d, 2H, J=9.0, H-2’), 7.13

(d, 2H, J=9.0, H-3’), 6.77 (d of d, 1H, J=8.7, 2.7, H-6), 6.69 (d, 1H, J=2.1, H-8), 4.62 (d
of d, 1H, J=11.0, 12.6, H-2), 4.32 (d of d, 1H, J=10.8, 3.6, H-2), 3.46 (d of d, 1H,
J=12.6, 3.9), 2.33 (s, 3H, CH3), 2.31 (s, 3H, CH3), 0.07 (s, 9H, Si(CH3)3). 13C-NMR: δ
169.1 (C=O), 168.9 (C=O), 159.7 (C8a), 153. 3 (C7), 150.0 (C4’), 149.4 (C4a), 147.3
(C1’) 130.2 (C5), 130.8 (C2’), 121.9 (C3’), 114.3 (C6), 103.8 (C8), 71.3 (C4), 69.0
(C2), 29.5 (C3), 22.3 (CH3), 0.02 (Si(CH3)3). CI-MS: m/z 440 (M+1, 100%), 367
(M+1-TMS, 26%). HR (CI+) MS: m/z calcd for [MH+] C23H25NO6Si: 440.1524, found:
440.1529.

Synthesis of 7-acetoxy-3-p-acetoxyphenyl-2cyano-2H-1-benzopyran (133)
The ketone 134a (0.317 g, 0.9324 mmol),

N
O

BF3.etherate (3 drops) and trimethylsilyl cyanide

5
6

O

(0.38mL) in dry toluene (3mL) was heated at reflux

4'
4a

4

7
O

8

8a O
1

3 1' 2'
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O

for 3.5 h. Pyridine (1.7mL) and freshly distilled POCl3 (0.35mL) was added and the
reaction mixture was heated at reflux for a further 2hr. The reaction mixture was then
poured into ice water (15mL) and extracted with diethyl ether (2 x 50mL). The diethyl
ether was evaporated in vacuo and the crude product was then purified through silica gel
chromatography using DCM as the eluant. This gave the product 133 in 12% (0.039 g,
0.1119mmol), mp 149-150ºC.
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1

H-NMR (500MHz, CDCl3): δ 7.56 (d, 2H, J=8.5, H2’), 7.42 (d, 1H, J=8.5, H-5), 7.18

(d, 2H, J=8.5, H-3’), 6.74 (d of d, 1H, J=8.5, 2.5, H-6), 6.65 (d, 1H, J=2.5, H-8), 4.05
(s, 2H, H-2), 2.28 (s, 3H, CH3), 2.25 (s, 3H, CH3).

13

C-NMR: 169.9 (C=O), 169.5

(C=O), 152.3 (C8a), 147.7 (C7), 144.6 (C4’), 131.9 (C3), 128.9 (C2’), 126.6 (C5),
126.4 (CN), 122.6 (C3’), 117.0 (C4a), 116.0 (C6), 110.4 (C8), 68.6 (C2), 21.4 (CH3),
21.3 (CH3). CI+-MS: m/z 350 (M+1, 100%), 334 (-16). HR (CI+) MS: m/z calcd for
[MH+] C20H15NO5: 350.1023, found: 350.1019.

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4-oxime -4H-1-benzopyran (142)
A mixture of the ketone 134a (0.347 g, 1.021 mmol),

OH

OH

N

5

hydroxylamine hydrochloride (0.203 g, 2.920 mmol) and

6

4a 4

7

sodium acetate (0.180 g, 2.188 mmol) in absolute ethanol

HO

8

8a O
1

4"
3

1"

3"
2"

2

(4 mL) was heated at reflux for 4 h. Mass spectral analysis revealed the acetate groups
had been removed with no oxime addition. An additional quantity of hydroxylamine
hydrochloride (0.304 g, 4.372mmol) was added. The mixture was heated at reflux for an
additional 4h. The resulting suspension was cooled to rt and filtered. The filtrate was
evaporated under reduced pressure at 50°C. The residue was dissolved in DCM and
ethyl acetate, then loaded onto a silica column. A column was run using 15% ethyl
acetate in DCM as the eluting solvent to give the product 142 as a glass (0.177 g, 0.6539
mmol) in 64% yield.
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1

H-NMR (300MHz, CD3OD): δ 7.72 (d, 1H, J=8.7, H-5), 7.07 (d, 2H, J=8.4, H-2’),

6.65 (d, 2H, J=8.4, H-3’), 6.43 (d of d, 1H, J=8.7, 2.1, H-6), 6.26 (d, 1H, J=2.7, H-8),
4.51 (bd, 1H, J=1.6, H-3), 4.39 (d of d, 1H, J=9.0, 1.6, H-2), 4.21 (d of d, 1H, J=2.7,
9.0, H-2). 13C-NMR (75MHz, CD3OD): δ 159.8 (C4), 158.8 (C7), 157.4 (C8a), 150.9
(C4’), 130.0 (C1’), 128.5 (C5), 125.4 (C2’), 114.9 (C3’), 110.8 (C4a), 110.1 (C6), 103.0
(C8), 70.9 (C2), 60.8 (C3). MS (CI+): m/z 272 (M+1, 100%), 257 (30, 47%). HRMS
(CI+): m/z calcd for [MH+] C15H13NO4: 271.0855, found: 271.0846.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-

phenylhydrazone (76)
A mixture of the ketone 134a (1.992 g, 5.858 mmol),
4"

phenylhydrazine hydrochloride (3.021 g, 20.891 mmol) and

3"
2"

sodium acetate (3.330 g, 40.60 mol) in absolute ethanol (27

1"
OH

NH
N

mL) was heated at reflux for 7 h. The resulting suspension

5
6

was cooled to room temperature and filtered. The filtrate was

4a 4

7
HO

8

8a O
1

4'
3 1'

3'
2'

2

evaporated under reduced pressure at 50°C. The residue was
dissolved in DCM and diethyl ether, then loaded onto a silica column. A gradient
column was run, starting with 100% DCM, then increasing polarity by 5% diethyl ether
increments and ending with 15% diethyl ether in DCM. This gave the phenyl hydrazone
76 as a yellow-brown glass (1.660 g, 4.80 mmol) in 82% yield and the ketone
intermediate 30 as a cream coloured powder (0.240 g, 0.94 mmol) in 16% yield.
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1

H-NMR (300MHz, d6-acetone): δ 8.03 (d, 1H, J=8.4, H5), 7.79 (bs, 1H, NH), 7.19 (m,

5H, H-2’, H3”, H4”), 6.78 (d, 2H, J=8.9, H-3’), 6.75 (t, 2H, J=7.2, H-2”), 6.54 (d of d,
1H, J=8.4, 2.1, H-6), 6.29 (d, 1H, J=2.4, H-8), 4.36 (d of q, 2H, J=11.4, 2.1, H-2), 4.20
(bs, 1H, H-3). 13C-NMR (75MHz, d6-acetone): δ 159.0 (C7), 157.4 (C8a), 156.9 (C4’),
146.2 (C4), 138.0 (C1”), 129.4 (C1’), 129.1 (C5), 128.5 (C3”), 125.7 (C2’), 119.3
(C4”), 115.6 (C2”), 114.6 (C3’), 112.9 (C4a), 110.4 (C6), 103.2 (C8), 71.5 (C2), 38.7
(C3). MS (CI+): m/z 347 (M+1, 22%), 330 (M-OH, 18%), 257 (30, 100%). HR (CI+)
MS: m/z calcd for [MH+] C21H18N2O3: 347.1390, found: 347.1393.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-

chlorophenyl hydrazone (159a)
A mixture of the ketone 134a (0.331 g, 0.974 mmol), pCl

chlorophenylhydrazine hydrochloride (0.6078 g, mmol)

4"

and sodium acetate (0.508 g, mmol) in absolute ethanol (4

1"

3"
2"

NH

OH

N

mL) was heated at reflux for 7 h. The resulting suspension

5
6

was cooled to rt and filtered. The filtrate was evaporated

4a

4

7
HO

under reduced pressure at 50°C. The residue was dissolved

8

8a O
1

4'
3

1'

3'
2'

2

in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run,
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and
ending with 15% diethyl ether in DCM. This gave the phenyl hydrazone product 159a
(0.239 g, 0.6271 mmol) as an orange glass in 64 %yield and the ketone intermediate 30
as a cream coloured powder (0.072 g, 0.2824 mmol) in 29% yield.
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1

H-NMR (300MHz, d6-acetone): δ 8.37 (s, 1H, NH), 8.06 (d, 1H, J=8.7, H-5), 7.13 (m,

6H, H-2’, H-2”, H-3”), 6.77 (d, 2H, J=12.3, H-3’), 6.59 (d of d, 1H, J=9.0, 2.7, H-6),
6.33 (d, 1H, J=2.4, H-8), 4.42 (d of d, 1H, J=11.1, 2.1, H-2), 4.33 (d of d, 1H, J=10.8,
3.0, H-2), 4.29 (bd, 1H, J=2.1, H-3).

13

C-NMR (75MHz, d6-acetone): δ 159.2 (C7),

157.5 (C8a), 156.9 (C4’), 145.1 (C4), 139.0 (C1”), 129.9 (C1’), 129.4 (C2’), 128.9
(C3’), 125.8 (C5), 123.2 (C4”), 115.8 (C2”), 115.6 (C4a), 114.3 (C3’), 110.5 (C6),
103.2 (C8), 71.4 (C2), 38.7 (C3). MS (EI+): m/z 382/381/380 (M+1, 36/27/100%). HR
(EI+) MS: m/z calcd for [MH+] C21H17ClN2O3: 380.0929, found: 380.0928.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-m-

chlorophenyl hydrazone (159b)
A mixture of the ketone 134a (0.333 g, 0.9791 mmol), m-

4"
5"

chlorophenylhydrazine hydrochloride (0.621 g, 3.468

Cl

3"
2"

6"
1"
NH

mmol) and sodium acetate (0.461 g, 5.624 mmol)

OH

N

5
6

absolute ethanol (4 mL) was heated at reflux for 7 h. The

4a 4

7
HO

resulting suspension was cooled to rt and filtered. The

8

8a O
1

4'
3

1'

3'
2'

2

filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in
DCM and ether, then loaded onto a silica column. A gradient column was run, starting
with 100% DCM, then increasing polarity by 5% diethyl ether increments and ending
with 15% ether in DCM. This gave the phenyl hydrazone product 159b (0.209 g, 0.5487
mmol) as a yellowy orange glass in 56% yield and the ketone intermediate 30 as a
cream coloured powder (0.088 g, 0.3427 mmol) in 35% yield.
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1

H-NMR (300MHz, d6-acetone): δ 8.69 (bs, 1H, OH), 8.57 (s, 1H, NH), 8.36 (bs, 1H,

OH), 8.00 (d, 1H, J=9.0, H-5), 7.21 (t, 1H, J=2.1, H2”), 7.17-7.14 (m, 1H, H-5”), 7.13
(d, 2H, J=8.7, H-2’), 7.00 (d of d of d, 1H, J=8.1, 2.1, 0.9, H-4”), 6.77 (d, 2H, J= 9.0,
H-3’), 6.73 (d of d of d, 1H, J=7.8, 2.1, 0.6, H-6”), 6.60 (d of d, 1H, J=8.7, 2.4, H-6),
6.32 (d, 1H, J=2.4, H-8), 4.46 (d of d, 1H, J=12.3, 3.3, H-2), 4.37 (d, 1H, J=2.7, H-2),
4.34 (bs,1H, H-3). 13C-NMR (75MHz, d6-acetone): δ 159.4 (C7), 157.6 (C8a), 156.9
(C4’), 147.6 (C4), 139.5 (C1”), 134.6 (C1’), 130.5 (C5), 129.3 (C2’), 128.2 (C3”),
125.8 (C2”), 118.7 (C5”), 115.8 (C3’), 114.1 (C4a), 112.5 (C4”), 111.4 (C6”), 110.5
(C6), 103.2 (C8), 71.4 (C2), 38.7 (C3). MS (EI+): m/z 382/381/380 (M+1, 36/27/100%).
HR (EI+) MS: m/z calcd for [MH+] C21H17ClN2O3: 380.0929, found: 380.0928.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-o-

chlorophenyl hydrazone (159c)
A mixture of the ketone 134a (0.325 g, 0.9568 mmol), o-

4"
3"

chlorophenylhydrazine hydrochloride (0.554 g, 3.0947

Cl

6"
1"
OH

NH

mmol) and sodium acetate (0.259 g, 3.154 mmol) in

N

5
6

absolute ethanol (4 mL) was heated at reflux for 7 h. The

7
HO

resulting suspension was cooled to rt and filtered. The

5"

2"

8

4a

4

8a O
1

4'
3

1'

3'
2'

2

filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in
DCM and diethyl ether, then loaded onto a silica column. A gradient column was run,
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and
ending with 15% diethyl ether in DCM. This gave the product 159c as an orange brown
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glass (0.226 g, 0.5932 mmol) in 62% yield the ketone intermediate 30 as a cream
coloured powder (0.074 g, 0.2870 mmol) in 30% yield.

1

H-NMR (300MHz, d6-acetone): δ 8.11 (d, 1H, J=8.7, H-5), 7.82 (s, 1H, NH), 7.74 (d

of d, 1H, J=8.4, 1.2, H-3”), 7.21 (d of d, 2H, J=8.7, 2.1, H-2’), 7.21 (m, 2H, H-4”, H5”), 6.85 (d, 2H, J=8.4, H-3’), 6.75 (d of t, 1H, J=8.1, 1.5, H-6”), 6.65 (d of d, 1H,
J=9.0, 2.7, H-6), 6.44 (d, 1H, J=2.7, H-8), 4.39 (d of d, 1H, J=11.0, 3.6, H-2), 4.35 (d of
d, 1H, J= 11.1, 2.7, H-2), 4.23 (t, 1H, J=3.0, H-3). 13C-NMR (75MHz, d6-acetone): δ
159.7 (C7), 158.1 (C8a), 157.3 (C4’), 142.1 (C4), 141.5 (C1”), 129.6 (C2’), 129.0 (C*),
128.2 (C*), 128.1 (C1’), 125.9 (C5), 120.0 (C6”), 117.3 (C2”), 116.2 (C3’), 114.2
(C4a), 114.1 (C3”), 110.8 (C6), 103.4 (C8), 71.9 (C2), 40.5 (C3).
C*: C4” or C5”
MS (EI+): m/z 382/381/380 (M+1, 36/27/100%). HR (EI+) MS: m/z calcd for [MH+]
C21H17ClN2O3: 380.0929, found: 380.0928.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4-p-

nitrophenyl hydrazone (159d)
A mixture of the ketone 143a (0.338 g, 0.9926 mmol), p-

NO2

4"
3"

nitrophenylhydrazine (0.488 g, 2.576 mmol) in absolute

2"
1"

ethanol (4 mL) was heated at reflux for 4 h. The resulting

NH

OH

N

5

suspension was cooled to rt and filtered. The filtrate was
evaporated under reduced pressure at 50°C. The residue

6
7
HO

8

4a 4

8a O
1

4'
3 1'

3'
2'

2

was dissolved in DCM and diethyl ether, then loaded onto a silica column. A gradient
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column was run, starting with 100% DCM, then increasing polarity by 5% diethyl ether
increments and ending with 15% ether in DCM. This gave the free phenolic product
159d (0.2681 g, 0.6849 mmol, 69%) as a red glass and the diacetate hydrazone 160 as a
red glass (0.071 g, 0.1489 mmol, 15%).

159d:
1

H-NMR (300MHz, d4-methanol): δ 8.58 ( s, 2H, OH), 8.07 (d, 2H, J=8.1, H-3”),

8.04 (d, 1H, J=7.5, H-5), 7.17 (d, 2H, J=9.0, H-2”), 7.07 (d, 2H, J=8.4, H-2’), 6.70 (d,
2H, J=8.4, H-3’), 6.53 (d of d, 1H, J=9.0, 2.1, H-6), 6.26 (d, 1H, J=2.1, H-8), 4.48 (d of
d, 1H, J=11.4, 2.1, H-2), 4.35 (d of d, 1H, J=11.4, 2.7, H-2), 4.25 (bs, 1H, H-3). 13CNMR (75MHz, d4-methanol): δ 160.0 (C7), 158.1 (C8a), 156.6 (C4’), 151.3 (C4), 142.8
(C1”), 139.3 (C4”), 128.9 (C2’), 127.8 (C5), 125.9 (C1’), 125.6 (C3”), 115.4 (C2”),
113.4 (C4a), 111.5 (C3’), 110.3 (C6), 102.8 (C8), 71.3 (C2), 39.0 (C3).
MS (EI+): m/z 392 (M+1, 25%), 391 (M+, 100%). HR (EI+) MS: m/z calcd for [MH+]
C21H17N3O5: 391.1168, found: 391.1169.

160:
1

H-NMR (300MHz, d4-methanol): Z isomer δ 8.18

NO2

4"
3"

(d, 1H, J=9.0, H-5), 8.05 (d, 2H, J=9.0, H-3”), 7.26

2"
1"

(d, 2H, J=8.7, H-2’), 7.16 (d, 2H, J=9.3, H-2”), 7.01
5

(d, 2H, J=8.7, H-3’), 6.77 (d of d, 1H, J=8.7, 2.4, H6), 6.14 (d, 1H, J=2.4, H-8), 4.46 (d, 1H, J=9.0, H-

O

NH
N

6
7

O
O

8

4a 4

8a O
1

4'
3 1'

3'

O

2'

2

2), 4.40 (bs, 1H, H-2), 4.00 (bd, 1H, J=3.0, H-3), 2.22 (s, 3H, CH3), 2.19 (2, 3H, CH3).
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13

C-NMR (75MHz, d6-acetone): δ 170.2 (C=O), 169.8 (C=O), 157.1 (C8a), 152.4 (C7),

150.9 (C4), 150.2 (C4’), 141.1 (C1”), 139.8 (C4”), 139.4 (C1’), 135.0 (C5), 128.9
(C2’), 125.7 (C3”), 121.9 (C3’), 115.4 (C4a), 111.9 (C2”), 110.5 (C6), 102.8 (C8), 71.0
(C2), 38.8 (C3), 19.8 (CH3), 19.7 (CH3).
MS (EI+): m/z 476 (M+1, 9%), 475 (M+, 23%), 433 (M+-OAc, 100%), 391 (M+-2xAc,
28%). HR (EI+) MS: m/z calcd for [MH+] C25H21N3O7: 475.1374, found: 475.1370.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-

methylphenyl hydrazone (159e)

CH3

4"
3"

A mixture of the ketone 134a (0.359 g, 1.057 mmol), p-

2"
1"

tolylhydrazine hydrochloride (0.580 g, 3.671 mmol) and

NH

OH

N

5

sodium acetate (0.312 g, 3.800 mmol) in absolute ethanol (4
mL) was heated at reflux for 4 h. The resulting suspension

6

4a

4

7
HO

8

8a O
1

4'
3

1'

3'
2'

2

was cooled to rt and filtered. The filtrate was evaporated
under reduced pressure at 50°C. The residue was dissolved in DCM and diethyl ether,
then loaded onto a silica column. A gradient column was run, starting with 100% DCM,
then increasing polarity by 5% diethyl ether increments and ending with 15% diethyl
ether in DCM. This gave the product 159e as an orange brown glass (0.255 g, 0.7064
mmol) in 67 % yield.

1

H-NMR (300MHz, d3-acetonitrile): δ 8.28 (bs, 2H, OH), 8.01 (d, 1H, J=8.7, H-5), 7.70

(bs, 1H, NH), 7.08 (d, 2H, J=8.4, H-2’), 7.00 (d, 1H, J=9.0, 3.3 H-3”), 6.97 (d, 1H,
J=9.0, H-2”), 6.75 (d, 2H, J=9.0, H-3’), 6.53 (d of d, 1H, J=9.0, 2.7, H-6), 6.29 (d, 1H,
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J=2.4, H-8), 4.37 (d of q, 2H, J=10.8, 2.1, 2.7, H-2), 4.18 (bs 1H, H-3), 2.22 (s, 3H,
CH3).

13

C-NMR (75MHz, d3-acetonitrile): δ 159.7 (C7), 158.3 (C8a), 157.6 (C4’),

146.3 (C4), 138.9 (C1”), 131.8 (C1’), 131.2 (C*), 130.6 (C*), 129.5 (C4”), 126.8 (C5),
116.7 (C4a), 116.3 (C3’), 114.1 (C3”), 111.8 (C6), 103.8 (C8), 73.1 (C2), 39.8 (C3),
20.9 (CH3).
C*: C2’ or C2”
MS(CI+): m/z 361 (M+1, 100%), 344 (M+1-OH, 30%), 256 (ketone, 43%). HR (CI+)
MS: m/z calcd for [MH+] C22H20N2O3: 361.1551, found: 361.1548.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-p-

cyanophenyl hydrazone (159f)
CN

A mixture of 134a (0.326 g, 0.9574 mmol), p-

4"
3"

cyanophenylhydrazine hydrochloride (0.524 g, 3.187

2"
1"

mmol) and sodium acetate (0.564 g, 6.876 mmol) in 4.5

NH

OH

N

5

mls absolute ethanol was heated at reflux for 7 hours. The
resulting suspension was cooled to rt and filtered. The

6

4a 4

7
HO

8

8a O
1

4'
3 1'

3'
2'

2

filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved in
DCM and ether, then loaded onto a silica column. A gradient column was run, starting
with 100% DCM, and ending with 35% ether in DCM. This gave the product 159f
(0.209 g, 0.5625mmol) in 59% yield, mp 224-225 °C decomp.

1

H-NMR (300MHz, d6-acetone): δ 9.06 (s, 1H, NH), 8.10 (d, 1H, J=8.7, H-5), 7.52 (d,

2H, J=9.3, H-3”), 7.25 (d, 2H, J=8.7, H-2”), 7.11 (d, 2H, J=8.4, H-2’), 6.77 (d, 2H,
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J=8.7, H-3’), 6.60 (d of d, 1H, J=9.0, 2.7, H-6), 6.32 (d, 1H, J=2.4, H-8), 4.49 (d of d,
1H, J=3.0, 12.0, H-2), 4.37 (m, 2H, H-2, H-3). 13C-NMR (75MHz, d6-acetone): δ 165.0
(C7), 163.1(C8a), 162.1(C4’), 154.5 (C4), 146.6(C1”), 138.7 (C3”), 134.5 (C2’), 133.1
(C5), 131.3(C1’), 125.1(CN), 121.0 (C3’), 119.0(C4a), 118.2 (C2”), 118.2 (C4”), 115.8
(C6), 108.4 (C8), 106.0, 76.5 (C2), 43.9 (C3). MS (CI+): m/z 369 (M-2, 7%), 257
(ketone +1, 100%). HR (CI+) MS: m/z calcd for [M+-2] C22H20N2O3: 369.1114, found:
369.1111.

Synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-benzopyran-4-(2-

pyridyl)hydrazone (159g)
4"

A mixture of the ketone 134a (0.323 mg, 0.9494 mmol), 2-

5"

3"

6"

N 2"
1" 3'

hydrazinopyridine (0.475 g, 4.352 mmol) in absolute

NH
N

ethanol (4mL) was heated at reflux for 4 h. The resulting

5
6

suspension was cooled to rt. The filtrate was evaporated

4a

4

7
HO

8

8a O
1

OH

4'
3 1' 2'
2

3'

under reduced pressure at 50°C. The residue was dissolved
in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run,
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and
ending with 35% ether in DCM. This gave the product 159g as a pale pink powder
(0.106 g, 0.321 mmol), mp 145-146°C in 34% yield.

1

H-NMR (300MHz, d6-acetone): δ 8.72 (bs, 1H, OH), 8.30 (bs, 1H, OH), 8.07 (d, 1H,

J=8.7, H-5), 7.99 (d of q, 1H, J=5.1, 0.9, H-3”), 7.61 (d of d of d, 1H, J=9.0, 7.2, 2.1, H5”), 7.35 (d of t, 1H, J=8.4, 0.9, 6”), 7.18 (d, 2H, J=8.7, H-2’), 6.80 (d, 2H, J= 8.7, H-
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3’), 6.72 (d of d of d, 1H, J=6.7, 4.8, 0.9, H-4”), 6.59 (d of d, J=9.0, 2.7, H-6), 6.36 (d,
J=2.1, H-8), 4.41 (bs, 1H, H-3), 4.39 (bs, 2H, H-2). 13C-NMR (75MHz, d6-acetone): δ
159.6 (C7), 158.0 (C8a), 157.6 (C4’), 157.1 (C1”), 147.9(C3”), 140.3 (C4), 137.9
(C5”), 129.4 (C2’), 128.5 (C1’), 125.8 (C5), 116.0 (C3’), 115.5 (C4”), 114.1 (C4a),
110.6 (C6), 107.0 (C2”), 103.3 (C8), 71.8 (C2), 39.3 (C3). MS (CI+): m/z 348 (M+1,
7%), 257 (ketone+1, 100%). MS (ES+): m/z 348 (M+1, 100%). HR (ES+) MS: m/z
calcd for [MH+] C20H17N3O3: 348.1348, found: 348.1348.

Attempted

synthesis

of

7-hydroxy-3-p-hydroxyphenyl-2,3-dihydro-4H-1-

benzopyran-4-diphenyl hydrazone (161)
A mixture of the ketone 134a (0.239 g, 0.7032 mmol), diphenylhydrazine hydrochloride
(0.803 g, 3.638 mmol) and sodium acetate (0.290 g, 3.540 mmol) in absolute ethanol (4
mL) was heated at reflux for 5 h. TLC analysis showed only the formation of the
diphenolic ketone product 30. The reaction mixture was heated at reflux for an
additional 12 h. The resulting suspension was cooled to room temperature and filtered.
The filtrate was evaporated under reduced pressure at 50°C. The residue was dissolved
in DCM and diethyl ether, then loaded onto a silica column. A gradient column was run,
starting with 100% DCM, then increasing polarity by 5% diethyl ether increments and
ending with 15% diethyl ether in DCM. This gave the deprotected ketone product 30
but no 161 could be detected by 1H-NMR and TLC analysis.
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Attempted synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4(2-imidazoyl) hydrazone (162)
A mixture of the ketone 134a (0.409 g, 1.1200 mmol), 2-imidazoylhydrazine
hydrobromide (0.571 g, 3.187 mmol) and sodium acetate (0.522 g, 6.361 mmol) in
absolute ethanol (4mL) was heated at reflux for 7 h. The solution was cooled to rt and
filtered. The filtrate was dried under reduced pressure and applied to a silica column. A
gradient column was then run in 15% ether in DCM, then increasing polarity by 5%
diethyl ether increments and ending with 35% ether in DCM. This gave the
benzofuranone 162 as a cream powder (0.119 g, 0.4928 mmol, mp >280°C) in 44
%yield.

1

H-NMR (300MHz, CD3OH): δ 8.13 (s, 1H, OH),

4
5

O

3a

HO

6.93 (d of d, 1H, J=9.0, 2.4, H-5), 6.84 (d, 2H,

3
1'

8.05 (d, 1H, J=8.7, H-4), 7.36 (d, 2H, J=8.7, H-2’),
6
7

7a O
1

2

4'
2'

OH

3'

J=8.4, H-3’), 6.84 (d, 1H, J=2.4, H-7), 5.15 (s, 1H, H-2). 13C-NMR (75MHz, CD3OH):
δ 164.5 (C3), 163.8 (C7a), 159.7 (C6), 156.9 (C4’), 129.9 (C2’), 129.5 (C4), 127.3
(C1’), 115.5 (C3’), 110.7 (C5), 110.0 (C3a), 102.7 (C7), 51.1 (C2). MS (CI+): m/z 243
(M+1, 100%). HR (CI+) MS: m/z calcd for [MH+] C14H10O4: 243.0619, found:
243.0616.
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Attempted Synthesis of 7-hydroxy-3-p-hydroxyphenyl-2,3-dihydrobenzopyran-4(p-trifluoro)pyrimidine hydrazone (164)
A mixture of the ketone 134a (0.326 g, 0.9588 mmol), 2-hydrazino-2-imidazole
hydrobromide (0.544 g, 3.040 mmol) and sodium acetate (0.521 g, 5.264 mmol) in
absolute ethanol (4mL) was heated at reflux for 7 h. The reaction mixture was then
filtered and the filtrate evaporated to dryness. The crude material was subjected to silica
chromatography, however 1H NMR and MS (CI+) analysis revealed only the ketone 30
was recovered.

Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-4hydroxy-4-(5-methylthien-2-yl)-3,4-dihydro-2H-1-benzopyran (144)
The ketone 134c (0.334 g, 0.6880 mmol) in THF (1 mL) was added dropwise to a
stirred a 0.5 M solution of 5-methylthien-2-ylzinc bromide 177 in THF (3 mL) and the
mixture was then stirred at rt overnight. The reaction mixture was added to ice-water
(50 mL) and DCM (2x50 mL) was added. The DCM fractions were combined and
washed with water (50 mL), saline (50 mL) and then dried over MgSO4. The DCM was
then evaporated under reduced pressure. The crude material was then redissolved in
DCM and applied to a silica column. A gradient column was then run over 25 min
initially using 50% Pet. Spirit (40-60) 50% DCM as the eluting solvent, then increasing
polarity by 10% DCM increments and ending with 100% DCM. This gave the desired
product 145 in 8% yield (0.027 g, 0.0550 mmol, ) 62-63°C mp as pale yellow crystals
and the benzofuran 178 in 80% yield (0.267 g, 0.5504 mmol), 57-58ºC mp as white
crystals.

228

144:
1
H-NMR (300MHz, CDCl3): δ 12.69 (s, 1H, OH), 7.60

4"

3"
2"

(d, 1H, J=8.7, H-5), 7.09 (d, 2H, J=8.7, H-2’), 6.98 (d,

5
6

1H, J=5.1, H-4”), 6.74 (d, 2H, J=8.7, H-3’), 6.68 (d,

1"

O

O

4a 4

3'

3 1' 2'
2

O

8

4'

OH

7

Si

1H, J=4.8, H-3”), 6.33 (d, 1H, J=2.4, H-8), 6.25 (d of d,

Si
S

1

1H, J=9.3,2.7, H-6), 4.65 (t, 1H, J=6.9, H-3), 4.44 (d of d, 1H, J=6.9, 14.7, H-2), 3.18
(d of d, 1H, J=7.5, 15.0, H-2), 1.96 (s, 3H, C4”CH3), 0.96 (s, 9H, SiC(CH3)3), 0.95 (s,
9H, SiC(CH3)3), 0.21 (s, 6H, SiCH3), 0.16 (s, 6H, SiCH3). 13C-NMR (75MHz, CDCl3)
δ: 203.6 (C4), 165.8 (C8a), 163.0 (C7), 155.2 (C4’), 135.3 (C1”), 134.4 (C1”), 132.3
(C5), 131.9 (C4”), 129.9 (C3”), 129.2 (C2’), 122.1 (C4”), 120.7 (C3’), 114.0 (C4a),
112.4 (C6), 108.3 (C8), 54.3 (C3), 32.1 (C2), 25.9 (SiC(CH3)3), 25.7 (SiC(CH3)3), 22.8
(ArCCH3), -4.2 (SiCH3), -4.2 (SiCH3). MS (ES-): m/z 581 (M-1, 5%), 492.5 (-tBu-H2O,
16%), 313 (, 100%). MS (ES+): m/z 583 (M+1, 18%), 485 (M-thienyl, double bond
compound, 100%). HR (ES+) MS: m/z calcd for [MH+] C32H46O4SSi2: 583.2734, found:
583.2740. Microanalysis: Found: C=67.09%; H=8.52; C32H46O4SSi2 requires:
C=65.93%; H=7.95%.

178:
1

Si

H-NMR (300MHz, CDCl3): δ 12.30 (s, 1H, OH), 7.24 (d,

O

4'

3'

1H, J=9.0, H-4), 7.10 (d, 2H, J=8.7, H-2’), 6.61 (d, 2H,

2'

J=8.7, H-3’), 6.23 (d, 1H, J=2.1, H-7), 6.08 (d of d, 1H,

4
5

1'
3a 3

Si
O

6

O

7

1

OH

2
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J=9.0, 2.1, H-5), 5.66 (s, 1H, CH2), 5.16 (s, 1H, CH2), 0.78 (s, 18H, CCH3), 0.05 (s, 6H,
SiCH3), 0.00 (s, 6H, SiCH3).

13

C-NMR (75MHz, CDCl3) δ: 206.4 (C3), 170.3 (C2),

168.0 (C7a), 160.6 (C6), 150.9 (C4’), 139.6 (C4), 134.1 (C1’), 132.1 (C2’), 124.7 (C3’),
120.1 (C=CH2), 118.5 (C3a), 116.6 (C5), 112.4 (C7), 30.1 (SiC(CH3)3), 29.9
(SiC(CH3)3), 22.6 (SiC(CH3)3), 0.1 (SiCH3). MS (ES+): m/z 485 (M+1, 100%). HR
(ES+) MS: m/z calcd for [MH+] C27H40O4Si2: 485.2543, found: 485.2542.

Attempted synthesis of 144
The ketone 143c (0.325 g, 0.9559 mmol) in THF and a 0.5 M solution of 5-methyl
thienlylzinc bromide in THF (2.5 mL) was added and stirred at room temperature
overnight. The reaction mixture was added to ice-water (50 mL) and DCM was added.
The DCM was collected and an addition DCM (3x50 mL) extraction was performed.
The DCM fractions were combined and washed with water (2x100mL), saline (100mL)
and dried over MgSO4. The DCM was then evaporated under reduced pressure. The
crude material was then redissolved in DCM and applied to a silica column. A gradient
column was then run in 2 hr initially using 50% Pet. Spirit (40-60) 50% DCM as the
eluting solvent, increasing polarity by 10% DCM increments and ending with 100%
DCM. This gave the benzofuran 178 (0.421 g, 0.8699 mmol) in 91% yield as white
crystals.
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Attempted dehydration of 144 using copper sulfate
A mixture of the thienyl alcohol 144 (0.269 g, 0.4625 mmol) and benzofuran 178 (0.336
g, 0.6938 mmol) was heated at reflux in a suspension of ground anhydrous CuSO4
(0.410 g, 2.567 mmol) in dry toluene (2.5 mL) for 2 h. TLC analysis and ES-MS
showed no reaction had occurred. The reaction mixture was then heated at reflux
overnight. The reaction mixture was filtered and the solvent removed under reduced
pressure. TLC and 1H-NMR analysis showed only the presence of the starting material
alcohol 144 and the benzofuran 178.

Attempted dehydration of 144 using P2O5
A crude mixture of the thienyl alcohol 144 (0.108 g, 0.1852 mmol) and 178 (0.135 g,
0.2778 mmol) was stirred with P2O5 (1.274 g, 13.851 mmol) at rt in DCM (10 mL) for 3
h. The reaction mixture was then poured into water and extracted with DCM (3x 50
mL). The DCM extracts were then combined, washed with water (50mL) and brine (50
mL) and dried with MgSO4. Evaporation of the solvent gave an off white powder which
was found to be the starting ketone 134c (0.075 g, 0.2214 mmol) by ES-MS, TLC
analysis and 1H-NMR spectroscopy.

Attempted dehydration of 144 using the Burgess reagent
A solution of the crude thienyl alcohol 144 (0.079 g, 0.1364 mmol), crude benzofuran
178 (0.099 g, 0.2044 mmol) and the Burgess reagent (CH3OCON-SO2N+(CH2CH3)3)
(0.039 g, 0.1632 mmol) in toluene (1.5 mL) was heated at reflux for 1 h. The solution
was poured into water and filtered through celite. The filtrate was extracted with DCM
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(2 x 50 mL), washed with brine and then dried over MgSO4. Evaporation of the solvent
gave a residue which did not contain any of the dehydrated product 143 on the basis of
1

H-NMR and ES-MS spectroscopic analysis.

Enolate Anion Stability Experiment
A solution of 134c (0.506 g, 1.0335mmol) in DMF (1 mL) was added dropwise to 60%
sodium hydride (0.085 g, mmol) in mineral oil in DMF (4 mL) at 0°C which produced
bubbling. The solution turned yellow and was stirred for 1 h. The solution was then
added to ice-water (100 mL) and extracted with DCM. There was a precipitate in the
water layer which was not DCM soluble, this precipitate was collected. The DCM layer
was evaporated to dryness. This gave a mixture of the rearranged product 178 and
ketone 134c in a 15% ratio of rearranged product to the starting ketone by NMR
analysis.

Attempted

Synthesis

of

7-tert-butyldimethylsilyloxy-3-p-tert-

butyldimethylsilyloxyphenyl-4-(5-methylthien-2-yl)-3,4-dihydro-2H-1-benzopyrene
(176)
A solution of 134c (0.602 g, 1.034 mmol) in DMF (2 mL) was added dropwise to 60%
sodium hydride (0.147 g, 1.608 mmol) in mineral oil in DMF (8 mL) at -48°C which
produced bubbling. The solution turned yellow and was stirred for 1 h. N-phenyl
bis(trifluoromethane) sulfonimide (1.213 g, 3.4081 mmol) was added at -48°C for 2 h,
then allowed to cool to rt at which the reaction mixture was stirred overnight. Thienyl
ZnBr 171 in THF (0.5 M, 7 mL, mmol), then Pd(PPh)4 (0.006 g, mmol) was added to
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the reaction mixture. The reaction mixture was poured into water and extracted with
DCM. The DCM was washed with water and brine. The DCM layer was then dried over
MgSO4. The 1H-NMR spectrum of the crude material obtained after evaporation of the
DCM did not reveal the presence of the desired thienyl product 143 as it did not contain
the diagnostic C2 signals expected between 5.0 ppm and 6.5 ppm.

Attempted synthesis of 145a
A solution of 134c (0.602 g, 1.034 mmol) in DMF (2 mL) was added dropwise to
sodium hydride (0.147 g, 1.608 mmol, 60% in mineral oil) in DMF (8 mL) at -48°C.
The solution turned yellow and was stirred for 1 h. N-phenyl bis(trifluoromethane)
sulfonimide (1.213 g, 3.4081 mmol) was added at -48°C and the mixture stirred at this
temperature for 2 h. The mixture was then allowed to warm to rt and then stirred
overnight. The reaction mixture was poured into water and extracted with DCM. The
DCM was washed with water and brine. The DCM layer was then dried over MgSO4.
The DCM was removed by evaporation in vacuo and the residue subjected to column
chromatography on alumina (eluting with 60% pet spirit in DCM and ending with 20%
pet. spirit in DCM, increasing polarity by 10% increments). However no characterisable
products were obtained.
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Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-4methoxy-2H-1-benzopyran 145b in DMF
A solution of 134c (0.298 g, 1.034 mmol) in DMF (1
O
O

mL) was added dropwise to 60% sodium hydride

5
6

(0.0643 g, 1.608 mmol) in mineral oil in DMF (4 mL)

4a

4

7

Si
O

8

4'

8a O
1

3 1' 2'

Si

3'

2

at -48°C which produced bubbling. The solution turned yellow and was stirred for 1.25
h. methyl iodide (0.3125 g, 2.202 mmol) was added and the reaction mixture stirred at 48°C for 4 h. The reaction mixture was allowed to warm to rt and stirred overnight. The
reaction mixture was poured into water and extracted with DCM (2x100 mL). The
DCM was washed with water and brine. The DCM layer was then dried over MgSO4.
After filtration, the DCM layer was evaporated under reduced pressure to dryness. The
crude material was then redissolved in DCM (2 mL) and applied to an alumina column.
Gradient chromatography was performed, starting with 5% DCM in pet. spirit, and
increasing in polarity by increments of 10% DCM, to 60% DCM in pet. spirit. This
gave the product 145b as a colourless glass (0.325 g, 0.6511 mmol), mp 67-68ºC in
63% yield.

1

H-NMR (500MHz, CDCl3): δ 7.89 (d, 1H, J=9.0, H-5), 7.13 (d, 2H, J=9.0, H-2’),

6.80 (d, 2H, J=8.5, H-3’), 6.61 (d of d, 1H, J=8.5, 2.0, H-6), 6.44 (d, 1H, J=2.0, H-8),
4.65-4.57 (m, 2H, H-2), 3.85 (s, 3H, OCH3) 0.97 (s, 18H, SiC(CH3)3), 0.18 (s, 6H,
SiCH3), 0.00 (s, 6H, SiCH3).

13

C-NMR (75MHz, CDCl3) δ: 169.3 (Cq), 169.0 (Cq),

151.4 (C8a), 150.5 (C7), 150.1 (C4’), 133.4 (C4), 128.9 (C5), 128.1 (C1’), 126.8 (C2’),
125.6 (), 121.8 (C3’), 119.4 (C3), 116.0 (C4a), 110.3 (C6), 91.7 (C8), 30.9 (OCH3),
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21.2 (SiC(CH3)3), 21.1 (SiC(CH3)3), 0.00 (SiCH3). MS (ES+): m/z 498 (M+, 12%), 441
(M-C(CH3)3, 100%), 385 (M-2(C(CH3)3), 42%). HR (ES+) MS: m/z calcd for [M+]
C28H42O4Si2: 498.2626, found: 498.2623.

Synthesis of 7-tert-butyldimethylsilyloxy-3-p-tert-butyldimethylsilyloxyphenyl-4methoxy-2H-1-benzopyran 145b in THF
The ketone 134c (0.5816 g, 1.1200 mmol) was reacted with 60% sodium hydride (0.132
g, 1.608 mmol), then iodomethane (0.266 g, 1.8746 mmol) in a similar method to that
described above, however using THF(2 mL, 8 mL) as the solvent. This produced the
product 145b in 75% yield (0.426 g, 0.8496 mmol).

Attempted synthesis of 143 from 145b
The thienylzinc bromide 177 in THF (0.5M, 2 mL, 1.0 mmol) was added to 145b (0.375
g, 0.7534 mmol) at -98 °C and the mixture stirred at -98 °C for 4 h. The reaction
mixture was then allowed to warm to rt and stirred at rt for 7 days. The reaction mixture
was then poured into water (50 mL) and extracted with DCM (2 x 50 mL). Evaporation
of the DCM solvent afforded a crude product which was subjected to a silica gradient
column was then run starting with 40% DCM in pet spirit, and the DCM was then
increased by 10% increments until 60% DCM in pet spirit was reached. This gave an
unidentified compound (0.007 g), together with the starting material 145b (0.338 g,
90% recovery).
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Unidentified compound
1

H-NMR (300MHz, CDCl3): δ 7.70 (d, 1H, J=9.0), 7.17 (d, 2H, J=9.0), 7.10 (s, 1H),

6.67 (d, 2H, J=9.0), 6.39 (d of d, 1H, J=8.7, 2.7), 6.18 (d, 1H, J=2.4), 4.65 (d, 1H,
J=12.0), 4.17 (d, 1H, J=12.0) , 3.63 (s, 2H), 3.59 (s, 3H).

13

C-NMR (75MHz,

CDCl3): δ 163.1, 159.0, 129.8, 127.8, 127.8, 120.2, 114.3, 110.3, 100.6, 75.4, 55.8,
55.4, 48.6, 25.8, 21.6. MS (EI+): m/z 568 (7%), 432 (39%), 376 (100%), 332 (57%).

Attempted synthesis of 143 from 145b using NiCl2 as a catalyst
The thienylzinc bromide 177 in THF (0.5M, 2 mL, 1.0 mmol), was added to the 4methoxy compound 145b (0.3752 g, 0.7534 mmol) and NiCl2 (0.003g, 0.02 mmol) at 98ºC and stirred at -98ºC for 4h, the reaction mixture was then allowed to warm to rt
and stirred at rt for 7 days. The reaction mixture was poured into water (50 mL) and
extracted with DCM (2 x 50 mL). Evaporation of the DCM in vacuo afforded a crude
solid, which was subjected to a silica gradient column, which was then run starting with
40% DCM in pet spirit, DCM was increased by 10% increments until 60% DCM in pet
spirit was reached. This produced 0.224 g, while none of the starting material 145b was
recovered
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8.3

Biological Experimental Section

Cellular Preparation
Testosterone treated and untreated LNCaP cells were cultured.

Protein Extraction
LNCaP cells were transferred from a T-75 culture flask into a 50 ml centrifuge
tube with its medium. The T-75 culture flask was washed with 3 mls of ice cold
phosphate buffer solution (PBS) to collect any residual cells. The cells were centrifuged
at 1000 rpm for 7 mins at 4°C. The supernatant was discarded and 1 ml of ice cold PBS
was added to the pellet in the 50 ml centrifuge tube. This was gently pipetted up and
down to create a suspension of the cells. This suspension was transferred to a 1.5 ml
eppendorph tube, which was then centrifuged on a microcentrifuge for 3 min. The
supernatant was then discarded and 1 ml of ice cold PBS was added to the pellet, then
gently pipetted up and down to create a suspension. This was then centrifuged in a
microcentrifuge for 3 min. The eppendorph tube was then placed on ice. 150 µL of
solubilization buffer was added to the pellet and gently pipetted up and down to create a
suspension. The tube was then placed into liquid nitrogen for 20 seconds and allowed to
thaw out at room temperature. This freeze thaw process was repeated 5 times. However,
the last thaw was done while the tube was on ice. After it has fully thawed, centrifuge
the tube at 11000 rpm at 4°C for 10 min. A cloudy supernatant was then collected. The
protein concentration was then determined according to the pierce instructions.212
Protein was stored on ice until use.
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Assay
The concentration of protein in the assay was 2 µg/ml, the concentration of
NADPH in the assay was 150 µΜ. The concentration of 3H testosterone and finasteride
were varied over a range from 10 nM to 500 nM and 0.5 µΜ to 2 µΜ respectively. Each
sample was made up with 50 mM tris-citrate buffer at ph6 to reach a final volume of
100 µL. Negative controls were carried out and the assay was carried out in duplicate.
The ingredients of the assay were added and mixed together, with the exclusion
of the testosterone. The inhibitors were allowed an incubation time of 30 min while
cooled on ice. The testosterone was then added, and the sample incubated for 1.5 h. The
assay was stopped by the addition of ethyl acetate (1 ml), and then the sample was
shaken. The sample was then stored in the freezer (-4ºC) overnight. The ethyl acetate
was then decanted from the ice and evaporated by passing nitrogen over the sample.
Then 20 µL of ethanol was added to the glass tube. The ethanol was then spotted onto a
silica TLC plate. The plate was developed with 15% diethylether in dichloromethane.
The spots corresponding to androstenedione, testosterone and dihydrotestosterone were
cut out and placed in a poly Q scintillation vial. 5ml of Scintillation fluid (5mL) was
added and the sample counted, on a Wallac 1409, 1480 Wizard™ 3” Gamma Counter
for 5 min each.

Note: Cell based assays for cell lines were performed by Novogen, Sydney.
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Appendix 1

Training Set Compounds

Three training sets containing inhibitors for human 5-α-reductase I and II, and rat
5-α-reductase type II are shown in this appendix.
The references for each molecule are included.
The naming of the compounds comprise of the reference number and the
compound number within the reference; protonation of any nitrogens are also
indicated in the naming system.
The initial number of the compound name is the reference number.
The following 3 or 4 o’s are included as spacers.
The following number/letter is the number of the compound within the reference.
If the name of the compound has an ending of ‘ooop’ the compound has been
protonated in the training set. If the name the compound does not have an
ending of ‘ooop’ the compound has not been protonated.
5α-Reductase inhibition activities are given as IC50’s (nM).
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Appendix 2

Processes log for the 5AR type II Pharmacophore Generation

Human 5AR type II Hypotheses Generation
Summary of parameters:
HyposReported
10
Spacing
300
MinPoints
4
MinSubsetPoints
4
SuperpositionError
1
Misses
1
FeatureMisses
1
CompleteMisses
0.0e+00
ToleranceFactor
1
CheckSuperposition
1
WeightVariation
0.3
MappingCoeff
0.0e+00
Mem
60
IdealHBondGeomOnly
0.0e+00
VariableWeight
0.0e+00
VariableTolerance
0.0e+00
Constraints on numbers of features:
Name:
HBA
HYDROPHOBIC HYDROPHOB aromaticNegIonizable RING
AROMATIC Total
Min:
0
0
0
0
0
3
Max:
5
5
5
5
5
10
Best records in pass 6.

dumping score for the 1st hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.52172
2.52172
2.52172
2.52172
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -6.04 -7.48 2.00
0.30 -0.45 2.75 4.03
: Y 1.25 2.75
-3.17 1.25 -1.21 -2.07 -4.40
: Z -0.14 -2.33 -4.82 1.24 -0.30 -1.64 -0.25
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 10.3 11.4
RING AROMATIC o6.5 8.7
7.7
---> 6.1 8.3
5.5
3.0
RING AROMATIC o9.5 11.3
3.4
5.0 3.6
---> 11.5 13.7
5.1
6.9 5.5 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
8.61 19 + [1 31 23 10 ] 0.16
7.26 12 - [* 13 18 1 ] 3.6
7.31 3 - [* 1 23 10 ] 3.2
7.23 9 + [* 22 14 1 ] 3.9
7.28 2 + [* 13 17 27 ] 3.4
7.04 3 - [* 13 18 1 ] 5.9
7.30 15 + [* 13 18 1 ] 3.2
7.25 16 + [* 38 14 1 ] 3.7
7.25 10 + [* 13 20 15 ] 3.7
7.11 7 + [* 13 17 1 ] 5.1
7.22 10 + [* 13 18 1 ] 4
7.20 19 - [* 22 14 1 ] 4.1
5.02 18 + [53 6 * * ] 620
6.70 13 + [* 13 18 1 ] 13
7.16 11 - [* 1 23 10 ] 4.5
7.23 31 - [* 22 14 1 ] 3.9
6.01 17 + [24 * 1 12 ] 63
4.90 3 + [12 * 19 * ] 820
6.08 149 + [50 * 19 33 ] 55
6.03 46 + [* 37 2 25 ] 61
5.00 28 + [* 17 * 1 ] 650
5.03 11 + [* 6 * 1 ] 610
4.97 2 + [* 23 * 1 ] 710
5.86 146 - [50 * 33 19 ] 90
5.79 167 + [* 24 17 12 ] 110
4.92 8 + [12 * 19 * ] 790
5.43 164 + [39 64 15 * ] 240

Act
Error Unc
0.29 - 1.8 3
0.56 + 6.3 3
0.57 + 5.7 3
1.1 + 3.5 3
1.5 + 2.3 3
2.5 + 2.4 3
2.7 + 1.2 3
3.4 + 1.1 3
4.1 - 1.1 3
6.4 - 1.3 3
7.3 - 1.8 3
9.3 - 2.3 3
9.8 + 63
3
10 + 1.3 3
11 - 2.4 3
12 - 3.1 3
38 + 1.7 3
52 + 16
3
56 - 1
3
59 + 1
3
60 + 11
3
71 + 8.5 3
220 + 3.2 3
230 - 2.6 3
300 - 2.8 3
320 + 2.5 3
330 - 1.4 3

18oooo8
5.00 4 + [* 23 * 1 ] 650
330 + 2
3
1oooo11
5.01 3 + [* 18 * 1 ] 630
340 + 1.9 3
3oooo6
5.04 4 + [15 17 * * ] 600
530 + 1.1 3
11ooooONO3805 5.03 92 + [62 2 * * ] 610
540 + 1.1 3
3oooo11
4.95 9 + [12 * 19 * ] 730
550 + 1.3 3
18oooo9
5.00 5 + [* 23 * 1 ] 650
640 + 1
3
3oooo12
5.00 28 + [* 17 * 1 ] 650
750 - 1.2 3
13oooo11
5.20 87 - [50 * 19 33 ] 410
810 - 2
3
3oooo9
5.03 4 + [* 17 46 * ] 610
830 - 1.4 3
17oooo19
5.03 2 + [* 6 * 1 ] 610
830 - 1.4 3
6oooo3
5.01 13 + [12 40 * * ] 630
870 - 1.4 3
13oooo2
5.16 119 - [65 * 7 19 ] 450
1200 - 2.7 3
6oooo9
4.94 10 + [12 * 19 * ] 740
1300 - 1.8 3
18oooo13
5.03 2 + [* 23 * 1 ] 610
2300 - 3.8 3
18oooo12
4.97 5 + [* 23 * 1 ] 700
4000 - 5.7 3
18oooo14
4.99 3 + [* 23 * 1 ] 670
4700 - 7
3
6oooo5a
4.88 6 + [12 * 19 * ] 860 10000 - 12
3
18oooo7
5.03 4 + [27 23 * * ] 610 10000 - 16
3
18oooo6
4.98 2 + [* 23 * 1 ] 690
10000 - 14
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=209.123 RMS=1.23867 correl=0.878901
Cost components: Error=190.015 Weight=2.61759 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 2nd hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.51074
2.51074
2.51074
2.51074
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -5.51 -6.42 3.60
3.00 2.78 0.51 1.86
: Y 2.02 3.57
-3.57 -2.07 0.36 1.16 3.09
: Z -0.02 -2.45 -3.22 0.38 -1.36 1.21 3.06
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 11.2 12.3
RING AROMATIC o9.5 11.3
3.9
---> 8.6 9.8
4.4
3.0
RING AROMATIC o6.2 8.2
7.2
4.2 3.5
---> 8.1 10.0
9.3
5.9 5.3 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
8.37 19 + [1 31 10 23 ] 0.19
7.16 9 - [* 13 1 18 ] 3.1
7.13 24 + [* 1 10 23 ] 3.3
7.14 7 + [* 22 1 14 ] 3.2
7.12 7 - [* 13 27 17 ] 3.4
6.89 2 + [* 13 1 18 ] 5.8
7.12 12 - [* 13 1 18 ] 3.4
7.09 13 - [* 38 1 14 ] 3.6
7.05 11 - [* 13 15 20 ] 4
6.87 7 + [* 13 1 17 ] 5.9
7.14 4 - [* 13 1 18 ] 3.2
7.14 35 + [* 22 1 14 ] 3.3
5.01 12 + [31 6 * * ] 430
6.39 2 + [* 13 1 18 ] 18
6.99 11 - [* 1 10 23 ] 4.6
7.20 7 - [* 22 1 14 ] 2.8
5.84 17 + [24 * 12 1 ] 64
4.75 3 + [12 * * 19 ] 800
5.30 126 - [48 * 19 7 ] 220
4.94 12 + [* 37 25 * ] 510
4.99 29 + [15 17 1 * ] 450
4.93 3 + [* 6 1 * ] 520
4.92 2 + [* 23 1 * ] 530
5.06 145 + [* 48 7 19 ] 390
5.43 176 - [27 * 12 1 ] 160
4.62 2 + [12 * * 19 ] 1100
5.41 164 + [39 64 * 15 ] 170

Act
Error Unc
0.29 - 1.5 3
0.56 + 5.5 3
0.57 + 5.8 3
1.1 + 2.9 3
1.5 + 2.3 3
2.5 + 2.3 3
2.7 + 1.2 3
3.4 + 1.1 3
4.1 - 1
3
6.4 - 1.1 3
7.3 - 2.3 3
9.3 - 2.9 3
9.8 + 44
3
10 + 1.8 3
11 - 2.4 3
12 - 4.3 3
38 + 1.7 3
52 + 15
3
56 + 4
3
59 + 8.6 3
60 + 7.5 3
71 + 7.3 3
220 + 2.4 3
230 + 1.7 3
300 - 1.8 3
320 + 3.3 3
330 - 1.9 3

18oooo8
4.98 6 + [27 23 * * ] 470
330 + 1.4 3
1oooo11
4.94 4 + [* 18 1 * ] 510
340 + 1.5 3
3oooo6
5.00 14 + [* 17 * 37 ] 450
530 - 1.2 3
11ooooONO3805 5.33 175 - [62 2 14 * ] 210
540 - 2.6 3
3oooo11
4.67 6 + [12 * * 19 ] 950
550 + 1.7 3
18oooo9
4.92 4 + [* 23 1 * ] 530
640 - 1.2 3
3oooo12
4.99 29 + [15 17 1 * ] 450
750 - 1.7 3
13oooo11
5.02 161 + [* 48 * 33 ] 430
810 - 1.9 3
3oooo9
4.99 40 + [* 17 * 46 ] 450
830 - 1.8 3
17oooo19
4.93 16 + [* 6 1 * ] 520
830 - 1.6 3
6oooo3
4.93 20 + [12 40 * * ] 520
870 - 1.7 3
13oooo2
5.25 145 - [65 * 33 19 ] 250
1200 - 4.8 3
6oooo9
4.62 4 + [12 * * 19 ] 1100
1300 - 1.3 3
18oooo13
4.92 8 + [* 23 1 * ] 530
2300 - 4.4 3
18oooo12
4.92 5 + [* 23 1 * ] 530
4000 - 7.5 3
18oooo14
4.96 2 + [27 23 * * ] 490
4700 - 9.5 3
6oooo5a
4.49 6 + [12 * * 19 ] 1400 10000 - 6.9 3
18oooo7
4.92 5 + [* 23 1 * ] 530
10000 - 19
3
18oooo6
4.99 7 + [27 23 * * ] 450 10000 - 22
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=212.105 RMS=1.29099 correl=0.867615
Cost components: Error=193.059 Weight=2.55542 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 3rd hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.37169
2.37169
2.37169
2.37169
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -5.42 -5.73 4.50
0.19 0.10 3.41 3.13
: Y 1.49 4.44
-1.87 -0.34 -1.05 -2.16 0.83
: Z -1.13 -1.53 -4.31 1.57 -1.34 -0.81 -0.69
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 10.9 12.3
RING AROMATIC o6.5 8.2
7.4
---> 6.1 8.0
5.4
3.0
RING AROMATIC o9.6 11.3
3.7
4.4 3.5
---> 8.6 9.6
4.7
3.9 3.6 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
7.94 19 + [1 31 23 10 ] 0.32
6.96 11 + [* 13 18 1 ] 3
6.95 3 - [* 1 23 10 ] 3.2
7.00 19 - [* 22 14 1 ] 2.8
6.99 2 + [* 13 17 27 ] 2.8
6.53 3 - [* 13 18 1 ] 8.2
7.01 15 + [* 13 18 1 ] 2.7
7.02 16 + [* 38 14 1 ] 2.7
6.86 10 + [* 13 20 15 ] 3.9
6.75 7 + [* 13 17 1 ] 5
6.84 10 + [* 13 18 1 ] 4
7.00 19 - [* 22 14 1 ] 2.8
4.74 10 + [* 6 * 1 ] 510
6.31 13 + [* 13 18 1 ] 14
6.73 11 - [* 1 23 10 ] 5.2
6.98 24 - [* 22 14 1 ] 2.9
6.07 17 + [24 * 1 12 ] 24
4.53 3 + [12 * 19 * ] 820
4.74 158 + [30 48 * * ] 510
4.74 3 + [* 37 * 25 ] 500
4.74 7 + [* 17 * 1 ] 500
4.74 9 + [* 6 * 1 ] 500
4.74 7 + [* 23 * 1 ] 510
4.81 47 + [* 48 19 33 ] 430
5.29 86 + [8 24 17 * ] 140
4.53 2 + [12 * 19 * ] 820
5.27 139 - [39 64 15 * ] 150

Act
Error Unc
0.29 + 1.1 3
0.56 + 5.4 3
0.57 + 5.6 3
1.1 + 2.5 3
1.5 + 1.9 3
2.5 + 3.3 3
2.7 + 1
3
3.4 - 1.3 3
4.1 - 1.1 3
6.4 - 1.3 3
7.3 - 1.8 3
9.3 - 3.4 3
9.8 + 52
3
10 + 1.4 3
11 - 2.1 3
12 - 4.1 3
38 - 1.6 3
52 + 16
3
56 + 9.1 3
59 + 8.5 3
60 + 8.4 3
71 + 7.1 3
220 + 2.3 3
230 + 1.9 3
300 - 2.1 3
320 + 2.6 3
330 - 2.2 3

18oooo8
4.74 6 + [27 23 * * ] 510
330 + 1.5 3
1oooo11
4.74 2 + [* 18 * 1 ] 510
340 + 1.5 3
3oooo6
4.74 43 + [* 17 * 1 ] 500
530 - 1.1 3
11ooooONO3805 4.81 175 - [62 2 * 14 ] 430
540 - 1.2 3
3oooo11
4.59 9 + [12 * 19 * ] 720
550 + 1.3 3
18oooo9
4.74 3 + [* 23 * 1 ] 500
640 - 1.3 3
3oooo12
4.74 7 + [* 17 * 1 ] 500
750 - 1.5 3
13oooo11
4.74 81 + [* 48 33 * ] 500
810 - 1.6 3
3oooo9
4.74 12 + [* 17 * 1 ] 500
830 - 1.6 3
17oooo19
4.74 6 + [* 6 * 1 ] 510
830 - 1.6 3
6oooo3
4.70 24 + [12 40 * * ] 550
870 - 1.6 3
13oooo2
4.95 103 + [65 * 7 19 ] 320
1200 - 3.8 3
6oooo9
4.52 10 + [12 * 19 * ] 840
1300 - 1.6 3
18oooo13
4.74 4 + [* 23 * 1 ] 510
2300 - 4.6 3
18oooo12
4.74 4 + [* 23 * 1 ] 500
4000 - 7.9 3
18oooo14
4.74 6 + [* 23 * 1 ] 510
4700 - 9.3 3
6oooo5a
4.47 6 + [12 * 19 * ] 950 10000 - 11
3
18oooo7
4.74 3 + [* 23 * 1 ] 510
10000 - 20
3
18oooo6
4.74 3 + [* 23 * 1 ] 500
10000 - 20
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=212.843 RMS=1.31453 correl=0.862115
Cost components: Error=194.469 Weight=1.88255 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 4th hypothesis
Definition:
HBA
HYDROPHOBIC RING AROMATIC RING AROMATIC
Weights:
2.30926
2.30926
2.30926
2.30926
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X 6.07 7.28
5.16
2.66 3.81 -1.24 -2.61
: Y -1.83 0.45
2.54
-0.68 -1.74 0.73 3.35
: Z -0.86 0.67
1.10
0.76 3.31 1.22 1.73
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
HYDROPHOBIC o 4.9 3.0
RING AROMATIC o3.9 4.8
4.1
---> 4.7 4.9
5.0
3.0
RING AROMATIC o8.0 8.5
6.7
4.2 6.0
---> 10.4 10.4
7.8
6.7 8.3 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
7.59 21 - [31 13 10 23 ] 0.99
8.43 8 + [15 38 1 18 ] 0.14
7.35 27 - [31 17 10 23 ] 1.7
7.28 19 - [22 8 1 14 ] 2
6.61 5 - [25 * 27 17 ] 9.4
6.45 3 - [15 * 1 18 ] 14
6.54 15 + [15 * 1 18 ] 11
6.81 16 + [39 8 1 14 ] 6
6.68 8 + [27 * 15 20 ] 8
6.46 7 + [14 * 1 17 ] 13
6.45 9 - [15 * 1 18 ] 14
7.29 2 + [22 8 1 14 ] 1.9
5.82 3 + [20 7 16 * ] 58
6.08 13 + [15 * 1 18 ] 32
6.69 8 + [5 * 10 23 ] 7.9
6.92 24 - [30 8 1 14 ] 4.6
5.96 42 - [* 58 12 1 ] 42
4.51 3 + [* 26 * 39 ] 1200
5.95 126 - [30 * 19 7 ] 43
4.90 21 + [39 27 * 2 ] 490
4.59 7 + [32 * 1 * ] 990
5.68 16 + [26 55 16 * ] 80
4.62 10 + [* 14 1 * ] 930
5.76 94 - [30 57 33 * ] 67
5.74 223 - [* 4 1 12 ] 69
4.61 5 + [* 48 * 19 ] 940
5.62 131 - [* 23 15 52 ] 92

Act
Error Unc
0.29 + 3.4 3
0.56 - 3.9 3
0.57 + 3
3
1.1 + 1.8 3
1.5 + 6.3 3
2.5 + 5.4 3
2.7 + 4.1 3
3.4 + 1.8 3
4.1 + 2
3
6.4 + 2.1 3
7.3 + 1.9 3
9.3 - 4.8 3
9.8 + 5.9 3
10 + 3.2 3
11 - 1.4 3
12 - 2.6 3
38 + 1.1 3
52 + 23
3
56 - 1.3 3
59 + 8.2 3
60 + 16
3
71 + 1.1 3
220 + 4.2 3
230 - 3.4 3
300 - 4.3 3
320 + 2.9 3
330 - 3.6 3

18oooo8
4.62 10 + [* 13 1 * ] 920
330 + 2.8 3
1oooo11
4.62 6 + [* 7 4 * ] 930
340 + 2.7 3
3oooo6
4.62 7 + [* 18 * 37 ] 920
530 + 1.7 3
11ooooONO3805 5.69 81 - [* 69 51 28 ] 78
540 - 6.9 3
3oooo11
4.60 9 + [* 48 * 19 ] 970
550 + 1.8 3
18oooo9
4.62 3 + [* 13 1 * ] 920
640 + 1.4 3
3oooo12
4.59 7 + [32 * 1 * ] 990
750 + 1.3 3
13oooo11
5.63 25 + [15 * 19 33 ] 89
810 - 9.1 3
3oooo9
5.38 19 + [* 5 46 26 ] 160
830 - 5.2 3
17oooo19
4.62 19 + [* 5 16 * ] 920
830 + 1.1 3
6oooo3
4.56 12 + [* 32 * 19 ] 1000
870 + 1.2 3
13oooo2
5.60 67 - [* 10 7 19 ] 95
1200 - 13
3
6oooo9
4.61 5 + [* 26 * 42 ] 930
1300 - 1.4 3
18oooo13
4.62 9 + [* 5 13 * ] 930
2300 - 2.5 3
18oooo12
4.62 11 + [* 13 1 * ] 920
4000 - 4.3 3
18oooo14
4.62 11 + [* 5 13 * ] 920
4700 - 5.1 3
6oooo5a
4.61 2 + [* 8 * 37 ] 950 10000 - 11
3
18oooo7
4.62 6 + [* 5 13 * ] 930
10000 - 11
3
18oooo6
4.62 8 + [* 5 13 * ] 920
10000 - 11
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=213.029 RMS=1.32144 correl=0.860472
Cost components: Error=194.888 Weight=1.6494 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 5th hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.35120
2.35120
2.35120
2.35120
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -4.47 -4.15 3.20
-0.15 1.06 2.14 2.06
: Y 3.46 6.01
-3.17 -0.39 0.26 -3.55 -6.53
: Z -0.33 -1.86 -4.02 1.82 4.49 -0.49 -0.82
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 10.8 12.0
RING AROMATIC o6.2 8.4
7.3
---> 8.0 10.0
9.4
3.0
RING AROMATIC o9.6 11.5
3.7
4.5 6.4
---> 11.9 14.0
4.8
7.0 8.7 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
Act
Error Unc
8.34 19 + [1 31 23 10 ] 0.12
0.29 - 2.4 3
6.91 9 - [* 13 18 1 ] 3.2
0.56 + 5.7 3
6.90 24 + [* 1 23 10 ] 3.3
0.57 + 5.7 3
6.92 7 + [* 22 14 1 ] 3.1
1.1 + 2.8 3
6.77 7 - [* 13 17 27 ] 4.4
1.5 + 3
3
6.60 2 + [* 13 18 1 ] 6.5
2.5 + 2.6 3
6.79 12 - [* 13 18 1 ] 4.2
2.7 + 1.6 3
6.77 13 - [* 38 14 1 ] 4.5
3.4 + 1.3 3
6.70 10 + [* 13 20 15 ] 5.1
4.1 + 1.3 3
6.59 7 + [* 13 17 1 ] 6.6
6.4 + 1
3
6.84 4 - [* 13 18 1 ] 3.8
7.3 - 1.9 3
6.92 35 + [* 22 14 1 ] 3.1
9.3 - 3
3
4.70 24 + [26 6 * * ] 520
9.8 + 53
3
6.21 2 + [* 13 18 1 ] 16
10 + 1.6 3
6.82 4 - [* 1 23 10 ] 4
11 - 2.8 3
6.90 34 - [* 22 14 1 ] 3.3
12 - 3.7 3
5.98 17 + [24 * 1 12 ] 28
38 - 1.4 3
4.45 3 + [12 * 19 * ] 930
52 + 18
3
5.04 23 - [48 * 7 19 ] 240
56 + 4.2 3
5.06 46 + [* 37 2 25 ] 220
59 + 3.8 3
4.70 7 + [* 17 * 1 ] 520
60 + 8.6 3
4.70 9 + [* 6 * 1 ] 520
71 + 7.3 3
4.69 7 + [* 23 * 1 ] 530
220 + 2.4 3
4.94 51 - [48 * 7 19 ] 300
230 + 1.3 3
4.96 85 - [24 * 17 12 ] 280
300 - 1.1 3
4.40 2 + [12 * 19 * ] 1000
320 + 3.3 3
5.21 164 + [39 64 15 * ] 160
330 - 2.1 3

18oooo8
4.70 2 + [* 23 * 1 ] 520
330 + 1.6 3
1oooo11
4.70 2 + [* 18 * 1 ] 520
340 + 1.5 3
3oooo6
4.70 13 + [* 17 * 1 ] 520
530 - 1
3
11ooooONO3805 4.70 171 + [* 2 51 * ] 520
540 - 1
3
3oooo11
4.43 9 + [12 * 19 * ] 960
550 + 1.7 3
18oooo9
4.70 3 + [* 23 * 1 ] 520
640 - 1.2 3
3oooo12
4.70 7 + [* 17 * 1 ] 520
750 - 1.5 3
13oooo11
4.84 87 - [50 * 19 33 ] 380
810 - 2.1 3
3oooo9
4.70 12 + [* 17 * 1 ] 520
830 - 1.6 3
17oooo19
4.70 6 + [* 6 * 1 ] 520
830 - 1.6 3
6oooo3
4.64 6 + [12 40 * * ] 600
870 - 1.5 3
13oooo2
5.50 41 + [65 * 7 19 ] 82
1200 - 15
3
6oooo9
4.42 4 + [12 * 19 * ] 990
1300 - 1.4 3
18oooo13
4.70 4 + [* 23 * 1 ] 520
2300 - 4.5 3
18oooo12
4.70 4 + [* 23 * 1 ] 520
4000 - 7.8 3
18oooo14
4.70 6 + [* 23 * 1 ] 520
4700 - 9.1 3
6oooo5a
4.31 6 + [12 * 19 * ] 1300
10000 - 7.9 3
18oooo7
4.70 3 + [* 23 * 1 ] 520
10000 - 19
3
18oooo6
4.70 3 + [* 23 * 1 ] 520
10000 - 19
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=213.09 RMS=1.31994 correl=0.860858
Cost components: Error=194.798 Weight=1.80132 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 6th hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.30525
2.30525
2.30525
2.30525
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -5.69 -8.11 4.01
0.19 0.65 3.37 5.70
: Y 2.59 1.33
-3.83 0.17 0.13 -1.11 0.55
: Z 0.30 1.54
-3.38 1.53 4.50 -1.25 -2.17
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 12.2 14.1
RING AROMATIC o6.5 8.4
7.4
---> 8.0 9.3
9.4
3.0
RING AROMATIC o9.9 12.1
3.5
4.4 6.5
---> 11.8 14.3
4.8
6.6 8.4 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
Act
Error Unc
8.67 44 + [1 31 23 10 ] 0.053
0.29 - 5.5 3
6.70 4 - [* 13 18 1 ] 4.9
0.56 + 8.8 3
6.79 24 - [* 1 23 10 ] 4
0.57 + 7.1 3
6.74 53 + [* 22 14 1 ] 4.5
1.1 + 4.1 3
6.80 7 + [* 13 17 27 ] 4
1.5 + 2.7 3
6.54 2 - [* 13 18 1 ] 7.3
2.5 + 2.9 3
6.62 12 + [* 13 18 1 ] 6
2.7 + 2.2 3
6.68 13 + [* 38 14 1 ] 5.2
3.4 + 1.5 3
6.69 11 + [* 13 20 15 ] 5.1
4.1 + 1.2 3
6.51 7 - [* 13 17 1 ] 7.7
6.4 + 1.2 3
6.65 4 + [* 13 18 1 ] 5.6
7.3 - 1.3 3
6.78 4 - [* 22 14 1 ] 4.1
9.3 - 2.2 3
4.98 29 - [31 6 * 1 ] 260
9.8 + 27
3
5.84 11 + [* 13 18 1 ] 36
10 + 3.6 3
6.63 4 + [* 1 23 10 ] 5.8
11 - 1.9 3
6.82 34 + [* 22 14 1 ] 3.8
12 - 3.2 3
5.40 200 - [24 * 1 12 ] 99
38 + 2.6 3
4.31 2 + [12 * 19 * ] 1200
52 + 23
3
4.95 23 + [48 * 7 19 ] 280
56 + 5
3
4.91 12 - [* 37 2 25 ] 310
59 + 5.2 3
4.61 11 + [* 17 * 1 ] 610
60 + 10
3
5.14 11 + [31 6 * 1 ] 180
71 + 2.5 3
4.61 2 + [* 23 * 1 ] 610
220 + 2.8 3
5.44 102 - [48 * 7 19 ] 90
230 - 2.6 3
5.27 162 + [24 * 1 12 ] 130
300 - 2.2 3
4.42 6 + [12 * 19 * ] 960
320 + 3
3
5.89 146 + [67 * 15 52 ] 32
330 - 10
3

18oooo8
4.61 6 + [* 23 * 1 ] 610
330 + 1.9 3
1oooo11
4.61 5 + [* 18 * 1 ] 610
340 + 1.8 3
3oooo6
4.61 19 + [* 17 * 1 ] 610
530 + 1.2 3
11ooooONO3805 4.75 97 - [3 * 51 28 ] 440
540 - 1.2 3
3oooo11
4.39 5 + [12 * 19 * ] 1000
550 + 1.8 3
18oooo9
4.61 4 + [* 23 * 1 ] 610
640 - 1
3
3oooo12
4.61 11 + [* 17 * 1 ] 610
750 - 1.2 3
13oooo11
4.88 20 + [50 * 7 19 ] 330
810 - 2.5 3
3oooo9
4.61 29 + [* 17 * 1 ] 610
830 - 1.4 3
17oooo19
5.32 5 + [31 6 16 * ] 120
830 - 6.9 3
6oooo3
4.45 7 + [12 40 * * ] 880
870 + 1
3
13oooo2
5.53 41 - [65 * 7 19 ] 73
1200 - 16
3
6oooo9
4.37 8 + [12 * 19 * ] 1100
1300 - 1.3 3
18oooo13
4.61 8 + [* 23 * 1 ] 610
2300 - 3.8 3
18oooo12
4.61 5 + [* 23 * 1 ] 610
4000 - 6.5 3
18oooo14
4.61 7 + [* 23 * 1 ] 610
4700 - 7.7 3
6oooo5a
4.42 4 + [12 * 19 * ] 950 10000 - 11
3
18oooo7
4.61 5 + [* 23 * 1 ] 610
10000 - 16
3
18oooo6
4.61 2 + [* 23 * 1 ] 610
10000 - 16
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=217.268 RMS=1.38964 correl=0.844335
Cost components: Error=199.141 Weight=1.63589 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 7th hypothesis
Definition:
HBA
HYDROPHOBIC RING AROMATIC RING AROMATIC
Weights:
2.02431
2.02431
2.02431
2.02431
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X 5.40 6.72
5.16
2.68 3.80 -1.39 -2.45
: Y -1.99 -3.80 2.54
-0.56 -1.85 1.07 3.81
: Z -1.40 -3.39 1.10
0.80 3.27 0.78 1.37
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
HYDROPHOBIC o 5.2 7.9
RING AROMATIC o3.8 6.7
4.0
---> 4.9 7.5
5.1
3.0
RING AROMATIC o7.8 10.3
6.7
4.4 6.5
---> 10.1 12.8
7.7
6.8 8.6 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
6.79 14 - [31 13 10 23 ] 2.6
7.95 8 + [15 38 1 18 ] 0.18
6.83 3 - [5 17 10 23 ] 2.3
6.89 19 - [22 8 1 14 ] 2
6.02 2 + [25 * 27 17 ] 15
5.88 3 - [15 * 1 18 ] 21
6.01 15 + [15 * 1 18 ] 15
6.69 16 + [39 8 1 14 ] 3.3
5.96 10 + [27 * 15 20 ] 17
5.85 7 + [14 * 1 17 ] 23
5.93 10 + [14 * 1 18 ] 19
6.86 19 - [22 8 1 14 ] 2.2
5.80 3 - [20 7 16 * ] 25
5.47 16 - [15 * 1 18 ] 54
6.44 11 - [5 13 10 23 ] 5.8
6.85 24 - [30 8 1 14 ] 2.3
5.53 130 + [8 * 12 17 ] 47
4.04 2 + [12 8 * * ] 1400
5.56 82 + [15 * 19 33 ] 44
4.99 46 + [38 31 * 2 ] 160
4.88 20 - [17 48 1 * ] 210
4.47 14 + [31 61 * 1 ] 540
4.05 8 + [* 13 1 * ] 1400
5.60 101 + [15 * 19 33 ] 40
5.66 235 - [8 20 * 49 ] 35
4.05 7 + [* 49 * 19 ] 1400
5.52 82 - [17 * 52 40 ] 48

Act
Error Unc
0.29 + 9
3
0.56 - 3.1 3
0.57 + 4.1 3
1.1 + 1.9 3
1.5 + 10
3
2.5 + 8.4 3
2.7 + 5.7 3
3.4 - 1
3
4.1 + 4.3 3
6.4 + 3.5 3
7.3 + 2.6 3
9.3 - 4.2 3
9.8 + 2.6 3
10 + 5.4 3
11 - 1.9 3
12 - 5.3 3
38 + 1.2 3
52 + 28
3
56 - 1.3 3
59 + 2.8 3
60 + 3.5 3
71 + 7.7 3
220 + 6.5 3
230 - 5.8 3
300 - 8.6 3
320 + 4.5 3
330 - 6.8 3

18oooo8
4.10 7 - [27 31 13 * ] 1300
330 + 3.9 3
1oooo11
4.88 2 - [27 22 1 * ] 210
340 - 1.6 3
3oooo6
5.02 35 + [32 52 1 * ] 150
530 - 3.5 3
11ooooONO3805 5.09 25 + [6 66 51 * ] 130
540 - 4.1 3
3oooo11
4.05 3 + [* 48 * 19 ] 1400
550 + 2.6 3
18oooo9
4.57 7 + [27 36 13 * ] 430
640 - 1.5 3
3oooo12
4.88 20 - [17 48 1 * ] 210
750 - 3.6 3
13oooo11
5.58 148 + [15 * 19 33 ] 42
810 - 19
3
3oooo9
4.94 19 + [* 5 46 26 ] 180
830 - 4.5 3
17oooo19
4.05 17 + [* 5 16 * ] 1400
830 + 1.7 3
6oooo3
4.04 2 + [12 34 * * ] 1500
870 + 1.7 3
13oooo2
5.27 114 - [15 * 19 33 ] 87
1200 - 14
3
6oooo9
4.05 11 + [* 26 * 42 ] 1400
1300 + 1.1 3
18oooo13
4.05 9 + [* 5 13 * ] 1400
2300 - 1.6 3
18oooo12
4.04 11 + [* 13 1 * ] 1400
4000 - 2.8 3
18oooo14
4.05 11 + [* 22 1 * ] 1400
4700 - 3.3 3
6oooo5a
4.04 2 + [* 26 37 * ] 1500
10000 - 6.8 3
18oooo7
4.05 6 + [* 13 1 * ] 1400 10000 - 7
3
18oooo6
4.04 8 + [* 13 1 * ] 1400 10000 - 6.9 3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=218.29 RMS=1.41336 correl=0.838323
Cost components: Error=200.67 Weight=1.12815 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 8th hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.16352
2.16352
2.16352
2.16352
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -5.70 -8.10 4.01
3.58 1.58 0.30 0.54
: Y 1.81 0.50
-3.83 -1.26 -3.00 0.43 -0.13
: Z 0.30 1.54
-3.38 -1.17 0.23 1.54 4.48
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 11.8 13.8
RING AROMATIC o9.9 12.1
3.4
---> 8.7 10.4
4.4
3.0
RING AROMATIC o6.3 8.4
7.5
4.6 3.9
---> 7.8 9.1
9.4
6.5 5.2 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
8.58 44 + [1 31 10 23 ] 0.03
6.29 2 + [* 13 1 18 ] 5.8
6.36 9 + [* 1 10 23 ] 5
6.34 22 - [* 22 1 14 ] 5.1
6.34 7 + [* 13 27 17 ] 5.1
6.36 2 - [* 13 1 18 ] 4.9
6.34 12 + [* 13 1 18 ] 5.1
6.38 13 + [* 38 1 14 ] 4.7
6.33 11 + [* 13 15 20 ] 5.3
5.99 2 - [* 13 1 17 ] 11
6.32 4 + [* 13 1 18 ] 5.4
6.34 20 + [* 22 1 14 ] 5.1
4.78 37 + [31 6 * 16 ] 190
4.93 2 - [* 13 1 18 ] 130
6.44 9 + [* 1 10 23 ] 4.1
6.26 4 - [* 22 1 14 ] 6.2
5.34 35 - [24 * 12 1 ] 52
3.89 2 + [12 * * 19 ] 1400
4.83 173 + [48 * 19 7 ] 170
4.32 31 + [* 37 25 * ] 530
4.44 19 - [15 17 1 * ] 410
4.79 14 + [31 6 * 16 ] 180
4.32 4 + [* 23 1 * ] 540
4.68 122 - [48 * 19 7 ] 230
5.03 176 + [27 * 12 1 ] 100
3.90 6 + [12 * * 19 ] 1400
5.09 146 + [67 * 52 15 ] 92

Act
Error Unc
0.29 - 9.7 3
0.56 + 10
3
0.57 + 8.7 3
1.1 + 4.7 3
1.5 + 3.4 3
2.5 + 2
3
2.7 + 1.9 3
3.4 + 1.4 3
4.1 + 1.3 3
6.4 + 1.8 3
7.3 - 1.3 3
9.3 - 1.8 3
9.8 + 19
3
10 + 13
3
11 - 2.7 3
12 - 1.9 3
38 + 1.4 3
52 + 28
3
56 + 3
3
59 + 9.1 3
60 + 6.8 3
71 + 2.6 3
220 + 2.4 3
230 + 1
3
300 - 2.9 3
320 + 4.4 3
330 - 3.6 3

18oooo8
4.32 6 + [* 23 1 * ] 540
330 + 1.6 3
1oooo11
4.32 5 + [* 18 1 * ] 540
340 + 1.6 3
3oooo6
4.97 16 + [15 17 1 * ] 120
530 - 4.4 3
11ooooONO3805 4.49 97 - [3 * 28 51 ] 370
540 - 1.5 3
3oooo11
3.87 5 + [12 * * 19 ] 1500
550 + 2.8 3
18oooo9
4.32 4 + [* 23 1 * ] 540
640 - 1.2 3
3oooo12
4.44 19 - [15 17 1 * ] 410
750 - 1.8 3
13oooo11
4.76 78 - [48 * 19 7 ] 190
810 - 4.2 3
3oooo9
4.35 40 + [15 17 * 46 ] 510
830 - 1.6 3
17oooo19
5.24 5 + [31 6 * 16 ] 65
830 - 13
3
6oooo3
4.31 7 + [12 40 * * ] 560
870 - 1.6 3
13oooo2
4.58 41 - [65 * 19 7 ] 300
1200 - 4
3
6oooo9
3.83 8 + [12 * * 19 ] 1700
1300 + 1.3 3
18oooo13
4.32 7 + [* 23 1 * ] 540
2300 - 4.3 3
18oooo12
4.32 3 + [* 23 1 * ] 540
4000 - 7.5 3
18oooo14
4.32 8 + [* 23 1 * ] 540
4700 - 8.8 3
6oooo5a
3.92 5 + [12 * * 19 ] 1400 10000 - 7.3 3
18oooo7
4.32 2 + [* 23 1 * ] 540
10000 - 19
3
18oooo6
4.32 5 + [* 23 1 * ] 530
10000 - 19
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=219.077 RMS=1.42322 correl=0.83587
Cost components: Error=201.314 Weight=1.27155 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 9th hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.10881
2.10881
2.10881
2.10881
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -6.23 -5.89 6.43
-0.02 1.01 4.15 6.15
: Y 3.70 6.66
-3.86 0.70 2.37 -2.12 0.10
: Z 1.62 1.14
-2.98 0.50 -1.77 -0.57 -0.84
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 15.4 16.7
RING AROMATIC o7.0 8.4
8.6
---> 8.1 8.6
8.3
3.0
RING AROMATIC o12.1 13.4
3.7
5.1 5.6
---> 13.1 13.8
4.5
6.3 5.7 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
Act
Error Unc
7.92 40 + [1 31 23 10 ] 0.084
0.29 - 3.5 3
6.07 18 + [* 13 18 1 ] 5.9
0.56 + 11
3
6.17 22 - [* 1 23 10 ] 4.6
0.57 + 8.1 3
6.19 48 + [* 22 14 1 ] 4.5
1.1 + 4.1 3
6.11 9 - [* 13 17 27 ] 5.3
1.5 + 3.5 3
6.19 6 - [* 13 18 1 ] 4.4
2.5 + 1.8 3
6.16 3 + [* 13 18 1 ] 4.7
2.7 + 1.8 3
6.19 18 - [* 38 14 1 ] 4.4
3.4 + 1.3 3
6.14 15 - [* 13 20 15 ] 5
4.1 + 1.2 3
6.13 12 + [* 13 17 1 ] 5.1
6.4 - 1.3 3
6.07 12 + [* 13 18 1 ] 5.8
7.3 - 1.3 3
6.21 55 - [* 22 14 1 ] 4.3
9.3 - 2.2 3
4.58 20 + [* 6 16 1 ] 180
9.8 + 19
3
4.74 15 - [* 13 18 1 ] 130
10 + 13
3
6.12 16 - [* 1 23 10 ] 5.2
11 - 2.1 3
6.17 37 - [* 22 14 1 ] 4.7
12 - 2.6 3
5.02 153 + [27 * 1 12 ] 66
38 + 1.7 3
3.64 2 + [12 * 19 * ] 1600
52 + 31
3
4.21 124 + [* 48 33 * ] 420
56 + 7.5 3
4.20 11 + [* 37 * 25 ] 430
59 + 7.3 3
4.20 2 + [* 17 * 1 ] 430
60 + 7.2 3
4.66 3 - [* 6 16 1 ] 150
71 + 2.1 3
4.20 4 + [* 23 * 1 ] 440
220 + 2
3
4.29 147 + [48 * 19 33 ] 350
230 + 1.5 3
5.29 99 + [* 24 12 1 ] 35
300 - 8.6 3
3.67 6 + [12 * 19 * ] 1500
320 + 4.6 3
4.63 163 + [67 * 15 52 ] 160
330 - 2
3

18oooo8
4.19 6 + [* 23 * 1 ] 440
330 + 1.3 3
1oooo11
4.19 4 + [* 18 * 1 ] 440
340 + 1.3 3
3oooo6
4.39 29 - [* 17 37 47 ] 280
530 - 1.9 3
11ooooONO3805 4.20 33 + [62 2 * * ] 430
540 - 1.2 3
3oooo11
3.84 9 + [12 * * 41 ] 990
550 + 1.8 3
18oooo9
4.20 4 + [* 23 * 1 ] 440
640 - 1.5 3
3oooo12
4.20 2 + [* 17 * 1 ] 430
750 - 1.7 3
13oooo11
5.48 96 - [50 * 7 19 ] 23
810 - 35
3
3oooo9
4.21 22 + [* 17 * 1 ] 420
830 - 2
3
17oooo19
4.20 7 + [* 6 * 1 ] 430
830 - 1.9 3
6oooo3
3.95 20 + [* 40 * 19 ] 770
870 - 1.1 3
13oooo2
4.19 202 + [* 64 19 * ] 450
1200 - 2.7 3
6oooo9
3.63 5 + [12 * 19 * ] 1600
1300 + 1.2 3
18oooo13
4.20 7 + [* 23 * 1 ] 440
2300 - 5.3 3
18oooo12
4.19 3 + [* 23 * 1 ] 440
4000 - 9.1 3
18oooo14
4.20 8 + [* 23 * 1 ] 440
4700 - 11
3
6oooo5a
3.49 4 + [12 * 19 * ] 2200
10000 - 4.5 3
18oooo7
4.20 3 + [* 23 * 1 ] 440
10000 - 23
3
18oooo6
4.19 5 + [* 23 * 1 ] 440
10000 - 23
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=220.681 RMS=1.44875 correl=0.8293
Cost components: Error=203 Weight=1.18983 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the 10th hypothesis
Definition:
HBA
NegIonizable RING AROMATIC RING AROMATIC
Weights:
2.01746
2.01746
2.01746
2.01746
Tolerances: 1.60 2.20
1.60
1.60 1.60 1.60 1.60
Coords: X -5.60 -8.00 5.08
3.64 6.10 -0.14 0.18
: Y 2.37 3.12
-2.95 -1.68 -0.06 -0.08 2.19
: Z 0.79 2.46
-4.14 -1.16 -0.63 1.56 -0.38
o--------->
o
o---------> o--------->
HBA
o
---> 3.0
NegIonizable o 12.9 15.9
RING AROMATIC o10.3 13.1
3.6
---> 12.0 14.8
4.7
3.0
RING AROMATIC o6.0 8.5
8.2
4.9 6.6
---> 5.9 8.7
8.0
5.2 6.3 3.0
Name
11ooo2o
12oooo2s
11ooo2r
11oooo2g
12oooo2g
12oooo2j
12oooo2l
11oooo2b
12oooo2f
12oooo2h
12oooo2r
11ooo2k
17oooo40
12oooo2k
11ooo2q
11oooo2c
13ooo22
6oooo6
13oooo12
12oooo2b
3oooo7
17oooo39
18oooo10
13oooo13
13ooo21
6oooo10
13ooo18

Fit Cnf/Enan
Mapping
Est
Act
Error Unc
7.96 72 + [1 31 10 23 ] 0.056
0.29 - 5.2 3
5.97 19 - [* 13 1 18 ] 5.6
0.56 + 10
3
6.03 32 + [* 1 10 23 ] 4.8
0.57 + 8.4 3
5.96 65 + [* 22 1 14 ] 5.6
1.1 + 5.1 3
5.77 9 - [* 13 27 17 ] 8.7
1.5 + 5.8 3
5.66 6 - [* 13 1 18 ] 11
2.5 + 4.6 3
5.82 20 + [* 13 1 18 ] 7.9
2.7 + 2.9 3
6.05 22 + [* 38 1 14 ] 4.6
3.4 + 1.4 3
5.78 16 + [* 13 15 20 ] 8.6
4.1 + 2.1 3
5.82 13 + [* 13 1 17 ] 7.8
6.4 + 1.2 3
5.97 8 - [* 13 1 18 ] 5.5
7.3 - 1.3 3
6.02 67 + [* 22 1 14 ] 4.9
9.3 - 1.9 3
5.03 13 - [31 6 * 16 ] 48
9.8 + 4.9 3
5.08 15 + [* 13 1 18 ] 43
10 + 4.3 3
6.02 14 - [* 1 10 23 ] 4.9
11 - 2.2 3
6.02 39 + [* 22 1 14 ] 5
12 - 2.4 3
4.82 152 + [27 * 12 1 ] 78
38 + 2.1 3
3.12 3 + [12 * * 19 ] 3900
52 + 75
3
5.34 117 + [50 * 19 7 ] 23
56 - 2.4 3
4.03 49 + [* 37 25 * ] 480
59 + 8.1 3
4.03 39 + [* 17 1 * ] 480
60 + 7.9 3
4.33 16 + [31 6 1 * ] 240
71 + 3.4 3
4.03 9 + [* 23 1 * ] 480
220 + 2.2 3
4.95 5 - [48 * 19 7 ] 58
230 - 4
3
5.03 9 - [27 * 12 1 ] 48
300 - 6.2 3
3.42 8 + [12 * * 19 ] 2000
320 + 6.1 3
4.68 31 - [67 * 52 15 ] 110
330 - 3.1 3

18oooo8
4.03 10 + [* 23 1 * ] 480
330 + 1.4 3
1oooo11
4.03 6 + [* 18 1 * ] 480
340 + 1.4 3
3oooo6
4.03 15 + [* 17 1 * ] 480
530 - 1.1 3
11ooooONO3805 4.03 128 + [* 2 * 51 ] 480
540 - 1.1 3
3oooo11
3.55 3 + [12 * * 19 ] 1500
550 + 2.7 3
18oooo9
4.03 8 + [* 23 1 * ] 480
640 - 1.3 3
3oooo12
4.03 39 + [* 17 1 * ] 480
750 - 1.6 3
13oooo11
4.98 20 + [30 48 * 8 ] 54
810 - 15
3
3oooo9
4.03 51 + [* 17 1 * ] 480
830 - 1.7 3
17oooo19
4.03 21 + [* 6 1 * ] 480
830 - 1.7 3
6oooo3
3.55 20 + [* 40 19 * ] 1400
870 + 1.7 3
13oooo2
4.62 24 + [65 * 19 7 ] 120
1200 - 9.7 3
6oooo9
3.42 10 + [12 * * 19 ] 2000
1300 + 1.5 3
18oooo13
4.03 10 + [* 23 1 * ] 480
2300 - 4.9 3
18oooo12
4.03 11 + [* 23 1 * ] 480
4000 - 8.4 3
18oooo14
4.03 11 + [* 23 1 * ] 480
4700 - 9.9 3
6oooo5a
3.43 6 + [12 * * 19 ] 1900 10000 - 5.2 3
18oooo7
4.03 7 + [* 23 1 * ] 480
10000 - 21
3
18oooo6
4.03 8 + [* 23 1 * ] 480
10000 - 21
3
*************************************************************
Mirror image used. To turn this option off, put
catHypo.forceAbsoluteStereochemistry=1 in the .Catalyst file.
*************************************************************
totalcost=221.249 RMS=1.45819 correl=0.826819
Cost components: Error=203.631 Weight=1.12658 Config=16.4912 Tolerance=0
Fixed Cost:
totalcost=172.342 RMS=0 correl=0
Cost components: Error=154.726 Weight=1.12491 Config=16.4912 Tolerance=0

dumping score for the null hypothesis:
totalcost=309.309 RMS=2.59249 correl=5.67491e-05
Cost components: Error=309.309 Weight=0 Config=0 Mapping=0 Tolerance=0
Version: catHypo 4.5 (272) Wednesday, July 28, 1999 at 04:56 AM
Confs (cpd): /birchfiles/jane/riihuman10-294Dir/
Spreadsheet: /birchfiles/jane/riihuman10-294Dir/riihuman10minus2.spst
Dictionary: /birchfiles/jane/riihuman10-294Dir/dict.chm
Host:
birch
Outname:
riihuman10
Logname:
riihuman10-294.log
CPU time = 74298 s System time = 408 s
Complexity 208.701
Concluded pass 6.
Finished generating a hypothesis.

